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ABSTRACT 
 
Application of Mathematical Modeling in Cancer, Blood Clotting Abnormalities and 
Migraine Headaches Research 
 
by 
 
Hamed Ghaffari 
 
Mathematical modeling of biological processes has contributed significantly to improving 
our understanding of how different biological systems function, how and why different 
diseases start and develop, and how the diseases can be prevented or treated. In the first part 
of this dissertation, we use mechanistic modeling together with local and global sensitivity 
analyses to explore why different patients and/or different cancer types respond differently 
to retinoic acid (RA), an anticancer drug. Our findings indicate that the efficacy of RA 
treatment highly depends on intracellular levels of four main RA binding proteins namely, 
retinoic acid receptor (RAR), cellular retinoic acid binding proteins (CRABP1 and 
CRABP2) and cytochrome P450 (CYP). These proteins are expressed at different levels in 
different patients and/or cell types. Our results indicate that CRABP2 and RAR are the most 
and the least important receptors, respectively, in regulating the response to RA treatment 
at physiological concentrations (1–10 nM). However, at pharmacological concentrations of 
RA (0.1–1 μM), CYP and RAR are the most sensitive parameters of the model. These 
results can help in the development of pharmacological methods to increase the efficacy of 
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the drug. In the second part of this dissertation, we study the positive side effects of RA 
therapy on blood clotting abnormalities in cancer patients. Although there are several lines 
of evidence regarding the improvement of hemostatic complications such as thrombosis and 
disseminated intravascular coagulation (DIC) in cancer patients undergoing RA therapy, 
the mechanisms underlying this improvement have yet to be understood. We build 
mechanistic and pharmacokinetics models and use in vitro and pharmacokinetics data from 
the literature to test the hypothesis that this improvement is due to RA-induced upregulation 
of thrombomodulin (TM) on the endothelial cells. Our results indicate that treatment with 
a single daily oral dose of 110 
𝑚𝑔
𝑚2
  RA, increases the TM concentration by almost two folds. 
We then show that this RA-induced TM upregulation reduces the peak thrombin levels and 
endogenous thrombin potential (ETP) up to 50 and 49%, respectively. Our results 
demonstrate that progressive reductions in plasma levels of RA, observed in continuous RA 
therapy with a once-daily oral dose of 110 
𝑚𝑔
𝑚2
 RA do not influence TM-mediated decrease 
in thrombin generation. This observation raises the hypothesis that continuous RA treatment 
will have more consistent therapeutic effects on coagulation disorders than on cancer. Our 
results reveal that the upregulation of TM expression on the endothelial cells over the course 
of RA therapy could significantly contribute to the treatment of coagulation abnormalities 
in cancer patients. In the last part of this dissertation, we use mechanistic modeling to study 
sodium homeostasis disturbance in the brain during migraines. Previous animal and human 
studies have revealed that migraine sufferers have higher levels of cerebrospinal fluid (CSF) 
and brain tissue sodium than control groups, while the underlying mechanisms of this 
increase are not known. Under the hypothesis that disturbances in sodium transport 
mechanisms at the blood-CSF barrier (BCSFB) and/or the blood-brain barrier (BBB) are 
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the underlying cause of the elevated CSF and brain, we develop a mechanistic model of a 
rat’s brain to compare the significance of the BCSFB and the BBB in controlling CSF and 
brain tissue sodium levels. Our model consists of the ventricular system, subarachnoid 
space, brain tissue and blood. We model sodium transport from blood to CSF across the 
BCSFB, and from blood to brain tissue across the BBB by influx permeability coefficients 
𝑃𝐵𝐶𝑆𝐹𝐵 and 𝑃𝐵𝐵𝐵, respectively, while sodium movement from CSF into blood across the 
BCSFB, and from brain tissue to blood across the BBB were modeled by efflux 
permeability coefficients 𝑃𝐵𝐶𝑆𝐹𝐵
′  and 𝑃𝐵𝐵𝐵
′ , respectively. We then perform a global 
sensitivity analysis to investigate the sensitivity of the ventricular CSF, subarachnoid CSF 
and brain tissue sodium levels to pathophysiological variations in 𝑃𝐵𝐶𝑆𝐹𝐵, 𝑃𝐵𝐵𝐵, 𝑃𝐵𝐶𝑆𝐹𝐵
′  and 
𝑃𝐵𝐵𝐵
′ . Our findings indicate that the ventricular CSF sodium concentration is highly 
influenced by perturbations of 𝑃𝐵𝐶𝑆𝐹𝐵, and to a much lesser extent by perturbations of 
𝑃𝐵𝐶𝑆𝐹𝐵
′ . Brain tissue and subarachnoid CSF sodium concentrations are more sensitive to 
pathophysiological variations of 𝑃𝐵𝐵𝐵 and 𝑃𝐵𝐵𝐵
′  than variations of 𝑃𝐵𝐶𝑆𝐹𝐵 and 𝑃𝐵𝐶𝑆𝐹𝐵
′  within 
30 minutes of the onset of the perturbations. However, 𝑃𝐵𝐶𝑆𝐹𝐵 is the most sensitive model 
parameter, followed by 𝑃𝐵𝐵𝐵 and 𝑃𝐵𝐵𝐵
′ , in controlling brain tissue and subarachnoid CSF 
sodium levels within 3 hours of the perturbation onset. Our findings suggest that increased 
influx permeability of the BCSFB to sodium caused by altered homeostasis of the enzymes 
which transport sodium from blood to CSF is the potential cause of elevated brain sodium 
levels in migraines. 
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Chapter 1 
Introduction 
Mathematical modeling is a powerful tool for not only understanding how different 
diseases start and progress, but also for the development of new treatments for the 
diseases. In this dissertation, we use mathematical modeling to study the mechanism of 
action of retinoic acid (RA), an anticancer drug, in the treatment of cancer and blood 
clotting disorders, as well as explore the regulatory mechanisms of sodium levels in the 
brain during migraine headaches. In chapter 2, we use mathematical modeling to provide 
further insight into why different patients and/or different cancers respond differently to 
retinoic acid (RA), an anticancer drug. It is believed that RA exerts its therapeutic effects 
by regulating gene expression through the classical retinoic acid signaling pathway. In the 
classical pathway of retinoic acid (RA) mediated gene transcription, RA binds to a nuclear 
hormone receptor dimer composed of retinoic acid receptor (RAR) and retinoid X 
receptor (RXR), to induce the expression of its downstream target genes. In addition to 
nuclear receptors, there are other intracellular RA binding proteins such as cellular 
retinoic acid binding proteins (CRABP1 and CRABP2) and cytochrome P450 (CYP) 
enzymes, whose contributions to the RA signaling pathway have not been fully 
understood. In this work, we develop a mechanistic model of the classical retinoic acid 
signaling pathway that RAR, CRABP1, CRABP2, and CYP enzymes. We then use global 
sensitivity analysis to investigate the contribution of the RA binding proteins to RA-
induced mRNA production, when the cells are treated with a wide range of RA levels, 
from physiological to pharmacological concentrations. Our results show that CRABP2 
and RAR are the most and the least important proteins, respectively, in controlling the 
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model performance at physiological concentrations of RA (1–10 nM). However, at higher 
concentrations of RA, CYP and RAR are the most sensitive parameters of the system. 
Furthermore, we found that depending on the concentrations of all RA binding proteins, 
the rate of metabolism of RA can either change or remain constant following RA therapy. 
The cellular levels of CRABP1 are more important than that of CRABP2 in controlling 
RA metabolite formation at pharmacological conditions (RA = 0.1–1 μM). Our results 
indicate a significant negative correlation between total mRNA production and total RA 
metabolite formation at pharmacological levels of RA. Our simulations indicate that the 
significance of the RA binding proteins in the RA pathway of gene expression strongly 
depends on intracellular concentration of RA. Our findings not only can explain why 
various cell types and/or various patients respond to RA therapy differently, but also can 
potentially help develop pharmacological methods to increase the efficacy of the drug.  
In chapter 3, we study the therapeutic effects of RA on coagulation disorders in cancer 
patients. Clinical studies have shown that RA, which is known as an anticancer drug, 
improves hemostatic parameters and bleeding complications such as thrombosis and 
disseminated intravascular coagulation (DIC) in cancer patients. However, the mechanisms 
underlying this improvement have yet to be elucidated. In vitro studies have reported that 
RA upregulates thrombomodulin (TM) expression on the endothelial cell surface. In this 
chapter, we investigate how and to what extent the TM concentration changes after RA 
treatment in cancer patients, and how this variation influences the blood coagulation 
cascade. In this regard, we introduce an ordinary differential equation (ODE) model of gene 
expression for the RA-induced upregulation of TM concentration. Coupling the gene 
expression model with a two-compartment pharmacokinetic model of RA, we obtain the 
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time-dependent changes in TM and thrombomodulin-mRNA (TMR) concentrations 
following oral administration of RA. Our results indicate that the TM concentration reaches 
its peak level almost 14 h after taking a single oral dose (110 
𝑚𝑔
𝑚2
) of RA. Continuous 
treatment with RA results in oscillatory expression of TM on the endothelial cell surface. 
We then couple the gene expression model with a mechanistic model of the coagulation 
cascade, and show that the elevated levels of TM over the course of RA therapy with a 
single daily oral dose (110 
𝑚𝑔
𝑚2
) of RA reduces the peak thrombin levels and endogenous 
thrombin potential (ETP) up to 50 and 49%, respectively. We show that progressive 
reductions in plasma levels of RA, observed in continuous RA therapy with a once-daily 
oral dose (110 
𝑚𝑔
𝑚2
) of RA, do not affect TM-mediated reduction of thrombin generation 
significantly. This finding prompts the hypothesis that continuous RA treatment has more 
consistent therapeutic effects on coagulation disorders than on cancer. Our results indicate 
that the oscillatory upregulation of TM expression on the endothelial cells over the course 
of RA therapy could potentially contribute to the treatment of coagulation abnormalities in 
cancer patients. Further studies on the impacts of RA therapy on the procoagulant activity 
of cancer cells are needed to better elucidate the mechanisms by which RA therapy 
improves hemostatic abnormalities in cancer. 
In chapter four, we investigate how sodium levels are regulated in the brain during the 
onset and propagation of migraine. There are several lines of evidence regarding that 
cerebrospinal fluid (CSF) and brain tissue sodium levels increase during migraine. 
However, little is known regarding the underlying mechanisms of sodium homeostasis 
disturbance in the brain during migraine. Exploring the cause of sodium dysregulation in 
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the brain is important, since correction of the altered sodium homeostasis could potentially 
treat migraine. Under the hypothesis that disturbances in sodium transport mechanisms at 
the blood-CSF barrier (BCSFB) and/or the blood-brain barrier (BBB) are the underlying 
cause of the elevated CSF and brain tissue sodium levels during migraines, we develop a 
mechanistic, differential equation model of a rat’s brain to compare the significance of the 
BCSFB and the BBB in controlling CSF and brain tissue sodium levels. The model includes 
the ventricular system, subarachnoid space, brain tissue and blood. Sodium transport from 
blood to CSF across the BCSFB, and from blood to brain tissue across the BBB were 
modeled by influx permeability coefficients 𝑃𝐵𝐶𝑆𝐹𝐵 and 𝑃𝐵𝐵𝐵, respectively, while sodium 
movement from CSF into blood across the BCSFB, and from brain tissue to blood across 
the BBB were modeled by efflux permeability coefficients 𝑃𝐵𝐶𝑆𝐹𝐵
′  and 𝑃𝐵𝐵𝐵
′ , respectively. 
We then perform a global sensitivity analysis to investigate the sensitivity of the ventricular 
CSF, subarachnoid CSF and brain tissue sodium concentrations to pathophysiological 
variations in 𝑃𝐵𝐶𝑆𝐹𝐵, 𝑃𝐵𝐵𝐵, 𝑃𝐵𝐶𝑆𝐹𝐵
′  and 𝑃𝐵𝐵𝐵
′ . Our results show that the ventricular CSF 
sodium concentration is highly influenced by perturbations of 𝑃𝐵𝐶𝑆𝐹𝐵, and to a much lesser 
extent by perturbations of 𝑃𝐵𝐶𝑆𝐹𝐵
′ . Brain tissue and subarachnoid CSF sodium 
concentrations are more sensitive to pathophysiological variations of 𝑃𝐵𝐵𝐵 and 𝑃𝐵𝐵𝐵
′  than 
variations of 𝑃𝐵𝐶𝑆𝐹𝐵 and 𝑃𝐵𝐶𝑆𝐹𝐵
′  within 30 minutes of the onset of the perturbations. 
However, 𝑃𝐵𝐶𝑆𝐹𝐵 is the most sensitive model parameter, followed by 𝑃𝐵𝐵𝐵 and 𝑃𝐵𝐵𝐵
′ , in 
controlling brain tissue and subarachnoid CSF sodium levels within 3 hours of the 
perturbation onset. Our findings prompt the hypothesis that increased influx permeability 
of the BCSFB to sodium caused by altered homeostasis of the enzymes which transport 
sodium from blood to CSF is the potential cause of elevated brain sodium levels in 
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migraines. This hypothesis needs to be tested experimentally. The current model can be 
used to simulate sodium transport across the BBB, the BCSFB and the ependymal surfaces 
for a particular migraine trigger, given that the effects of the migraine trigger on the BBB 
and the BCSFB permeabilities are known. 
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Chapter 2 
Identification of influential proteins in the classical retinoic acid signaling 
pathway 
 
2.1. Introduction 
Retinoic acid (RA), a biologically active form of vitamin A, plays essential roles in the 
growth and development of various cell types. RA has also been widely used as an 
anticancer drug due to its ability to inhibit cancer cell growth and induce cell differentiation. 
It is believed that RA mainly exerts its effects by regulating gene expression. The classical 
pathway of RA-induced gene transcription involves binding of RA to retinoic acid receptor 
(RAR), a member of the nuclear hormone family. The liganded RAR binds as a heterodimer 
(RA:RAR:RXR) to DNA and regulates gene expression. RAR:RXR heterodimer is the 
main transcription factor in the classical RA signaling pathway. The formation rate of 
RA:RAR:RXR complex, is highly affected by other intracellular RA binding receptors such 
as cellular retinoic acid binding proteins (CRABPs) and cytochrome P450 (CYP) enzymes. 
CRABPs are high affinity cytosolic receptors for RA that can potentially limit the access of 
RA to the RARs; CRABP1 and CRABP2 are the main members of the CRABP family. It 
has been reported that CRABP1 is responsible for sequestering RA in the cytosol, and thus 
controlling the level of free intracellular RA available for binding to RARs [1]. CRABP1 
can also facilitate RA degradation by directing RA molecules to RA-degrading 
enzymes, cytochrome P450 (CYP) [2]. However, other in vitro studies have indicated that 
CRABP1 is dispensable in the RA signaling pathway [3, 4]. CRABP2, whose expression 
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pattern is different from CRABP1 [5], delivers RA to both nuclear hormone receptors and 
CYP enzymes [6, 7]. CRABPs are bound to CYPs prior to adding RA to the cell [6, 8]. 
CYP enzymes are the main components of the pathway by which RA is cleared from 
the body. It is believed that liver cells which express high levels of CYP enzymes mainly 
mediate the synthesis and the clearance of RA [9, 10]. However, CYPs are found at various 
expression levels across different tissues and cell types [10]. Even though CRABP1, 
CRABP2, RAR and CYP are the main RA binding proteins, little is known about their 
expression levels across different human cell types. It is important to note that the cellular 
level of a protein can also vary considerably from cell to cell within a population of cells of 
the same type. Furthermore, to the best of our knowledge, the extent of contribution of the 
RA binding receptors to RA-induced gene transcription has yet to be elucidated. 
Understanding the roles and significance of RA binding receptors in the RA signaling 
pathway is important since it can help in the development of pharmacological approaches 
to limit or induce the activity of RA binding receptors, with the aim of increasing drug 
efficacy. Few previous in vitro studies have investigated the impacts of overexpression of 
CRABP1 and CRABP2 on RA-induced gene expression [3, 11]. However, their results were 
cell type-dependent, since different cell types have different expression levels of RA 
binding receptors. Furthermore, it is not clear whether the significance of the RA binding 
receptors in the RA pathway of gene expression depends on the RA concentration. In this 
study, we developed a new mathematical model to investigate the importance of various 
RA binding receptors in the RA signaling pathway in broad regions of RA concentrations. 
In this regard, we used a variance-based global sensitivity analysis (GSA) technique called 
Sobol’s method [12], which assesses the impacts of the model’s unknown parameters and 
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the interactions between them on the model output. Total mRNA production and total RA 
metabolite formation within 24 hours after RA treatment were selected as the model outputs, 
while the unknown parameters included kinetic rate constants and total concentrations of 
the RA binding receptors. Our results showed that all RA binding receptors could 
potentially influence mRNA production and RA metabolite formation by the RA pathway. 
However, the impact of a particular RA binding receptor on the model response largely 
depends on the concentrations of all RA binding receptors.  
The main advantage of the current study over previous in vitro studies is that our results 
were obtained using wide ranges of RA receptor concentrations for any given RA 
concentration, thus our results are applicable to most cell types or to a population of cells 
of the same type. Furthermore, our study is able to reveal the synergistic effects of a 
combination of parameters across a broad range of parameter values. In contrast, the 
obtained results from previous experimental studies [3, 11] reveal the sensitivity of the 
system with respect to one parameter when the rest of the parameters remain unchanged.  
 
2.2. Methods 
2.2.1. Model development 
We formulated a well-mixed ODE model of the RA signaling pathway. The model 
consisted of 17 species, which included proteins, mRNAs, protein-protein complexes and 
RA (Table 1).  
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Table 1. List of the model parameters 
Parameter Description 
RA Retinoic acid 
CRABP1 Cellular retinoic acid binding protein 1 
RA:CRABP1 Holo-cellular retinoic acid binding protein 1 
CRABP2 Cellular retinoic acid binding protein 2 
RA:CRABP2 Holo-cellular retinoic acid binding protein 2 
CYP CYP enzyme 
RA:CYP Liganded CYP 
RAR Retinoic acid receptor 
RA:RAR Activated retinoic acid receptor 
RA:CRABP1:CYP Activated CRABP1-CYP complex 
RA:CRABP2:CYP Activated CRABP2-CYP complex 
RA:CRABP2:RAR Activated CRABP2-RAR complex 
CRABP1:CYP CRABP1-CYP complex 
CRABP2:CYP CRABP2-CYP complex 
𝐶𝑅𝐴𝐵𝑃2𝑚𝑅𝑁𝐴 Cellular retinoic acid binding protein 2 mRNA 
𝐶𝑌𝑃𝑚𝑅𝑁𝐴 CYP enzyme mRNA 
𝑅𝐴𝑅𝑚𝑅𝑁𝐴 Retinoic acid receptor mRNA 
 
 
The model included gene transcription, protein translation, and degradation of mRNA 
and protein. The model involved the mechanisms by which RA is degraded. The core set of 
reactions describing the RA metabolism process were taken directly from [6]. We simulated 
RA-induced gene transcription through the interactions between liganded transcription 
factor and DNA (Supplementary Information in Section 2.6). The model also describes how 
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RA binding receptors interact with each other in the absence or presence of RA (Fig. 1). In 
the absence of RA, CRABPs complex with CYP enzymes, while RARs are  not bound to 
CRABPs or CYPs [6, 8]. Once RA diffuses into the cell, it binds to different RA binding 
receptors with various binding affinities. CRABP1, which has the highest binding affinity 
for RA compared to the other RA receptors, regulates the metabolic fate of RA by directing 
RA molecules to CYP enzymes. In theory, CRABP1 can also transport RA to RAR. This 
process involves dissociation of RA from CRABP1, followed by association of RA with 
RAR. CRABP2 is the second high-affinity receptor for RA [5] and can deliver RA to RAR 
and CYP. RA is transported from CRABP2 to RAR by a mechanism that involves direct 
interactions between CRABP2 and RAR [5]. 
RA is transferred to CYP enzymes either freely or bound to CRABPs. RA-induced gene 
transcription depends on the rate of transfer of RA to RAR. Free RA molecules can interact 
with RARs directly. CRABP1 and CRABP2 can also deliver RA to RAR by different 
mechanisms. Liganded transcription factors can enhance the transcriptional activation of 
CYP, RAR and CRABP2 genes after binding to DNA at a retinoic acid response element 
(RARE). We also assumed that RA was degraded only by CYP, while RA binding 
receptors, i.e. RAR, CRABP1, CRABP2, CYP were degraded by first-order reactions.  
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Figure 1. Simplified schematic of RA signaling pathway. CRABP1 is shown in green, while 
CRABP2 is shown in blue. Red circles, gray ellipsoids and yellow hexagons represent RA 
molecules, CYP enzymes and RAR molecules, respectively.   
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The full list of reactions in our model is presented in Table 2 
Table 2. List of reactions in the RA signaling pathway 
Number Reaction 
1 
RA + CRABP1⇔  RA: CRABP1 
2 
RA + CRABP2⇔  RA: CRABP2 
3 
RA + CYP⇔  RA: CYP 
4 
RA: CYP⇒ CYP + (RA metabolites) 
5 
RA + RAR⇔  RA: RAR 
6 
𝑅𝐴𝑅mRNA⇒RAR 
7 
𝐶𝑅𝐴𝐵𝑃2mRNA⇒ CRABP2 
8 
𝐶𝑌𝑃mRNA⇒CYP 
9 
RA: CRABP1 + CYP⇔ RA: CRABP1: CYP 
10 
RA: CRABP1: CYP⇒ CRABP1: CYP + (RA metabolites) 
11 
RA: CRABP2 + CYP⇔ RA: CRABP2: CYP 
12 
RA: CRABP2: CYP⇒ CRABP2: CYP + (RA metabolites) 
13 
RA: CRABP2 + RAR⇔RA: CRABP2: RAR 
14 
RA: CRABP2: RAR⇒ RA:RAR + CRABP2 
15 
CRABP1 + CYP⇔ CRABP1: CYP 
16 
CRABP2 + CYP⇔ CRABP2: CYP 
17 
CRABP1⇒∅  
18 
CRABP2⇒∅ 
19 
CYP⇒∅ 
20 
RAR⇒∅ 
21 
RA: CRABP1⇒RA + ∅ 
22 
RA: CRABP2⇒RA + ∅ 
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RA-induced expression of RAR, CRBAP2 and CYP genes are modeled using Eq. 4.  
 
 
Analysis of the model behavior required the initial concentrations of the species and the 
kinetic parameters. Our model had 44 parameters, which included total concentrations of 
the RA binding receptors, the kinetic rate constants for binding/unbinding reactions, 
transcription and translation rate constants and mRNA and protein degradation rates. We 
assumed that total concentrations of CRABP1, CRABP2, CYP and RAR were unknown, 
which implies that these proteins are expressed in various levels across different tissues and 
across a population of cells of the same type. In the absence of RA, total concentrations of 
RA receptors were given by  
 
[CRABP1𝑡] = [CRABP1𝑓] + [CRABP1: CYP]                                                                           (1)                                  
[CRABP2𝑡] = [CRABP2𝑓] + [CRABP2: CYP]                                                                           (2)                           
[CYP𝑡] = [CYP𝑓] + [CRABP1: CYP] + [CRABP2: CYP]                                                           (3)        
 
23 
RA: RAR⇒RA + ∅ 
24 
𝑅𝐴𝑅mRNA⇒∅ 
25 
𝐶𝑅𝐴𝐵𝑃2mRNA⇒∅ 
26 
𝐶𝑌𝑃mRNA⇒∅ 
27 
CRABP1: CYP⇒CYP + ∅ 
28 
CRABP1: CYP⇒CRABP1 + ∅ 
29 
CRABP2: CYP⇒CYP + ∅ 
30 
CRABP2: CYP⇒CRABP2 + ∅ 
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where [] indicates molar concentration, while subscripts 𝑡 and 𝑓 stand for total and free 
receptors. RAR does not have any interaction with the remainder of the RA binding 
receptors, i.e. CRABP1, CRABP2 and CYP, before RA treatment. However, RAR can 
homodimerize, and heterodimerize with other proteins such as RXR in the absence of RA. 
In this study, we assumed that RA molecules can bind to free RARs, and to RARs bound to 
other proteins, with the same binding affinity. Thus, all RARs are receptive to RA binding.   
We used in vitro values for 30 model parameters (see Supplementary Information in 
Section 2.6), while the remaining 14 parameters were unknown for which we considered 
some physiological bounds (Table 3).  We also assumed that for a given gene the values of 
transcription rate constants, translation rate constants, forward and reverse rate constants of 
the binding reactions and the elimination rates of proteins and mRNAs can vary within the 
in vitro values by a factor of two. This is because not only can these parameters vary across 
cell type and across cells of the same type, but also all in vitro parameters are subject to 
error.  
Table 3. List of the independent model parameters 
Parameter Description Range Reference 
CRABP1 Total concentration of CRABP1 1 nM – 10 µM 
Unknown. A 
large range is 
used. 
CRABP2 Total concentration of CRABP2 1 nM – 10 µM 
Unknown. 
A large range 
is used. 
CYP Total concentration of CYP 1 nM – 10 µM 
Unknown. A 
large range is 
used. 
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RAR Total concentration of RAR 1 nM – 1 µM 
Unknown. A 
large range is 
used. 
𝑘𝑑3 
Equilibrium dissociation constant of reaction 
#3 
1nM -64 nM [6] 
𝑘𝑜𝑛13 Forward rate of reaction #13 
3.6 × 109
− 3.6 × 1010 
[13] 
𝑘𝑑13 
Equilibrium dissociation constant of reaction 
# 13 
0.1 nM-10nM [14] 
𝑘𝑜𝑛14 Forward rate of reaction #14 50-200 1/hr [15] 
𝑘𝑜𝑛15 Forward rate of reaction #15 
3.6 × 109
− 3.6 × 1010 
[13] 
𝑘𝑜𝑛16 Forward rate of reaction #16 
3.6 × 109
− 3.6 × 1010 
[13] 
𝑓𝑅𝐴𝑅 Transcription factor fraction for RAR gene 0-1 By definition 
𝑓𝐶𝑅𝐴𝐵𝑃2 
Transcription factor fraction of CRABP2 
gene 
0-1 By definition 
𝑓𝐶𝑌𝑃 Transcription factor fraction for CYP gene 0-1 By definition 
𝑓𝐺𝑂𝐼 Transcription factor fraction for the GOI 0-1 By definition 
Reactions are shown in Table 2. 
Transcription factor fractions are defined in Section 3.1.  
 
We used large ranges for unknown initial concentrations of CRABP1, CRABP2, CYP 
and RAR [16]. This is because the cellular levels of these proteins can vary significantly 
across cell types, or in a particular cell type as a consequence of cancer and cancer therapy. 
We then performed a global sensitivity analysis to identify the influential unknown 
parameters in the RA signaling pathway.  
2.2.2. Global Sensitivity Analysis of the Model 
Global sensitivity analysis (GSA) is a numerical technique designed to analyze the 
impacts of uncertain parameters on a model’s output. In contrast to local sensitivity analysis 
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which analyzes the changes of model output by making small changes to each parameter 
while keeping the remaining parameters unchanged [17], GSA considers variations of all 
parameters over their entire range. Thus, GSA is useful for understanding the contribution 
of various model parameters to the variations in model output.  In this study, we used a 
MATLAB toolbox for global sensitivity analysis, called SAFE [18]. We used a variance-
based sensitivity analysis approach called Sobol’s method, which can quantitatively rank 
the relative importance of the model’s parameters [12, 19, 20]. Sobol’s method evaluates 
the first- and total-order sensitivity indices for each parameter. The first-order index (𝑆𝑖) 
represents the individual effects of each input on the variance of the output, while the total-
effect index (𝑆𝑇𝑖) accounts for the total contribution of the input that includes its first-order 
effect plus all higher-order effects. The higher-order effects for a given input are due to 
interactions of the input with other model inputs. The total-effect sensitivity indices are 
useful in identifying the noninfluential parameters which can be fixed anywhere over their 
range of variability without influencing the output significantly [12]. If 𝑆𝑇𝑖 ≤ 0.01 and the 
total-effect index of 𝑥𝑖 is much smaller than that of the rest of parameters, then 𝑥𝑖 can be 
fixed at any value within its range [21-23]. 
2.3. Results   
2.3.1. Gene expression through RA pathway 
We investigated the importance of various RA binding receptors in the RA signaling 
pathway after treating the model with various concentrations of RA. In this regard, we 
calculated the total mRNA production by a gene of interest (GOI) within 24 hours after RA 
therapy. The rate of production of a mRNA of interest by the classical RA signaling pathway 
is modeled by (see Supplementary Information in Section 2.6 for details) 
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d[mRNA]
dt
= 𝐼max (𝐺𝑂𝐼) (
𝑓𝐺𝑂𝐼[RA: RAR]
𝑓𝐺𝑂𝐼[RA: RAR] + 𝑘𝑑(𝑇𝐹:𝐷𝑁𝐴)
),                                                        (4) 
where 𝐼max (𝐺𝑂𝐼) and 𝑘𝑑(𝑇𝐹:𝐷𝑁𝐴) are the maximal transcription rate by an activated 
transcription factor (TF𝑎) which initiates the transcription of the mRNA’s gene, and the 
equilibrium dissociation constant of binding of the transcription factor to DNA, 
respectively. 𝑓𝐺𝑂𝐼 is the transcription factor fraction of the GOI, defined as the ratio of the 
concentration of total transcription factor (TF𝑡) to the concentration of total RAR (RAR𝑡),  
 𝑓𝐺𝑂𝐼 =
[TF𝑡]
[RAR𝑡]
 ,                                                                                                                              (5) 
and is a number between 0 and 1. TF𝑡 represents those heterodimerized RAR isotypes which 
can activate the transcription of the GOI after binding to RA. Some RA target genes can be 
expressed by various RAR:RXR heterodimers, while others are expressed by a particular 
heterodimer. Thus, the concentration of total transcription factor (TF𝑡) is less than or equal 
to total concentration of RAR (RAR𝑡). In general, the value of  𝑓𝐺𝑂𝐼 depends on gene- and 
cell-type. For a given cell-type, 𝑓𝐺𝑂𝐼 varies for different genes since the value of TF𝑡 
depends on gene-type.  
Figure 2a shows the variations in the transcription rate of the GOI within 24 hours after 
adding various concentrations of RA to a model with a randomly sampled set of parameters.   
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(a) (b) 
Figure 2. Changes in the transcription rate of the GOI (a) after adding various concentrations of 
RA to a model with a set of random parameters:  [CRABP1𝑡]=10 nM, [CRABP2𝑡]=1.9 µM, 
[CYP𝑡]=15 nM, [RAR𝑡]=0.17 µM. (b) after adding 1 µM of RA to various models with different 
sets of parameters; Green: [CRABP1𝑡]=1 nM, [CRABP2𝑡]=7.7 µM, [CYP𝑡]=3.5 nM, [RAR𝑡]=9 
nM. Red: [CRABP1𝑡]=10 nM, [CRABP2𝑡]=1.9 µM, [CYP𝑡]=15 nM, [RAR𝑡]=0.17 µM. Blue: 
[CRABP1𝑡]=2.6 nM, [CRABP2𝑡]=3.2 µM, [CYP𝑡]=0.1 µM, [RAR𝑡]=3 nM. 
 
The RA-induced transcription rate strongly depends on RA concentration and model 
parameters, i.e. initial concentrations of the RA receptors and kinetic rate constants (Fig. 2). 
The transcription rate peak time, duration of transcription, and transcription rate peak level 
can change or remain unchanged after modifying RA concentration or model parameters. 
In order to investigate the significance of the model’s unknown parameters in the regulation 
of GOI expression, we calculated the time integral of the transcription rate within 24 hours 
after RA treatment.   
Model Output = ∫ 𝐼max (𝐺𝑂𝐼) (
𝑓𝐺𝑂𝐼[RA: RAR]
𝑓𝐺𝑂𝐼[RA: RAR] + 𝑘𝑑(𝑇𝐹:𝐷𝑁𝐴)
)
24
0
 dt .                                  (6) 
  
 
19 
We then calculated the sensitivity of the model output to variations in the model 
parameters when the cells were treated with 1 nM of RA (Fig. 3). The model parameters, 
including total concentration of the RA binding proteins, kinetic rate constants, transcription 
factor fractions and maximal transcription rates were varied within their ranges of 
variability (full details in Supplementary Information in Section 2.6).  
 
 
Figure 3. Sensitivity ranking of the model parameters. The model output was set to the time 
integral of the transcription rate of the GOI within 24 hours after adding 1 nM of RA to the model. 
Blue bars indicate first-order sensitivity indices, while red bars represent total-effect sensitivity 
indices. The error bars show the bootstrap confidence intervals (95% confidence intervals) of the 
mean values [24]. Detailed parameter description is provided in Supplementary Information in 
Section 2.6. 
 
First-order and total-effect sensitivity indices of the model parameters indicated that the 
system performance was mainly controlled by the transcription factor fraction of the GOI 
(𝑓𝐺𝑂𝐼) and the total concentrations of RA binding receptors (Fig. 3). The sensitivity of the 
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output to variations in 𝑓𝐺𝑂𝐼 is trivial, since 𝑓𝐺𝑂𝐼 represents what portion of RARs can activate 
the transcription of the GOI.  
CRABP2 and RAR were the most and the least important RA receptors controlling RA-
mediated mRNA production when RA= 1 nM, respectively. CYP was the second most 
sensitive parameter in the model, followed by CRABP1. The maximal transcription rate of 
the GOI (𝐼𝑚𝑎𝑥(𝐺𝑂𝐼)) and the equilibrium dissociation constant of the transcription factor 
binding to DNA (𝑘𝑑(𝑇𝐹:𝐷𝑁𝐴)) were other sensitive parameters in the model (Fig. 3). The 
maximal transcription rate of a given gene can change from cell to cell since the elongation 
rate of the gene by RNA polymerase can vary across cell lines and across a population of 
cells of the same type [25]. RA upregulates the expression of the CRABP2, RAR and CYP 
genes [26]. We modeled these pathways using Eq. 4 with different values of transcription 
factor fractions and maximal transcription rates, i.e. 𝑓𝐶𝑅𝐴𝐵𝑃2, 𝑓𝑅𝐴𝑅 , 𝑓𝐶𝑌𝑃, 𝐼𝑚𝑎𝑥(𝐶𝑅𝐴𝐵𝑃2), 
𝐼𝑚𝑎𝑥(𝑅𝐴𝑅), and 𝐼𝑚𝑎𝑥 (𝐶𝑌𝑃) (see Supplementary Information in Section 2.6 for details). Our 
results, however, indicated that these pathways did not considerably affect the model output 
when RA= 1 nM, since the total-effect indices of 𝑓𝐶𝑅𝐴𝐵𝑃2, 𝑓𝑅𝐴𝑅 , 𝑓𝐶𝑌𝑃, 𝐼𝑚𝑎𝑥(𝐶𝑅𝐴𝐵𝑃2), 
𝐼𝑚𝑎𝑥(𝑅𝐴𝑅) and 𝐼𝑚𝑎𝑥 (𝐶𝑌𝑃) were smaller than 0.01 (Fig. 3).  
We then calculated the sensitivity indices of the model parameters when the model was 
treated with other concentrations of RA ranging from 10 nM to 1 µM. Our results showed 
that transcription factor fraction of the GOI, maximal transcription rate of the GOI and total 
concentration of RA binding receptors mainly controlled the system performance at all 
concentrations of RA (see Supplementary Information, Section 2.6, Fig. S1). Figure 4 
compares the sensitivity indices of RA binding proteins at various concentrations of RA.  
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Figure 4.  Significance of the RA binding proteins in influencing total mRNA production after 
treatment with various concentrations of RA. The blue bars show first-order sensitivity indices, 
while the red bars show total-effect sensitivity indices. The error bars indicate the bootstrap 
confidence intervals (95% confidence intervals) of the sensitivity indices. 
 
RAR is the least important protein in influencing mRNA production when the cells are 
treated with physiological levels of RA (1-10 nM). That is because RA is mainly bound to 
CRABP1, CRABP2 and CYP at low concentrations of RA, as those proteins have higher 
binding affinities than RAR for RA. Thus, variation in total concentration of RAR is less 
important than variations of the rest of RA binding proteins concentrations in changing the 
formation rate of RA:RAR, since there are not many free RA molecules available to bind 
to RARs at physiological levels of RA. However, a change in CRABP2, CRABP1 and CYP 
concentrations can remarkably accelerate or slow down the transport of RA molecules to 
RARs, which are mainly unbound at physiological conditions. In other words, RA is the 
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limiting and RAR is the excess species at physiological levels of RA, while RAR is the 
limiting and RA is the excess species at higher concentrations of RA.     
Total concentration of RAR is more important in influencing mRNA production when 
the RA concentration is RA=1 µM compared to physiological concentrations of RA. This 
is because RAR is close to saturation with RA at higher levels of RA, since there are more 
RA molecules accessible to RARs. Thus, enhancement of total RAR concentration can 
increase the activation rate of the transcription factor, which leads to an increase in the 
mRNA production rate according to Eq. 4. Figure 5 shows the variations of the RA binding 
receptors’ saturation indices at different concentrations of RA. The saturation index of each 
receptor is defined as the maximum value of the bound fraction of the receptor within 24 
hours after RA treatment. The bound fraction of a receptor changes over time, and is 
expressed as: 
Bound fraction of a receptor
=
Liganded receptor concentration
Liganded receptor concentration + free receptor concentration 
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Figure 5. Variation in the saturation index of various RA binding proteins at different 
concentrations of RA. 10000 points were randomly sampled, following a uniform distribution over 
a 44-dimensional parameter space. The models were treated with various concentrations of RA 
and the saturation indices were calculated.   
 
CRABP1 and CRABP2 are less important than RAR when the concentration of RA is 
1 µM, even though they are also close to saturation (Fig. 5). This is because RAR is almost 
saturated with RA at high levels of RA, and providing RARs with more RA molecules 
through changing CRABP1 and CRABP2 concentrations does not change the formation 
rate of activated RAR significantly.    
Another factor that makes RAR more important than other binding proteins in mRNA 
production at pharmacological conditions (RA= 0.1-1 µM) is the higher expression rate of 
CRABP2, RAR and CYP genes at pharmacological levels of RA compared to physiological 
levels. Total concentrations of RAR, CRABP2 and CYP increase after adding RA to the 
system. Figure 6 shows the variations in RA binding protein expression indices at different 
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RA concentrations. The expression index of each RA binding protein is defined as the 
average concentration of each RA binding protein within 24 hours after RA treatment, 
divided by the initial concentration of RA binding protein before the RA therapy. Our 
results show that the expression indices of all RA binding receptors increase with RA 
concentration. The expression indices of CRABP2 and CYP are larger than the expression 
index of RAR at all concentrations of RA. This is because CRABP2 and CYP have larger 
maximal transcription rates, translation constants, and smaller degradation rates than RAR 
(see Supplementary Information in Section 2.6).  
 
(a) 
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(b) 
 
 
(c) 
Figure 6. Variation in the expression index of (a) CRABP2, (b) CYP, (c) RAR at various 
concentrations of RA. 10000 points were randomly sampled following a uniform distribution over 
a 44-dimensional parameter space to generate this Figure. 
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The total concentration of CYP contributes almost equally to variations in mRNA 
production at all concentrations of RA (Fig. 4). This is because CYP level affects the 
concentrations of free CRABPs available for transferring RA to the nuclear receptors 
(according to Eq. 1 to Eq. 3).  
From Figure 4, it can be understood that CRABP2 is a more important factor in the RA 
signaling pathway when the model was treated with physiological levels of RA (1-10 nM) 
compared to pharmacological levels of RA (0.1-1 µM). This is because RAR is barely 
saturated with RA at physiological conditions, so that variations in CRABP2 concentration 
can significantly change the rate of RA transport to RARs. 
The fact that CRABP2 is more influential in mRNA production at physiological 
conditions compared to pharmacological conditions is in qualitative accordance with 
previous experimental studies [7]. A previous in vitro study [7] indicated that exogenous 
levels of CRABP2 increased the transcriptional activity of RAR only when the 
concentrations of RA or RAR were limiting (Fig. 7a-b). We performed a local sensitivity 
analysis to investigate the effect of a constant change in CRABP2 concentration on total 
mRNA production, over broad regions of RA and RAR concentrations. For this purpose, 
we sampled several sets of parameters within their ranges of variability, which characterized 
various cell types or various cells of the same type. We then calculated fold change values 
of the total mRNA production for each model after increasing CRABP2 concentration by 
200% (Fig. 7c). Our results indicated that for a vast majority of cell types, a constant change 
in CRABP2 concentration is more important in the RA signaling pathway at lower 
concentrations of RA. We also obtained fold change values of total mRNA production after 
increasing CRABP2 concentration by 200% in the absence or presence of exogenous levels 
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of RAR. Our results showed that variation of CRABP2 concentration is more important at 
lower concentrations of RAR. This result is in qualitative agreement with experimental 
observations [7] in COS-7 cells culture (Fig.7).  
  
(a) (b) 
  
(c) (d) 
 
Figure 7. Effects of CRABP2 on transcriptional activity of RAR at various levels of RA and 
RAR. COS-7 cells were transfected with a luciferase reporter construct driven by a RAR 
responsive element and the activity level of the reporter was measured in different conditions. (a) 
Luciferase activity level after adding exogenous levels of CRABP2 to the cells at various 
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concentrations of RA. Data are presented as fold induction relative to luciferase reporter activity 
level before overexpression of CRABP2. Experimental data was obtained from [7]. (b) Luciferase 
activity level after adding exogenous levels of CRABP2 to the cells, in the presence of 
endogenous RAR or upon overexpression of RAR.  Data are presented as fold induction relative to 
luciferase reporter activity level before overexpression of CRABP2. Experimental data was given 
from [7]. (c) Fold change in total mRNA production after increasing CRABP2 concentration by 
200%. Data are normalized by total mRNA production before CRABP2 overexpression. 10000 
points were randomly sampled following a uniform distribution over a 44-dimensional parameter 
space, to generate this Figure. (d) Fold change in total mRNA production after increasing 
CRABP2 concentration by 200% in the presence of endogenous RAR or exogenous RAR, i.e. 
RAR= 10 µM.  Data are normalized by total mRNA production before CRABP2 overexpression. 
10000 points were randomly sampled following a uniform distribution over a 44-dimensional 
parameter space, to generate this Figure.  
 
The total-effect sensitivity index of CRABP2 is larger than that of CRABP1 when RA= 
1-10 nM, while CRABP2 and CRABP1 contribute almost equally to variations in the model 
output when RA= 0.1-1 µM (Fig. 4).  Total-effect sensitivity indices should be used to 
compare the total contributions of different inputs to variations in the model response. For 
example, CRABP2 has a larger first-order sensitivity index than CRABP1 when RA 
concentration is 0.1 or 1 µM, while the total-effect sensitivity index of CRABP1 is slightly 
larger than that of CRABP2 (Fig. 4). This suggests that CRABP1 interacts stronger than 
CRABP2 with other parameters.   
The calculated sensitivity indices at each RA concentration indicate the relative 
importance of the parameters at the specified RA concentration. Thus, these indices cannot 
be used to compare the absolute values of the produced mRNA when the cells were treated 
with various levels of RA. CRABP2, for instance, has a larger sensitivity index in 
physiological concentration of RA compared to pharmacological concentrations.  However, 
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this does not mean that a change in CRABP2 concentration results in a larger variation in 
molar production of the mRNA at physiological levels of RA compared to the 
pharmacological concentration of RA. In general, with a fixed set of values for RA binding 
receptor concentrations, total mRNA production increases by RA dose.   
2.3.2.  RA degradation pathway  
RA metabolism is crucial in RA signaling not only because the CYP can limit the 
amount of RA available to interact with RARs, but also because some RA metabolites can 
induce the transcription of some target genes through specific pathways [27, 28]. 
Furthermore, RA resistance, observed in continuous RA treatment in cancer patients, is at 
least in part due to RA degradation. RA metabolism is mediated mainly by CYP enzymes, 
which are found in different cell types. Even though several studies have investigated the 
role of various families of CYP in biosynthesis of RA, little is known about the contribution 
of CRABPs and RARs in the RA degradation pathway. In this section we investigated the 
contributions of the RA binding receptors to production of RA metabolites. In our model, 
RA was only degraded via CYP enzymes, while interacting with CYP directly or indirectly. 
In the direct mechanism, free RA molecules can bind to CYP, while the indirect process 
involves CRABP1 and CRABP2 as carrier proteins that transfer RA to CYP. Thus, the total 
rate of RA degradation is obtained by 
d[RA metabolites]
dt
= 𝑘𝑜𝑛4[RA: CYP] + 𝑘𝑜𝑛10[RA: CRABP1: CYP] + 𝑘𝑜𝑛12[RA: CRABP2: CYP],                 (7) 
where 𝑘𝑜𝑛4, 𝑘𝑜𝑛10 and 𝑘𝑜𝑛12 are degradation rates of RA: CYP, RA: CRABP1: CYP and 
RA: CRABP2: CYP, respectively.   
We performed GSA to investigate the sensitivity of total RA metabolite production 
within 24 hours after RA therapy, to variations in the model’s unknown parameters.  
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Model Output = ∫ 𝑘𝑜𝑛4[RA: CYP] + 𝑘𝑜𝑛10[RA: CRABP1: CYP] + 𝑘𝑜𝑛12[RA: CRABP2: CYP]
24
0
 dt.            (8) 
As in the previous section, we considered physiological bounds for the parameters and 
used the Sobol’s method to calculate the sensitivity indices. Our results showed that the 
production of RA metabolites was mainly affected by cellular concentrations of the RA 
binding proteins (Fig. S2 in Supplementary Information, Section 2.6). CYP had the largest 
total-effect sensitivity index at all RA concentrations, which shows that total concentration 
of CYP was the most important parameter controlling the system performance (Fig. 8). 
CRABP1 and CRABP2 contribute almost equally to variation in the model response when 
RA= 1 nM, while CRABP1 is more important than CRABP2 in the RA degradation 
pathway when RA= 0.01-1 µM. 
 
Figure 8. Relative importance of various RA binding proteins in total RA metabolite 
formation at various concentrations of RA. The model output was set to total RA metabolite 
formation within 24 hours of treatment with various concentrations of RA. The blue bars show 
first-order sensitivity indices, while the red bars show total-effect sensitivity indices. The error 
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bars indicate the bootstrap confidence intervals (95% confidence intervals) of the sensitivity 
indices. 
 
RAR becomes more important in the RA degradation pathway as RA concentration 
increases. This can be explained by the fact that at high concentrations of RA, RAR is the 
most important parameter that controls RA-induced gene expression (Fig. 4). The cellular 
level of RAR can significantly influence RA-induced upregulation of CYP, CRABP2 and 
RAR. Our results indicated that RA-induced upregulation of CYP had significant effects on 
total RA metabolite formation when RA= 0.01-1 µM (see Section 2.6, Supplementary 
Information, Fig. S2). From Figure 8, it can be understood that for a given RA 
concentration, the rank order of first-order sensitivity indices of the parameters is not 
necessarily the same as the rank order of total-effect sensitivity indices. This is due to 
different levels of interaction of each parameter with the rest of the parameters. 
Furthermore, our results were obtained using GSA, which gives some insights into the 
functions of various receptors by covering the entire parameter space. However, it might be 
possible that for a specific set of initial concentrations the rank order of parameter 
sensitivities would be different. 
Comparing Figure 4 with Figure 8, one can observe that for a given RA concentration, 
the rank order of sensitivity of the RA binding receptors is not the same for total mRNA 
production and total RA metabolite formation. To further investigate the relationship 
between mRNA production and RA metabolite formation by the RA signaling pathway, we 
calculated Spearman’s rank correlation coefficient between total mRNA production and 
total RA product formation within 24 hours of treatment with 1 µM of RA. Our results 
revealed a significant negative correlation (ρ= - 0.7, p= 0, n= 10000) between total mRNA 
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production and total RA metabolite formation (Fig. 9). However, Spearman’s rank 
correlation coefficient decreased with the reduction of RA concentration (Section 2.6, 
Supplementary Information, Fig. S3). 
 
Figure 9. The relationship between total RA metabolite formation and total mRNA production 
within 24 hours of treatment with 1 µM of RA. 10000 points were randomly sampled following a 
uniform distribution over a 44-dimensional parameter space.   
 
One serious drawback of the clinical use of RA is that RA has a rapid and variable 
degradation rate [29, 30]. Thus, a relatively high concentration of RA is required to induce 
the expression of target genes in various cell types. The pattern of RA degradation is 
important since it can directly influence cell differentiation and gene expression by RA. In 
this section, we simulated the variations in total concentration of RA within 24 hours after 
RA treatment. For this purpose, we sampled several sets of parameters within their ranges 
of variability, which characterized various cell types or various cells of the same type. We 
then added 0.1 µM of RA to each model and obtained the changes in total RA concentration 
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over time. Our results showed that RA exhibited different elimination patterns depending 
on intracellular concentrations of the RA binding proteins, i.e. CRABP1, CRABP2, CYP 
and RAR (Fig. 10). Furthermore, RA can both down- and up-regulate its own degradation.  
 
Figure 10. Various forms of elimination of RA after treating different models with 0.1 µM of 
RA. Three models with various parameter sets are shown in blue, green and red. Green: 
[CRABP1𝑡]=8.6 µM, [CRABP2𝑡]=16.1 nM, [CYP𝑡]=11.2 nM, [RAR𝑡]=0.24 µM. Red: 
[CRABP1𝑡]=2.7 nM, [CRABP2𝑡]=11.4 nM, [CYP𝑡]=30 nM, [RAR𝑡]=0.22 µM. Blue: 
[CRABP1𝑡]=3 µM, [CRABP2𝑡]=11 nM, [CYP𝑡]=2.26 nM, [RAR𝑡]=0.71 µM. Full list of the 
models’ parameters is reported in Supplementary Information, Table S2. 
 
2.3.3.  Effects of the RA binding proteins on the efficacy and toxicity of RA 
An understanding of the roles and significance of RA binding proteins in the RA 
signaling pathway is important for both therapeutic and toxicological reasons. The results 
presented in this study can be used to develop pharmacological methods to increase the 
maximal response produced by RA. These pharmacological approaches can vary depending 
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on cancer type, as different cell types have different expression levels of RA binding 
proteins. For example, in pharmacological conditions (RA= 1 µM), induction of expression 
of the RAR gene or inhibition of expression of the CYP gene have more significant effects 
than overexpression of the CRABP2 gene on the expression levels of the GOI in a given cell 
type (Fig. 4). To further investigate how the total mRNA production at various RA 
concentrations is sensitive to variation in each RA binding protein concentration, we 
performed a local sensitivity analysis. In this regard, 10000 sets of parameters were 
randomly sampled, following a uniform distribution over a 44-dimensional parameter 
space. Variation in the total mRNA production was calculated for each model after 
increasing the concentration of each RA binding protein by 25% while the rest of the 
parameters remained unchanged (Fig. 11).   
 
 
Figure 11. Variation in total mRNA production after a 25% increase in each RA binding 
protein concentration, while the rest of the parameters are constant. 10000 points were randomly 
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sampled following a uniform distribution over a 44-dimensional parameter space, to generate this 
Figure.   
 
Our results indicate that a 25% increase in CRABP1 or CRABP2 concentrations is more 
important at physiological concentrations of RA compared to pharmacological 
concentrations, which is in accordance with our global sensitivity analysis results (Fig. 4). 
CRABP2 is the most influential protein at physiological concentration, while RAR and CYP 
are the most important proteins when RA= 1 µM. From Figure 11, it can be understood that 
a 25% increase in the total concentration of RAR enhances mRNA production for all 
models. A 25% increase in total concentration of CYP and CRABP1 decreases total mRNA 
production for most of the models, while a 25% increase in CRABP2 concentration 
enhances total mRNA production for the majority of models. In general, the way that the 
variation in total concentrations of CRABP1, CRABP2 or CYP affects mRNA production 
depends on the cellular concentrations of all RA binding receptors. Overexpression of 
CRABP1, for example, can increase or decrease the transcriptional activity of the target 
gene, depending on total concentrations of the other RA receptors. This is because these 
proteins complex with each other in the absence or presence of RA.  
The results presented in this paper can provide insight into the efficacy and safety of 
RA therapy in treatment of different cancer types and cancer patients. CRABP1, CRABP2, 
CYP and RAR expressions can be upregulated or downregulated depending on the cancer 
type [31-34] and administrated anticancer drugs [35, 36]. Cancer patients usually take 
different medications at the same time. Concurrent use of other drugs with RA can influence 
the RA signaling pathway in at least two ways. First, interaction with other medicines can 
cause variations in the pharmacokinetics and pharmacodynamics of RA, significantly 
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changing its efficacy and toxicity. For instance, it is possible that two or more drugs 
compete for the same CYP enzyme in a cancer cell, since CYP-mediated metabolism is a 
major route of elimination for many drugs. This competitive inhibition can decrease the 
availability of CYP enzymes to RA, therefore decreasing its metabolism rate and increasing 
its toxicity. Second, some drugs can inhibit or induce the expression of RA binding proteins 
such as CYP [34, 35]. Variations in the concentrations of RA binding proteins may affect 
the efficacy of RA over the course of cancer therapy. For instance, CRABP1 and CRABP2 
are the least important parameters in the model when RA= 1 µM (Fig. 4). Thus, up-
regulation or down-regulation of these proteins due to other factors such as disease progress, 
drug interactions, etc should not change the rate of mRNA production by RA significantly. 
However, if for example use of a strong RAR inhibitor or CYP inducer is unavoidable for 
the patient, the therapeutic effects of RA may be decreased significantly.  
 
 
2.4. Discussion 
Retinoic acid, a metabolite of vitamin A, modulates a wide variety of biological 
processes such as cell growth, cell differentiation and cell proliferation. RA has also been 
known to be effective in treatment of various types of cancer. Even though a vast number 
of studies have focused on exploring the regulatory target genes for RA, the significance 
and roles of various intracellular RA receptors in transduction of the RA signal have not 
been fully understood. CRABP1, CRABP2, CYP enzymes and RARs are the main 
intracellular proteins which can bind to RA as receptors. Few previous studies have 
attempted to investigate the effects of overexpression of CRABPs on the RA signaling 
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pathway, and in some cases somewhat contradictory results have been reported for different 
cell lines [2-4]. In this study, we developed a mathematical model to analyze the importance 
of CRABP1, CRABP2, CYP and RAR in production of mRNA and RA metabolites. In this 
regard, after proposing a well-mixed model of the RA signaling pathway, we performed a 
global sensitivity analysis to investigate the relative importance of RA binding receptors in 
total mRNA production via the RA pathway. Our results indicate that CRABP2 is the most 
important RA receptor at physiological levels of RA, while RAR concentration has the least 
importance among all four RA receptors. At pharmacological levels of RA, the total mRNA 
production was more sensitive to variations in RAR and CYP levels than CRABP1 and 
CRABP2 levels. It is important to note that all RA binding receptors could influence RA-
induced mRNA production within the entire region of parameter space where the 
concentrations of RA binding proteins change considerably. They are all important since 
their sensitivity indices were of the same order of magnitude. These results can explain the 
conflict between previous experimental results regarding the effects of CRABP1 on 
transcriptional activity of target genes [1, 3, 4]. Our results were obtained using GSA, which 
quantifies the effects of the model inputs on the model output by perturbing the inputs 
within large ranges. Therefore, our results indicate that in a broader region of parameter 
space, which represents various cells with various levels of RA receptors, all of the RA 
binding receptors are influential. However, there is a possibility that for a certain parameter 
set which specifies a specific tissue or cell, CRABP1 is unimportant in the RA pathway. 
Thus, for a given cell type, an accurate parameter set is necessary to determine whether a 
parameter has a substantial control on the system performance.  
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Our local sensitivity analysis indicated that CRABP2 is more important in the RA 
signaling pathway at lower concentrations of RA or RAR. This result is in qualitative 
agreement with in vitro observations in COS-7 cells[7]. Our model can be applied to various 
cell types and our results can be validated experimentally once more information is 
available about the expression levels of RA binding proteins in the cell types of interest.  
Our GSA analysis indicated that RAR-mediated increases in CRABP2 and CYP 
concentrations after RA therapy were more important in the regulation of GOI expression 
than the RAR-mediated increase in RAR concentration (see Supplementary Information in 
Section 2.6, Fig. S1). This is because total-effect sensitivity indices of 𝐼𝑚𝑎𝑥(𝐶𝑅𝐴𝐵𝑃2) and 
𝐼𝑚𝑎𝑥 (𝐶𝑌𝑃) were larger than total-effect sensitivity index of 𝐼𝑚𝑎𝑥(𝑅𝐴𝑅). Furthermore, total-
effect sensitivity indices of 𝑓𝐶𝑅𝐴𝐵𝑃2 and 𝑓𝐶𝑌𝑃 were larger than total-effect sensitivity index 
of 𝑓𝑅𝐴𝑅 at all concentrations of RA (Supplementary Information in Section 2.6, Fig. S1).  
The time-dependent increases of CRABP2, CYP and RAR concentrations after RA therapy 
can alter the relative concentrations of RA binding proteins. Thus, RA receptors can become 
increasingly or decreasingly important in the RA signaling pathway as time goes on. In this 
study, we calculated the sensitivity of the model’s outputs, i.e. total mRNA production and 
total RA metabolite formation, to variations in total concentrations of the RA binding 
receptors before RA treatment. Thus, the significance of RAR-mediated upregulation of 
CRABP2, CYP and RAR genes in the RA signaling pathway is mainly shown by the 
sensitivity index of total RAR concentration, since RAR is the only RA receptor mediating 
the transcription of target genes. 
This study has some limitations. First, we assumed that RA influences gene expression 
through the classical pathway, which involves binding of RA to a nuclear hormone receptor 
  
 
39 
heterodimer (RAR:RXR). The liganded heterodimer can initiate the transcription of target 
genes after binding to a DNA response element. However, there may be other intermediate 
transcription factors or nonclassical pathways that can transduce RA signal, thus our results 
can only be applied to the genes which are direct targets of the classical RA signaling 
pathway. Second, we assumed that all RA binding proteins undergo first-order degradation 
processes. This may not be the case for all types of tissues with various expression levels 
of degradation enzymes. The mechanisms mediating the elimination of RA binding 
receptors have not been fully understood, thus the model can be improved once more 
information regarding these mechanisms is available. Third, we used the kinetic rate 
constants of CYP26B1 in the model.  CYP26B1 is a member of the 26 family (CYP26s) of 
the CYP enzymes which is mainly responsible for metabolism of RA during adult life [6, 
37-39]. However, RA can also be degraded by other families of CYP which are different 
from CYP26B1 in terms of rate constants and binding affinities. In the current model, we 
assumed that the kinetic rate constants of degrading enzymes can vary by a factor of two 
around the in vitro values for CYP26B1. This assumption increases the applicability of our 
results to other cell types with different types of CYP. Thus, our results are applicable to 
those cell lines that express higher levels of CYP26B1 compared to other CYP families and 
to those cell types which have CYP enzymes with kinetic rate constants within the specified 
ranges in this study. The current simulation can be run using the kinetic rate constants of 
any arbitrary CYP enzyme. In that case, this model can be expanded to include the effects 
of RA metabolites on RA-induced gene expression if the CYP of interest forms high levels 
of active RA metabolites. The current model is applicable to those cell types whose main 
degrading enzyme is CYP26B1. The primary metabolite formed by CYP26B1 from RA is 
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4-OH-RA [40, 41]. CYP26B1 forms non-bioactive dehydroxylated products from 4-OH-
RA[41]. Thus, we believe that the endogenous levels of RA metabolites formed by 
CYP26B1 do not play significant roles in the RA signaling pathway. However, there are 
other active RA metabolites such as 4-oxo-RA which can potentially compete with RA for 
binding to RAR and activate the transcription of target genes [28]. Fourth, we neglected the 
possible effects of RA treatment on the model parameters such as translation rate constants, 
transcription rate constants, and degradation rate constants of proteins and mRNAs. Fifth, 
for simplicity, we proposed a well-mixed model, thus our model is not able to capture the 
dynamics of protein diffusion through the nuclear membrane. RARs are located inside the 
cell nucleus. RA must diffuse across the nucleus membrane to be able to bind to RARs. In 
reality, RA binds to CRABPs after diffusing across the cellular membrane. RA can diffuse 
across the nuclear membrane alone or bound to CRABPs. We believe that our well-mixed 
model can approximate this process due to the rank order of binding affinity of RA for 
various RA receptors. RA binds to CRABP1 and CRABP2 with higher affinity than to RAR, 
which implies that RA is primarily available for CRABPs. The remaining RA molecules 
can bind to RARs and CYP enzymes. Finally, we assumed that the ratio of total transcription 
factor concentration to total RAR concentration (𝑓) remains constant after adding RA to the 
cell. However, this depends on the gene- and cell-type. It is believed that RARs and RXRs 
each have three isotypes, namely RARα, RARβ, RARγ, RXRα, RXRβ, RXRγ, which can form 
nine different heterodimers. Depending on the gene-type, one or some of these heterodimers 
can initiate the transcription of the target gene after binding to RA. Little is known about 
the expression levels of the nuclear hormone receptors in various cell types, and their 
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interactions with each other.  The model presented in this paper can be expanded once there 
is more information about the nuclear hormone receptor expression levels and functions.  
 
2.5. Conclusions  
Cellular levels of retinoic acid receptor (RAR), cytochrome P450 (CYP) enzymes and 
cellular retinoic acid binding proteins (CRABP1 and CRABP2) significantly affect the rate 
of gene expression through the classical retinoic acid (RA) signaling pathway. In this study, 
we used computational modeling to investigate the significance of various RA binding 
proteins in the regulation of expression of a gene of interest (GOI) under physiological or 
pharmacological conditions. A better understanding of the roles and significance of RA 
binding proteins in the RA signaling pathway could lead to the development of 
pharmacological methods to induce or block the activity of specific RA binding receptor 
(s), thereby improving the efficacy of the RA. Our results indicate that CRABP2 and CYP 
concentrations are more influential than CRABP1 and RAR concentrations in controlling 
mRNA production by the RA signaling pathway in physiological concentrations of RA (1-
10 nM). However, RAR is the most sensitive parameter of the model in pharmacological 
conditions (RA=0.1-1 µM). We also identified the critical proteins in the RA metabolism 
pathway, and showed that there is a significant negative correlation between RA-induced 
mRNA production and RA metabolite formation after 24 hours of treatment with 1 µM of 
RA. Our results demonstrate that the pattern of RA degradation following RA therapy 
depends on the cell type.  
 
2.6. Supplementary Information 
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2.6.1. Formulation of the model 
The model described how RA is eliminated from the cell by CYP enzymes. CYP 
enzymes can metabolize not only free RA but also RA molecules bound to CRABP1 and 
CRABP2 [6]. RA degradation was modeled by Michaelis-Menten kinetics with in vitro 
enzyme kinetics parameters  
E + S
𝑘𝑑
⇔ES
𝑘𝑐𝑎𝑡
⇒  E + Product, 
𝐾𝑀 =
𝑘𝑜𝑓𝑓 + 𝑘𝑐𝑎𝑡
𝑘𝑜𝑛
 , 
𝑘𝑑 =
𝑘𝑜𝑓𝑓
𝑘𝑜𝑓𝑓
 , 
where 𝐾𝑀 and 𝑘𝑑 are the Michaelis constant and the equilibrium dissociation constant of 
the enzyme substrate complex. Formation of products from RA:CRABP1 had a 𝑘𝑑 of 0.024 
nM and a 𝐾𝑀 of 21.7 nM, while formation of products from RA:CRABP2 had a 𝑘𝑑 of 0.059 
nM and a 𝐾𝑀 of 24.3 nM [6]. The 𝐾𝑀 value was set at 64.6 nM for the interaction between 
CYP and free RA, while the equilibrium dissociation constant of RA:CYP complex was 
unknown. Formation of RA metabolites had catalytic rate constants of 10.2, 16.8 and 27 
1/ℎ𝑟 from RA:CRABP1, RA:CRABP2 and free RA, respectively [6].   
Most of the cellular impacts of RA rely on variation in gene expression. The expression 
of a gene of interest (GOI) is initiated once the activated transcription factor (TF𝑎) binds to 
DNA at a retinoic acid response element (RARE). RAR/RXR heterodimer is the main 
transcription factor in the classical RA signaling pathway, and becomes activated once it 
binds to RA. The transcription rate of a target gene depends on the promoter occupancy. 
The binding of an activated transcription factor to a promoter can be described by 
TF𝑎 + Promoter
𝑘𝑑(𝑇𝐹:𝐷𝑁𝐴)
⇔       TF𝑎: Promoter 
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where 𝑘𝑑(𝑇𝐹:𝐷𝑁𝐴) is the equilibrium dissociation constant of the transcription factor binding 
to the promoter, and ranges from 15 to 33 nM [42]. The fraction of time that any given 
promoter spends in the transcription factor-bound state is given by [43-45] 
Fraction of binding time =
[TF𝑎]
[TF𝑎] + 𝑘𝑑(𝑇𝐹:𝐷𝑁𝐴)
 .                                                                 (S1) 
The rate of the gene transcription is proportional to the fraction of the binding time, 
𝐼
𝐼max (𝐺𝑂𝐼)
=
[TF𝑎]
[TF𝑎] + 𝑘𝑑(𝑇𝐹:𝐷𝑁𝐴)
 ,                                                                                              (S2) 
where 𝐼max (𝐺𝑂𝐼) is the maximal transcription rate of the GOI by the activated transcription 
factor (TF𝑎). The value of 𝐼max (𝐺𝑂𝐼) depends on gene-type, cell-type and the transcription 
factor [16]. RA can regulate the expression of RAR, CRABP2 and CYP genes [26]. The 
values of 𝐼max (𝑅𝐴𝑅), 𝐼max (𝐶𝑅𝐴𝐵𝑃2) and 𝐼max (𝐶𝑌𝑃) were set at  4.1 × 10
−11, 1.5 × 10−10,  and  
1.06 × 10−10  
M
hr
, respectively. These values were obtained by dividing the average elongation 
rate of RNA polymerase by the gene lengths. The average elongation rate for RNA 
polymerase is 2 
kbp
min
  [46], while the lengths of RAR, CRABP2 and CYP genes are 48.4 kbp 
(chr 17, GRCh38.p7), 13.4 kbp (chr 1, GRCh38.p7) and 18.6 kbp (chr 2, GRCh38.p7), 
respectively [47-49].   
Assuming that RA binds to various RAR isoforms with the same binding affinity, the 
ratio of the activated transcription factor (TF𝑎) concentration to the total transcription factor 
(TF𝑡) concentration is the same as the ratio of the liganded RAR concentration to total RAR 
concentration, thus 
[TF𝑎]
[TF𝑡]
=
[RA: RAR]
[RAR𝑡]
                                                                                                                      (S3) 
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The concentration of total transcription factor which can activate the transcription of the 
GOI is a portion of the concentration of total RAR, 
𝑓𝐺𝑂𝐼 =
[TF𝑡]
[RAR𝑡]
                                                                                                                              (S4) 
where  𝑓𝐺𝑂𝐼 represents the transcription factor fraction of the GOI with a value between 0 
and 1. Transcription factor fraction is cell-dependent for a given gene. The rate of mRNA 
production via the RA pathway is obtained by combining Eqs. S2 to S4. 
𝐼
𝐼max (𝐺𝑂𝐼)
=
𝑓𝐺𝑂𝐼[RA: RAR]
𝑓𝐺𝑂𝐼[RA: RAR] + 𝑘𝑑(𝑇𝐹:𝐷𝑁𝐴)
 .                                                                             (S5) 
It is important to note that we assumed that the association/dissociation between DNA 
and transcription factor is in equilibrium because it occurs much faster than the other 
binding/unbinding reactions in the model [43, 50-52]. 
In our model, proteins and mRNAs are degraded by first-order reactions. Species are 
degraded in both bound and unbound forms. For example, CRABP1:CYP may undergo 
either CRABP1 degradation or CYP degradation.  
CRABP2, CYP and RAR genes had both basal transcription rate (𝐼0) and RA-induced 
transcription rate (Eq. S5), while CRABP1 had a constant rate of protein expression, since 
CRABP1 gene is not a target for RA [26, 53].   
The full set of reactions and rate constants in the current model are shown in Table 2 
and Table S1, respectively.  
We then modeled the chemical reactions by ODEs.  
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d[RA]
dt
= −𝑘𝑜𝑛1[RA][CRABP1] + 𝑘𝑜𝑓𝑓1[RA: CRABP1] − 𝑘𝑜𝑛2[RA][CRABP2] + 𝑘𝑜𝑓𝑓2[RA: CRABP2]
− 𝑘𝑜𝑛3[RA][CYP] + 𝑘𝑜𝑓𝑓3[RA: CYP] − 𝑘𝑜𝑛5[RA][RAR] + 𝑘𝑜𝑓𝑓5[RA: RAR] + 𝑘𝑜𝑛21[𝑅𝐴: 𝐶𝑅𝐴𝐵𝑃1]
+ 𝑘𝑜𝑛22[RA: CRABP2]
+ 𝑘𝑜𝑛23[RA: RAR]                                                                                                                             (S6) 
 
d[CRABP1]
dt
= −𝑘𝑜𝑛1[RA][CRABP1] + 𝑘𝑜𝑓𝑓1[RA: CRABP1] − 𝑘𝑜𝑛17[CRABP1] + 𝐾 − 𝑘𝑜𝑛15[CYP][CRABP1]
+ 𝑘𝑜𝑓𝑓15[CYP: CRABP1]
+ 𝑘𝑜𝑓𝑓28[CYP: CRABP1]                                                                                                                  (S7) 
 
d[RA: CRABP1]
dt
= 𝑘𝑜𝑛1[RA][CRABP1] − 𝑘𝑜𝑓𝑓1[RA: CRABP1] − 𝑘𝑜𝑛21[RA: CRABP1] − 𝑘𝑜𝑛9[CYP][RA: CRABP1]
+ 𝑘𝑜𝑓𝑓9[RA: CRABP1: CYP]                                                                                                                                           (S8) 
 
d[CRABP2]
dt
= −𝑘𝑜𝑛2[RA][CRABP2] + 𝑘𝑜𝑓𝑓2[RA: CRABP2] + 𝑘𝑜𝑛25[𝐶𝑅𝐴𝐵𝑃2mRNA]−𝑘𝑜𝑛16[CYP][CRABP2]
+ 𝑘𝑜𝑓𝑓16[CYP: CRABP2] + 𝑘𝑜𝑛30[CYP: CRABP2] + kon14[RA: CRABP2: RAR]
− 𝑘𝑜𝑛18[CRABP2]                                                                                                                                                          (S9) 
 
d[RA: CRABP2]
dt
= 𝑘𝑜𝑛2[RA][CRABP2] − 𝑘𝑜𝑓𝑓2[RA: CRABP2] − 𝑘𝑜𝑛22[RA: CRABP2] − 𝑘𝑜𝑛13[RA: CRABP2][RAR]
+ 𝑘𝑜𝑓𝑓13[RA: CRABP2: RAR] − 𝑘𝑜𝑛11[RA: CRABP2][CYP]
+ 𝑘𝑜𝑓𝑓11[RA: CRABP2: CYP]                                                                                                                                      (S10) 
 
d[CYP]
dt
= −𝑘𝑜𝑛15[CYP][CRABP1] + 𝑘𝑜𝑓𝑓15[CYP: CRABP1]−𝑘𝑜𝑛16[CYP][CRABP2]
+ 𝑘𝑜𝑓𝑓16[CYP: CRABP2] + 𝑘𝑜𝑛8[𝐶𝑌𝑃mRNA] − 𝑘𝑜𝑛9[CYP][RA: CRABP1]
+ 𝑘𝑜𝑓𝑓9[RA: CYP: CRABP1] − 𝑘𝑜𝑛11[RA: CRABP2][CYP] + 𝑘𝑜𝑓𝑓11[RA: CRABP2: CYP]
+ 𝑘𝑜𝑛27[CRABP1: CYP] + 𝑘𝑜𝑛29[CRABP2: CYP] − 𝑘𝑜𝑛19[CYP]
+ 𝑘𝑜𝑛4[RA: CYP]                                                                                                                         (S11) 
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d[RA: CYP]
dt
= 𝑘𝑜𝑛3[RA][CYP] − 𝑘𝑜𝑓𝑓3[RA: CYP]
− 𝑘𝑜𝑛4[RA: CYP]                                                                                                                        (S12) 
 
d[RAR]
dt
= −𝑘𝑜𝑛5[RA][RAR] + 𝑘𝑜𝑓𝑓5[RA: RAR] − 𝑘𝑜𝑛20[RAR] − 𝑘𝑜𝑛13[RA: CRABP2][RAR]
+ 𝑘𝑜𝑓𝑓13[RA: CRABP2: RAR]
+ 𝑘𝑜𝑛6[𝑅𝐴𝑅mRNA]                                                                                                                   (S13) 
 
d[RA: RAR]
dt
= 𝑘𝑜𝑛5[RA][RAR] − 𝑘𝑜𝑓𝑓5[RA: RAR] + 𝑘𝑜𝑛30[RA: CRABP2: RAR]
− 𝑘𝑜𝑛23[RA: RAR]                     (S14) 
d[𝑅𝐴𝑅mRNA]
dt
= 𝐼0(𝑅𝐴𝑅) + 𝐼𝑚𝑎𝑥 (𝑅𝐴𝑅) (
𝑓𝑅𝐴𝑅[RA: RAR]
𝑓𝑅𝐴𝑅[RA: RAR] + 𝑘𝑑(𝑇𝐹:𝐷𝑁𝐴)
)
− 𝑘𝑜𝑛24[𝑅𝐴𝑅mRNA]                                                                                                                (S15) 
d[𝐶𝑅𝐴𝐵𝑃2mRNA]
dt
= 𝐼0(𝐶𝑅𝐴𝐵𝑃2) + 𝐼𝑚𝑎𝑥 (𝐶𝑅𝐴𝐵𝑃2) (
𝑓𝐶𝑅𝐴𝐵𝑃2[RA: RAR]
𝑓𝐶𝑅𝐴𝐵𝑃2[RA: RAR] + 𝑘𝑑(𝑇𝐹:𝐷𝑁𝐴)
)
− 𝑘𝑜𝑛25[𝐶𝑅𝐴𝐵𝑃2mRNA]                                                                                                        (S16) 
d[𝐶𝑌𝑃mRNA]
dt
= 𝐼0(𝐶𝑌𝑃) + 𝐼𝑚𝑎𝑥 (𝐶𝑌𝑃) (
𝑓𝐶𝑌𝑃[RA: RAR]
𝑓𝐶𝑌𝑃[RA: RAR] + 𝑘𝑑(𝑇𝐹:𝐷𝑁𝐴)
)
− 𝑘𝑜𝑛26[𝐶𝑌𝑃mRNA]                                                                                                                           (S17) 
d[RA: CRABP1: CYP]
dt
= 𝑘𝑜𝑛9[CYP][RA: CRABP1] − 𝑘𝑜𝑓𝑓9[RA: CRABP1: CYP]
− 𝑘𝑜𝑛10[RA: CRABP1: CYP]                                                                                                           (S18) 
d[RA: CRABP2: RAR]
dt
= 𝑘𝑜𝑛13[RA: CRABP2][RAR] − 𝑘𝑜𝑓𝑓13[RA: CRABP2: RAR]
− 𝑘𝑜𝑛14[RA: CRABP2: RAR]                                                                                                         (S19) 
d[RA: CRABP2: CYP]
dt
= 𝑘𝑜𝑛11[CYP][RA: CRABP2] − 𝑘𝑜𝑓𝑓11[RA: CRABP2: CYP]
− 𝑘𝑜𝑛12[RA: CRABP2: CYP]                                                                                                         (S20) 
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d[CRABP1: CYP]
dt
= 𝑘𝑜𝑛15[CYP][CRABP1] − 𝑘𝑜𝑓𝑓15[CRABP1: CYP] − 𝑘𝑜𝑛27[CRABP1: CYP] − 𝑘𝑜𝑛28[CRABP1: CYP]
+ 𝑘𝑜𝑛10[RA: CRABP1: CYP]                                                                                                         (S21) 
d[CRABP2: CYP]
dt
= 𝑘𝑜𝑛16[CYP][CRABP2] − 𝑘𝑜𝑓𝑓16[CRABP2: CYP] − 𝑘𝑜𝑛29[CRABP2: CYP] − 𝑘𝑜𝑛30[CRABP2: CYP]
+ 𝑘𝑜𝑛12[RA: CRABP2: CYP]                                                                                                         (S22) 
 
where the numbers in the subscripts of the rate constants refer to the index of the reactions 
(Table 2).   
The model had 14 independent unknown parameters including unknown rate constants, 
unknown initial concentrations and unknown transcription factor fractions (Main Text, 
Table 3). We considered some physiological bounds for the unknown parameters. We also 
assumed that the values of maximal transcription rate constants, translation rate constants, 
forward and reverse rate constants, equilibrium dissociation rate constants, Michaelis 
constants, catalytic rate constants and elimination rates of proteins and mRNAs varied 
within a factor of two around the in vitro values. Overall, our model had 44 independent 
parameters varying within their ranges. 
 
 
2.6.2. Uncertainty Analysis of the Model 
The independent parameters were sampled uniformly over their range of possible values 
(number of samples=10000). The rest of the unknown parameters (Table S1), and the 
unknown initial concentrations (Main Text, Table 1) were obtained using the independent 
parameters.  To do so, we assumed that the system was at steady state prior to RA treatment. 
After obtaining all the parameters, the model was used to obtain total mRNA production 
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within 24 hours of RA treatment. We then used a GSA technique to assess the sensitivity 
of the model output to variations in model inputs.    
 
2.6.3. Global Sensitivity Analysis  
In this study, we used a MATLAB toolbox for global sensitivity analysis, called SAFE 
[18]. We ranked the model’s parameters in terms of their importance using Sobol’s method, 
which has been shown to be one of the most effective GSA methods for determining 
individual and cooperative sensitivities [54-56]. Sobol’s method is a variance-based 
sensitivity analysis approach that uses the principle of variance decomposition to obtain the 
sensitivity of each parameter. Given an integrable function 𝑓 over a k-dimensional 
parameter space Ω𝑘,  
𝑦 = 𝑓(𝑥1, 𝑥2, … , 𝑥𝑘)                                                                                                             (S23)  
Sobol’s method decomposes the response into a set of functions of increasing 
dimensionality, 
𝑓(𝑥) = 𝑓0 +∑𝑓𝑖
𝑘
𝑖=1
+∑∑𝑓𝑖𝑗
𝑘
𝑗>𝑖
𝑘
𝑖=1
+⋯+ 𝑓123…𝑘    ,                                                                 (S24) 
where each individual term is a function of the parameters in its index. The unconditional 
variance of the output 𝑉(𝑌) is defined as  
𝑉(𝑌) = ∫ 𝑓2(𝑥) 𝑑𝑥 − ( ∫ 𝑓(𝑥) 𝑑𝑥
Ω𝑘
)2
Ω𝑘
.                                                                               (S25) 
The total variance is decomposed into partial variances using the expansion of 𝑓 into 
terms of increasing dimensions (Eq. S24).  
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𝑉(𝑌) =∑𝑉𝑖(𝑌)
𝑘
𝑖=1
+∑∑𝑉𝑖𝑗(𝑌)
𝑘
𝑗>𝑖
𝑘
𝑖=1
+⋯+ 𝑉123…𝑘(𝑌) .                                                       (S26) 
Based on Sobol’s method, the first-order sensitivity index for each parameter is 
calculated by 
𝑆𝑖 =
𝑉𝑖(𝑌)
𝑉(𝑌)
 ,                                                                                                                                  (S27) 
where 𝑉𝑖(𝑌) is the fraction of the total variance, which is related to changes in the parameter 
𝑥𝑖 over its range of variability. The Sobol total-effect index for the parameter 𝑥𝑖  is obtained 
by the sum of all sensitivity indices which have 𝑖 in their index 
𝑆𝑇𝑖 = 𝑆𝑖 +∑𝑆𝑖𝑗
𝑖≠𝑗
+ ∑ 𝑆𝑖𝑗𝑙
𝑖≠𝑗,𝑖≠𝑙,𝑗<𝑙
+⋯                                                                                 (S28) 
The total-effect indices account for total contribution of the input to response variation. 
Total-effect indices can be used to determine the noninfluential parameters in the model. 𝑥𝑖 
can be fixed anywhere within its range of uncertainty if  𝑆𝑇𝑖 = 0. However, previous studies 
have shown that parameters with total-effect indices smaller than 0.01 can be considered 
noninfluential [21-23]. 
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Table S1. Reaction rate constants 
 𝒌𝒐𝒏 𝒌𝒐𝒇𝒇 
Number Range Unit Reference Range Unit Reference 
1 2.13e11 M−1hr−1 [5] 13.2 hr−1 [5] 
2 1.85e11 M−1hr−1 [5] 25.2 hr−1 [5] 
3 Unknown M−1hr−1  Unknown hr−1  
4 27 hr−1 [6] -   
5 Unknown* M−1hr−1  36-140 hr−1 [57] 
6 135.6 hr−1 [16] -   
7 870.7 hr−1 [16] -   
8 190.4 hr−1 [16] -   
9 Unknown M−1hr−1  Unknown hr−1  
10 10.2 hr−1 [6] -   
11 Unknown M−1hr−1  Unknown hr−1  
12 16.8 hr−1 [6] -   
13 Unknown M−1hr−1  Unknown hr−1  
14 Unknown hr−1  -   
15 Unknown M−1hr−1  Unknown hr−1  
16 Unknown M−1hr−1  Unknown hr−1  
17 0.0385 hr−1 [58] -   
18 0.0385 hr−1 [58] -   
19 0.00835 hr−1 [16] -   
20 0.173 hr−1 [14] -   
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21 0.0385 hr−1 [58] -   
22 0.0385 hr−1 [58] -   
23 0.173 hr−1 [14] -   
24 0.138 hr−1 [59] -   
25 0.0347 hr−1 [60] -   
26 0.11 hr−1 [16] -   
27 0.0385 hr−1 [58] -   
28 0.00835 hr−1 [16] -   
29 0.0385 hr−1 [58] -   
30 0.00835 hr−1 [16] -   
* Forward rate constant of reaction 5 is obtained using an equilibrium dissociation constant between 
6 and 20 nM [51, 57].   
 
 
 
 
Table S2. Randomly sampled parameters of the models shown in Figure 10. 
Parameters Blue curve Green curve Red curve 
CRABP1 2.99E-06 8.60E-06 2.73E-09 
CRABP2 1.09E-08 1.61E-08 1.14E-08 
CYP 2.26E-09 1.12E-08 2.91E-08 
RAR 7.08E-07 2.36E-07 2.22E-07 
𝑘𝑑3 1.72E-08 2.68E-08 2.45E-08 
𝑘𝑜𝑛13 4.25E+09 1.2E+10 2E+10 
𝑘𝑑13 7.88E-10 1.60E-10 1.84E-10 
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𝑘𝑜𝑛14 152.592 74.9655 72.16303 
𝑘𝑜𝑛15 2.58E+10 1.85E+10 1.96E+10 
𝑘𝑜𝑛16 7.51E+09 2.96E+10 3.46E+10 
𝑓𝑅𝐴𝑅 0.790299 0.083393 0.332411 
𝑓𝐶𝑅𝐴𝐵𝑃2 0.116596 0.543783 0.287017 
𝑓𝐶𝑌𝑃 0.826228 0.558422 0.03116 
𝑓𝐺𝑂𝐼 0.592287 0.978981 0.404229 
𝑘𝑜𝑛6 103.5768 75.87115 71.91922 
𝑘𝑜𝑛7 439.5742 962.9376 978.0601 
𝑘𝑜𝑛8 145.5691 276.7654 234.8322 
𝑘𝑜𝑛18 0.067334 0.051427 0.049882 
𝑘𝑜𝑛19 0.005092 0.005032 0.014976 
𝑘𝑜𝑛20 0.227853 0.125652 0.149364 
𝑘𝑜𝑛24 0.245181 0.074328 0.119889 
𝑘𝑜𝑛25 0.049549 0.027726 0.049374 
𝑘𝑜𝑛26 0.146517 0.154336 0.12501 
𝐼max (𝑅𝐴𝑅) 7.17E-11 6.33E-11 3.20E-11 
𝐼max (𝐶𝑅𝐴𝐵𝑃2) 2.61E-10 8.20E-11 7.56E-11 
𝐼max (𝐶𝑌𝑃) 1.37E-10 1.99E-10 9.54E-11 
𝐼max (𝐺𝑂𝐼) 0.780444 1.926296 1.293431 
𝑘d (𝑇𝐹:𝐷𝑁𝐴) 2.10E-08 2.70E-08 1.64E-08 
𝐾𝑀3 1.20E-07 9.41E-08 5.53E-08 
𝐾𝑀9 1.55E-08 1.15E-08 4.23E-08 
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𝐾𝑀11 3.86E-08 2.79E-08 4.81E-08 
𝑘𝑜𝑛1 1.99E+11 2.51E+11 2.46E+11 
𝑘𝑜𝑓𝑓1 18.31229 22.79166 20.27421 
𝑘𝑜𝑛2 3.22E+11 2.62E+11 1.03E+11 
𝑘𝑜𝑓𝑓2 22.66635 29.69411 14.14157 
𝑘𝑜𝑓𝑓5 98.29141 76.1627 117.3805 
𝑘𝑑5 1.01E-08 1.66E-08 8.89E-09 
𝑘𝑜𝑛10 20.04989 17.52512 19.15578 
𝑘𝑜𝑛4 35.2612 49.85688 15.49563 
𝑘𝑜𝑛12 19.36441 18.11537 8.855135 
𝑘𝑑15 8.16E-08 8.86E-08 8.18E-08 
𝑘𝑑16 4.64E-08 7.50E-08 9.29E-08 
𝑘𝑑9 1.57E-11 4.00E-11 3.07E-11 
𝑘𝑑11 1.08E-10 7.91E-11 7.74E-11 
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Figure S1. (a)  
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Figure S1. (b) 
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Figure S1. (c)  
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Figure S1. Sensitivity ranking of the model parameters. The model output was set to the time 
integral of the transcription rate of the GOI within 24 hours after adding (a) 10 nM, (b) 0.1 µM 
and (c) 1 µM of RA to the model. Blue bars indicate the first-order sensitivity indices, while the 
red bars represent total-effect sensitivity indices. The error bars show the bootstrap confidence 
intervals (95% confidence intervals) of the mean values. 
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Figure S2. (a)  
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Figure S2. (b)  
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Figure S2. (c)  
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Figure S2. (d)  
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Figure S2. Sensitivity ranking of the model parameters. The model output was set to the time 
integral of the total RA metabolite formation within 24 hours after adding (a) 1 nM, (b) 10 nM, (c) 
0.1 µM and (d) 1 µM of RA to the model. Blue bars indicate the first-order sensitivity indices, 
while the red bars represent total-effect sensitivity indices. The error bars show the bootstrap 
confidence intervals (95% confidence intervals) of the mean values. 
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Figure S3. (a) 
 
Figure S3. (b) 
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Figure S3. (c) 
Figure S3. The relationship between total RA metabolite formation and total mRNA 
production within 24 hours of treatment with (a) 1 nM, (b) 10 nM, (c) 0.1 µM of RA. The results 
were obtained by random sampling of 10000 points following a uniform distribution over a 44-
dimensional parameter space.  The Spearman’s correlation coefficients and P values were (a) ρ=-
0.44, p=0, (b) ρ=-0.5, p=0, (c) ρ=-0.63, p=0. 
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Chapter 3 
Analysis of the role of thrombomodulin in all-trans retinoic acid treatment of 
coagulation disorders in cancer patients 
 
3.1. Introduction 
All-trans retinoic acid (RA) plays key roles in cancer treatment and prevention. Breast, 
lung, bladder, prostate, and acute promyelocytic leukemia (APL) cancers were shown to be 
suppressed by RA [1-5]. RA therapy can also improve blood clotting disorders such as 
thrombosis and disseminated intravascular coagulation (DIC) in cancer patients [6-12]. 
DIC, a life-threatening coagulation disorder associated with uncontrolled clot formation 
and/or excessive bleeding, was reported in patients with different types of cancer[13-16]. 
Some of the mechanisms involved in the occurrence of DIC in cancer patients are known, 
and others are still under investigation. Tissue factor (TF) upregulation by tumor cells is 
one of the main causes of the observed hypercoagulable state in cancer patients [17-20]. TF 
binds to factor VIIa and forms a complex which activates factors X and IX. Activation of 
factor X leads to formation of the prothrombinase complex, which converts prothrombin to 
thrombin. Expression of the cancer procoagulant (CP), a specific enzyme that directly 
activates factor X, by tumor cells is another important mechanism for the initiation of the 
coagulation cascade in cancer [21, 22]. Tumor cells can also affect the coagulation cascade 
through interactions with other cell types such as monocytes and endothelial cells. Previous 
studies showed that circulating tumor cells increased the expression of TF by monocytes 
and endothelial cells [17, 23-25]. Platelet aggregation and induction of inflammatory 
cytokine release are the other phenomena which can be responsible for blood clotting 
system abnormalities in cancer patients [26, 27]. 
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Clinical studies have indicated that RA treatment improved the plasma levels of 
hemostatic markers such as D-dimer, thrombin-antithrombin complex, and fibrinogen in 
APL patients in hypercoagulable states [11, 12]. Theories have been proposed to explain 
how RA therapy improves coagulation disorders. In vitro studies showed that RA 
significantly decreased the expression of TF in cancer cells [28, 29]. An in vivo study on 
the procoagulant activity of bone marrow blasts from APL patients under RA treatment 
revealed that TF and CP in the patients’ marrow blasts decreased after RA therapy [12]. RA 
can also affect the fibrinolytic system by increasing the synthesis of urokinase plasminogen 
activator (u-PA) in  cancer cells and tissue plasminogen activator (t-PA) in endothelial cells 
[30, 31]. Thereafter, however, RA induces the expression of plasminogen activator 
inhibitors (PAIs), such as PAI-1 and PAI-2 [32]. The way these two contradictory pathways 
influence fibrinolysis in cancer patients has not been fully understood. RA also affects the 
procoagulant and anticoagulant properties of endothelial cells and monocytes [33, 34]. 
Previous studies have reported that RA increased the antithrombotic potential of 
microvascular endothelial cells by downregulating TF and upregulating thrombomodulin 
(TM) expression [34-36]. TM, a surface high-affinity receptor for thrombin, plays a key 
role in activation of the protein C (PC) anticoagulant pathway. Activated PC, produced by 
the TM-thrombin complex, inactivates cofactors fVa and FVIIIa, thus inhibiting thrombin 
generation. Although TM has significant effects on the blood coagulation system, its role 
in RA treatment of coagulation disorders in cancer patients has not yet been studied. 
Furthermore, to the best of our knowledge, there is no experimental or computational study 
that has investigated the extent and forms of variation in TM levels over the course of RA 
therapy in cancer. Thus, the main objective of this study was to investigate if, how and to 
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what extent the RA-induced TM upregulation over the course of RA therapy with a single 
daily oral dose of RA affects thrombin generation profiles in cancer patients. Analysis of 
the variations of the thrombin generation profile is a classic/standard way of studying the 
significance of blood factors in the coagulation cascade. In this regard, we developed an 
ordinary differential equation (ODE) model of gene expression for the RA-induced 
upregulation of TM concentration on the endothelium. The expression rate of TM on the 
endothelium depends on the rate of RA diffusion from plasma into the endothelial cells. In 
plasma, a large fraction of RA (~99%) circulates bound to albumin. However, only free RA 
molecules in plasma can diffuse passively across the endothelial cell membrane and 
subsequently bind to RA receptors and activate transcription of the TM gene. The large 
amount of bound RA in plasma acts as a reservoir from which the RA is slowly released to 
the unbound form to maintain the equilibrium. Thus, we derived a new formula which 
expresses the TM transcription rate as a function of free RA concentration. Coupling the 
gene expression model with three other models, namely a two-compartment 
pharmacokinetic model of RA, an sTM release model and a mechanistic model of the 
human coagulation cascade, we investigated the effects of RA-induced TM upregulation on 
thrombin generation. Our results indicated that overexpression of TM over the course of 
RA therapy with a daily oral dose of 45 
𝑚𝑔
𝑚2
 or 110 
𝑚𝑔
𝑚2
 reduced thrombin level significantly. 
We also investigated how the progressive reduction in the plasma concentrations of RA 
over the course of continuous RA therapy with a single daily dose of (110 
𝑚𝑔
𝑚2
) RA can affect 
the corrective effects of RA therapy on thrombin generation. Increasing reductions in 
plasma concentration of RA over the course of RA treatment with a constant daily dose of 
RA is a potential sign of RA resistance at least in some cancer patients. The exact 
  
 
72 
mechanism of development of resistance to RA has yet to be determined. Genetic mutations 
of retinoic acid receptors, increased metabolism of RA, and upregulation of cellular retinoic 
acid binding proteins which play important roles in the RA signaling pathway [37], have 
been proposed as possible reasons for RA resistance [38]. Our model predictions of RA 
resistance effects on the efficacy of RA therapy in treatment of coagulation abnormalities 
are applicable only to those cancer patients whose plasma levels of RA decrease over 
continuous treatment days. 
3.2. Method 
In this section, we first develop a gene expression model that describes TM upregulation 
on the endothelial cell surface following RA treatment. We train the gene expression model 
using in vitro data from the literature. We then build a two-compartment pharmacokinetic 
model of RA, which describes the plasma concentration of RA in cancer patients. We couple 
the gene expression model with the pharmacokinetic model, to obtain the variations of TM 
level on the endothelial cell surface during the course of RA therapy. We then simulate the 
time-dependent variations of soluble thrombomodulin (sTM) concentration using an ODE 
model, called the sTM release ODE model. Finally, we use the output of the sTM release 
ODE model in an ODE model of the coagulation cascade to investigate the effects of RA-
induced TM upregulation on thrombin generation. The gene expression model, 
pharmacokinetic model and sTM release model are explained in the following sub-sections, 
while the ODE model of the coagulation cascade is fully explained in [39]. Figure 1 shows 
the interactions between the different models in this study. 
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Figure 1. Coupling four models to study how taking an oral dose of RA affects thrombin 
generation. Each block represents a model, while the arrows before and after each block indicate 
the input and output of the model, respectively. 
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3.2.1. Gene expression model 
3.2.1.1. Experimental Data 
There are several lines of evidence regarding the upregulation of TM gene expression 
by RA [35, 40, 41]. This upregulation is due to transcriptional changes in the TMR 
expression level [41]. In this study, we used the experimental data presented by Horie et al. 
[40], which includes time-dependent variations in TMR levels, and dose-dependent changes 
in TM levels after treating human pancreas BxPC-3 cells with RA (Fig. 2). Human pancreas 
BxPC-3 cells were used in that study, as their characteristics of RA-dependent TM 
expression are the same as those of endothelial cells [40]. The cultured BxPC-3 cells 
became confluent with fetal calf serum, whose major component is albumin, prior to adding 
RA to the medium. The TM levels in Fig. 2a were measured after treating the cells with 
various concentrations of RA for 24 hours. The relative values for TMR level in Fig. 2b 
were obtained after treating the cells with 10μM of RA.  
  
(a) (b) 
Figure 2. (a) Effects of RA treatment on TM levels in BxPC-3 cells. The reported values for TM 
level were obtained after treating the cells with RA for 24 h. Figure adopted from [40]. (b) 
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Changes in relative levels of TMR in BxPC-3 cells treated with 10µM RA. The mRNA level 
without incubation is defined as 1.  Figure adopted from [40]. 
 
3.2.1.2. Formulation of the model 
We formulated an ODE model to study the RA-induced upregulation of TM gene 
expression. The model included gene transcription, protein translation, and mRNA and 
protein degradation. The model consisted of two species, namely TM and TMR, with ten 
parameters (Table 1). 
d[TMR]
dt
 = 𝐼 + 𝐼0
− 𝑘dm[TMR]                                                                                                        (1) 
d[TM]
dt
= 𝑘trans[TMR]
− 𝑘dp[TM],                                                                                                  (2) 
where [TMR] and [TM] indicate molar concentration of TMR and TM, respectively. [TM] 
and [TMR] are functions of time. The molar concentration of TM, which is a membrane-
bound protein, was calculated by dividing the number of moles of TM by the cell volume. 
The cell volume was set to [42-44] 
𝑉cell = 10
−13L.    
The transcription rate (I) of the TM gene was the only parameter in the model that 
depended on RA concentration. An increase in RA concentration leads to activation of a 
transcription factor, which is responsible for the activation of the TM gene. Considering the 
mechanism of action of RA, we derived an expression for the TM transcription rate (𝐼), 
(Proof in Supplementary Information in Section 3.6) 
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𝐼
= 𝐼𝑚𝑎𝑥
[RA][REC1t]
[RA][REC1t] + 𝑘d2([RA] + 𝑘d1)
 ,                                                                                   (3) 
 
where [RA] and [REC1t] in Eq. 3 indicate free RA concentration and total concentration of 
the specific transcription factor which can activate the transcription of the TM gene, 
respectively. 𝐼 is time-dependent, since [RA] can change over time, while 𝐼max and [REC1t] 
are constant for the TM gene in a given cell type. The rest of the parameters in Eq. 3 are 
defined in Table 1. RA is highly bound to albumin in the culture medium [40] and in plasma 
[45]. We assumed that the unbound fraction of RA is about 1% of the total RA 
concentration[45, 46]. It is important to note that only the free drug in the culture medium 
or plasma is able to have a therapeutic effect. 
Table 1. List of the model parameters 
Parameters Description Range Reference 
𝐼0 
Basal transcription rate by 
transcription factors, which are 
not affected by RA (M/hr) 
1.6 × 10−12 − 1.6
× 10−9 
[47] 
𝑘dm TMR degradation rate (1/hr) 0.256   [48] 
𝑘trans Translation rate(1/hr) 1-10000  [47] 
𝑘dp TM degradation rate (1/hr) 0.0845 [49] 
𝐼𝐶TMR 
TMR initial concentration 
(M) 
1.6 × 10−11 − 1.6 ×
10−8  
[47, 50] 
𝐼𝐶TM 
TM initial concentration 
(M) 
1.65 × 10−5 − 2.14
× 10−5 
[40] 
𝐼max 
Maximal transcription rate 
of the TM gene (M/hr) 
1.6 × 10−12 − 1.6
× 10−9 
[47] 
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𝑘d1 
Equilibrium dissociation 
constant of RA binding to 
retinoic acid receptor (M) 
8 × 10−9 [51] 
𝑘d2 
Equilibrium dissociation 
constant of DNA-transcription 
factor complex (M) 
15 × 10−9 [52] 
[REC1t] 
Total concentration (M) of 
the specific transcription factor 
which can activate the TM gene 
transcription  
1 × 10−11 − 1 × 10−6 
Unknown. A 
large range is 
used. 
 
The translation rate (𝑘trans) and basal transcription rate (𝐼0) were the only parameters 
that depended on the other parameters. Assuming that the TM and TMR concentrations 
were in steady state before RA treatment, we calculated 𝑘trans  and 𝐼0 by  
    𝑘trans
=
𝑘dp𝐼𝐶TM
𝐼𝐶TMR
,                                                                                                                            (4) 
       𝐼0 = 𝑘dm𝐼𝐶TMR .                                                                                                                                              (5)                                                                                                              
The model had six unknown parameters, for which we considered some bounds (Table 
1). The bounds for 𝐼𝐶TM were due to the experimental errors, while the other unknown 
parameters, namely 𝐼max, 𝐼𝐶TMR, 𝑘trans, 𝐼0 and [REC1t] had physiological bounds. We 
estimated the model’s unknown parameters by minimizing the residual between simulation 
results and empirical measurements, following a parameter estimation algorithm. In this 
regard, we used a particle swarm optimization (PSO) technique [53] (See Supplementary 
Information in Section 3.6 for full details regarding the parameter estimation algorithm and 
PSO). Our simulation results for the time-dependent variations in TM and TMR 
concentrations compared reasonably well with the experimental data (Fig. 3). 
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(a) (b) 
  
© (d) 
 
Figure 3. The gene expression model training simulations. The model’s unknown parameters 
were estimated using PSO. The red lines show the mean simulated results for (a) TMR, (b) TM at 
RA= 0.1 µM, (c) TM at RA= 1 µM and (d) TM at RA= 10 µM. The shaded regions denote 99% 
confidence interval of the mean results [53, 54]. The black dots indicate the experimental data, 
while the standard deviation of each experimental data point is half the length of the total error 
bar. 
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The solid lines in Figure 3 show the mean simulated results, while the shaded regions 
in Figure 2 show the 99% confidence interval of the mean simulated results. From Figure 
3a, it can be seen that TMR reached steady state almost 18 hours after administration of 
RA, while TM did not reach steady state even after 24 hours (Fig. 3b-d).  
Using the estimated parameters from the training data set [40], we compared the model’s 
predictions with another data set [41] for the RA-induced upregulation of TM on endothelial 
cells. In this regard, fold change values of TM concentration after 24 hours of treatment 
with various concentrations of RA were obtained (Fig. 4). Figure 4 indicates that simulation 
results compared reasonably well with experimental data. 
 
Figure 4. Comparison between the simulated results for fold change values of TM concentration 
after 24 hours of treatment with various concentrations of RA with experimental data not used 
during model training. The simulation results were obtained using the gene expression model 
trained by the experimental data shown in Fig. 2,  while the experimental data in Figure was 
reproduced from [41]. 
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3.2.2.  Pharmacokinetic model 
Some cancer patients take RA as a part of their cancer treatment within three to four 
months of diagnosis [55]. The plasma concentration of RA changes significantly after oral 
administration of various doses of the drug (Fig. 5). 
 
 
Figure 5. Plasma concentration of RA after ingestion of various doses of RA on day 1 of 
treatment [48, 49]. Dots show the pharmacokinetic data, while lines indicate the simulation results 
by a two-compartment pharmacokinetic model. 
 
Oral administration of RA can be modeled via a two-compartment pharmacokinetic 
model (Fig. 6), since the plasma concentration-time curve of RA exhibits a biexponential 
decline [56, 57]. After oral administration of the drug, RA is absorbed into the bloodstream, 
which is a part of the central compartment. The central compartment includes the plasma 
and organs, where the distribution of RA is assumed to be instantaneous. The RA is 
eliminated by a first order process from the central compartment or distributed to the rest 
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of the body that represents the peripheral compartment. RA elimination mainly occurs in 
the liver and kidney, which are included in the central compartment. The peripheral 
compartment includes tissues where RA distribution occurs with a slower rate than in the 
central compartment.  
 
Figure 6. Schematic of a two compartments model for describing RA pharmacokinetics. The 
model included two main compartments namely, central compartment and peripheral 
compartment. 𝑘a, 𝑘d , 𝑘cp, 𝑘pc are first order absorption rate constant, degradation rate constant, 
distribution rate constant and redistribution rate constant. 
 
RA exchange between different compartments can be described by a system of ODEs 
dD
dt
= −𝑘aD                                                                                                                                      (6)  
d[RAc]
dt
=
𝑘aD
𝑉cM
− (𝑘d + 𝑘cp)[RAc] +
𝑘pc𝑉p
𝑉c
[RAp]                                                                  (7) 
d[RAp] 
dt
=
𝑘pc𝑉c
𝑉p
[RAc] − 𝑘pc[RAp]                                                                                           (8) 
where D, [RAc] and [RAp] represent RA dose, total RA concentration in the central 
compartment, and total RA concentration in the peripheral compartment, respectively. D, 
[RAc] and [RAp] vary over time, and are represented in g, molar
 and molar, respectively. 
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𝑘a, 𝑘d , 𝑘cp, 𝑘pc, 𝑉c and 𝑉p are the first-order absorption rate constant, first-order degradation 
rate constant, distribution rate constant, redistribution rate constant, central compartment 
volume and peripheral compartment volume, respectively. M is the molar mass of RA, and 
is set to 300.4 gmol-1. We also assumed that the average body surface area is 1.75 m2. We 
built the model, shown in Figure 6, in MATLAB SimBiology and fit the model parameters 
to the pharmacokinetic data (dots in Figure 5). Solid lines in Figure 5 show the model 
prediction for plasma concentration of RA ([RAc]) after taking an oral dose of 45 or 110 
mg/m2 of RA. Further details regarding the pharmacokinetic model were provided in the 
Supplementary Information file (section 3.6). We coupled the gene expression model with 
the pharmacokinetic model to study the effects of oral administration of RA on the 
expression levels of TM and TMR during the course of RA therapy (Section 3.1). Free RA 
concentration in the gene expression model ([RA] in Eq. 3) is obtained by  
[RA] = 0.01[RAc].                                                                                                                          (9)  
 
3.2.3.  sTM release model 
TM plays a key role in controlling fibrin formation. A modified form of TM is also 
found in human plasma and urine [58]. Both cellular TM and soluble TM (sTM) act as an 
anticoagulant by activating protein C [59, 60]. It is believed that soluble TM (sTM) is a 
marker for endothelial cell injury [61, 62]. Endothelial cell injury can occur due to several 
reasons, such as elevated levels of cytokines, hyperlipidemia, activation of leukocytes and 
neutrophils, hypercholesterolemia, obesity, diabetes and smoking. Blood vessel damage is 
also a common occurrence in cancer patients, as many of them undergo surgery or 
chemotherapy. It has been reported that TM is cleaved from the endothelium and released 
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into the plasma by some degrading enzymes such as protease and glycosidase upon 
endothelial cell injury [61]. Assuming the RA therapy does not affect the mechanisms 
mediating the release of cellular TM into the plasma, we modeled the rate of sTM 
production by 
d[sTM]
dt
= 𝑐1[TM] − 𝑐2[sTM] ,                                                                                                  (10) 
where 𝑐1 and 𝑐2 are the release rate constant of cellular TM into the plasma by the degrading 
enzymes and the elimination rate constant of sTM from plasma, respectively. [TM] 
represents the cellular concentration of TM, while [sTM] indicates the plasma concentration 
of sTM. 𝑐2 was set at 0.11 
1
ℎ𝑟
 [63] 
Assuming the sTM concentration to be at steady state prior to RA treatment, we 
calculated the value of 𝑐1 using the physiological concentrations of TM and sTM 
𝑐1 =
𝑐2[sTM]0 
[TM]0
,                                                                                                                             (11) 
where [sTM]0 and [TM]0 are physiological concentrations of sTM and TM, and are 
expressed in molar.  We assumed that [sTM]0 = 1nM, while [TM]0 is the steady state level 
of TM in Eq. 2 after treating the model with a physiological concentration of RA 
(RAplasma = 5 nM) [46].  
The sTM release model was used to link the gene expression model to the ODE model 
of the coagulation cascade (Section 3.3) 
 
3.3. Results 
3.3.1. Pharmacokinetics-pharmacodynamics 
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RA is mainly transported in plasma bound to serum albumin [45, 57]. The unbound 
fraction of RA in plasma is about 1% of the total RA concentration [45, 46]. Since the bound 
drugs are pharmacologically inactive, we calculated the unbound fraction of RA in plasma 
by multiplying the total concentration of RA by 0.01 (Eq. 9). We then used the plasma 
concentration of free RA as input to the gene expression model, with the parameters 
estimated in the section 2.1, to study the dynamics of the TM concentration on the first day 
of treatment. To do so, the free RA concentration in Eq. 3 varied according to the time-
dependent levels of free drug in plasma ([RA]) following RA therapy.   
 
RA treatment resulted in variations in TM and TMR concentrations (Fig. 7). The TMR 
and TM concentrations reached their peak levels almost 7 and 13 hours after taking a 45 
mg/m2 oral dose of RA, respectively (Fig. 7a). However, the peak times of TMR and TM 
levels were shifted by almost 1 hour when the RA dose was increased to 110 mg/m2 (Fig. 
7b). 
  
(a) (b) 
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Figure 7. Variations in RA, TMR, and TM concentrations following a single dose of RA (a) 45
𝑚𝑔
𝑚2
  
and (b) 110 
𝑚𝑔
𝑚2
 . The lines show the mean simulated results, while the shaded regions denote the 
99% confidence interval of the mean simulated results. 
 
The solid lines in Fig. 7 denote mean simulated results, while the shaded regions denote 
99% confidence interval of the mean simulated values. The maximum concentration of TM 
after taking a 110 
𝑚𝑔
𝑚2
 oral dose of RA (Fig. 7b) was similar to that of taking a 45 
𝑚𝑔
𝑚2
 oral 
dose of RA (Fig. 7a). This is because the transcription rate levels were comparable for both 
RA doses (Fig. 8).  
 
Figure 8. Variation of the TM transcription rate (I) following various doses of RA. 
 
3.3.2. Continuous treatment with RA  
Patients on RA therapy usually take the drug on a daily basis. We simulated the effects 
of daily administration of RA for three days, on TM expression (Fig. 9).  
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(a) (b) 
 
Figure 9. TM expression on the endothelial cell surface within three days of RA treatment. 
Daily doses of RA are taken at t=0 hr, t= 24 hr, and t=48 hr. (a) 45
𝑚𝑔
𝑚2
  and (b) 110 
𝑚𝑔
𝑚2
. The lines 
show the mean simulated results, while the shaded regions denote the 99% confidence interval of 
the mean simulated results. 
 
Continuous treatment with RA resulted in oscillatory alterations in the TM 
concentration. These oscillatory changes are important, as they can affect the blood 
coagulation cascade (Section 3.3). Taking 110 
𝑚𝑔
𝑚2
 RA per day increased the TM 
concentration to approximately twice its normal level (i.e. no RA treatment) almost 14 hours 
after drug ingestion. Daily administration of RA did not allow the TM level to return to its 
initial concentration, since it took almost 72 hours for TM to return to its initial 
concentration (data not shown).  
 
3.3.3.  RA resistance 
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In some cancers, RA resistance is associated with increasing reductions in the plasma 
concentration of RA [57]. A clinical trial of RA [64] showed that continuous treatment with 
RA caused a progressive reduction in the plasma level of RA in half of the patients that 
were on RA treatment (Fig. 10). The mechanisms involved in the progressive reduction in 
RA plasma concentration over the course of continuous RA therapy are not known. The 
mechanisms might be cancer- and patient- specific. Other pharmacokinetic patterns were 
observed in the remainder of the patients under study [64]. In some patients, the peak plasma 
level of RA remained unchanged during the RA treatment, while other patients had peaks 
that varied weekly.   
 
Figure 10. Changes in the total plasma level of RA concentration on treatment days 1, 8 and 
15 of a continuous treatment period with daily dose of 110 
𝑚𝑔
𝑚2
  RA [49]. 
 
Using the clinical data shown in Fig. 10, we simulated the effects on TM expression of 
the consistent decrease in peak plasma level of RA (Fig. 11).  
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Figure 11. TM expression on day 1, day 8, and day 15 of the treatment period. Solid lines are 
the mean simulated values. Dotted lines show the 99% confidence estimate of the mean results. 
 
The solid lines in Fig. 11 show the mean simulated values of the TM concentration, 
while the dotted lines denote the 99% confidence interval of the mean results. Figure 11 
shows that the peak level of TM on various days decreased in the order of day 8 > day 1 > 
day 15, while the peak RA plasma concentration decreased in the order of day 1 > day 8 > 
day 15. Higher TM levels on day 8 compared to day 1 was because of higher plasma levels 
of RA after 6 hours of drug administration on day 8 compared to day 1 (Fig. 10). The results 
presented in Figure 11 were obtained using the pharmacokinetic data from [64]. Thus, these 
results are not applicable to all patients with different cancer types. However, the current 
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model can be used to study the variation of TM expression over the course of RA therapy 
for different patients with different cancer types, once more pharmacokinetic data on 
different treatment days is available. In the next section we will investigate the effects of 
RA-induced TM upregulation on the coagulation cascade. We also investigate how the 
progressive reduction in the RA concentration over the course of RA therapy can decrease 
the corrective effects of RA therapy on the coagulation disorders.   
 
 
3.3.4. Effects of RA-induced TM upregulation on the blood coagulation 
system 
3.3.4.1. Effects of continuous RA therapy on thrombin generation  
In this section, we investigate whether the elevated levels of TM over the course of RA 
therapy can affect thrombin generation. In this regard, we used an ODE model of the blood 
coagulation cascade that incorporates a mechanistic description of the protein C pathway 
[39]. The coagulation model was developed based on in vitro phospholipid-based assays to 
study the contribution of various coagulation factors to thrombin generation in protein C 
deficient patients. TM was modeled at 1 nM in that study, which is an estimate of the 
physiological concentration of soluble TM (sTM) in plasma. However, our gene expression 
model predicts the variation in the concentration of TM in endothelial cells. It is believed 
that sTM is entirely derived from the TM expressed on the endothelial cell surface. To 
couple the RA model with the coagulation model, we need to obtain the time-dependent 
variations in the sTM level following the RA therapy. In this regard, we coupled the gene 
expression model with the sTM release model to obtain the variations of sTM over the 
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course of RA therapy. Figure 12 compares the variation of the cellular level of TM with that 
of the plasma level of sTM when the patient takes the drug on a daily basis for three 
consecutive days.     
 
  
(a) (b) 
Figure 12. Variations in the cellular level of TM and the plasma concentration of sTM within three 
days of RA treatment. Daily doses of RA are taken at t=0 hr, t= 24 hr, and t=48 hr. (a) 45
𝑚𝑔
𝑚2
  and 
(b) 110 
𝑚𝑔
𝑚2
. Solid lines are the mean simulated values. Shaded regions show the 99% confidence 
interval of the mean results. 
 
To run the coagulation model, we assumed that all coagulation factor concentrations 
were physiological concentrations, except the TF and sTM concentrations. The TF 
concentration was set to 5 pM to initiate the clot formation process, while the sTM 
concentration varied according to the RA treatment (Fig. 12). Since the time scale of the 
coagulation cascade (20 min) is much shorter than that of TM expression (days), the sTM 
concentration was assumed to be constant during the coagulation process. Taking once-
daily oral dose 45 
𝑚𝑔
𝑚2
 or 110 
𝑚𝑔
𝑚2
  of RA for three consecutive days reduced the peak level 
of thrombin up to 45% and 50%, respectively (Fig. 13). The endogenous thrombin profile 
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(ETP), which is defined as the time integral of thrombin generation, was decreased up to 
45% and 49% within three days of treatment with 45 
𝑚𝑔
𝑚2
 or 110 
𝑚𝑔
𝑚2
  oral dose of RA, 
respectively (Fig. 13). 
  
(a) (b) 
 
Figure 13. Impacts of RA-induced TM upregulation following drug ingestion (a) 45
𝑚𝑔
𝑚2
  and 
(b) 110 
𝑚𝑔
𝑚2
 , on thrombin generation. The blue lines indicate the thrombin generation profile in the 
control group with physiological levels of RA.  The red lines show the maximum impact of RA 
therapy on thrombin generation. The shaded red regions indicate the range of the thrombin 
generation profile within three days of continuous RA therapy. 
 
The shaded regions in Fig. 13 indicate the range of thrombin generation after RA 
therapy, with different doses of RA. The shaded regions in Fig. 13 are not only due to the 
uncertainty of the results caused by the error bars in the experimental data (Fig. 2), but also 
due to the changes in sTM level after RA treatment (Fig. 12). In fact, we obtained the range 
of thrombin generation profiles using different values of sTM, that could be expected over 
the course of RA therapy (Fig. 12). Our results indicate that the endothelium could 
potentially play a key role in RA treatment of coagulation disorders, by upregulating TM 
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and sTM. Since the sTM concentration fluctuates over time, the efficacy of RA treatment 
in preventing or treating hemostatic abnormalities is dependent upon the timing of the 
treatment.  
 
 
3.3.4.2. Effects of RA resistance on thrombin generation 
Our results indicated that the progressive reductions in plasma concentration of RA over 
the course of RA therapy with a daily oral dose (110 
𝑚𝑔
𝑚2
) of RA (Fig. 10) resulted in 
variations of cellular TM concentration (Fig. 11). Using the sTM release model, we obtained 
the variations of sTM concentration on different treatment days. We then ran the 
coagulation model using the predicted values of sTM concentration on different treatment 
days (Fig. 14), according to the procedure explained in the previous section. The blue line 
in Figure 14 indicates the thrombin generation profile for the control condition with a 
physiological level of RA, while the dashed lines show thrombin generation profiles at sTM 
peak time after taking different oral doses of RA. Thus, the area between the blue line and 
a given day’s dashed line shows the range of variation of thrombin generation on the given 
day.  
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Figure 14. Thrombin generation profile on days 1, 8 and 15 of treatment period with a daily 
dose of 110 
𝑚𝑔
𝑚2
 RA. Dashed lines show the maximum impact of RA therapy on thrombin 
generation on different treatment days. The area between each dashed line and the solid blue line 
indicates the range of the thrombin generation profile on different treatment days. RA 
concentration in plasma on different treatment days is shown in Fig. 10. 
Our simulation results indicated that the peak thrombin level was reduced up to 41%, 
44% and 32% on day 1, day 8 and day 15 of treatment period, respectively. However, the 
ETP was reduced up to 40%, 43% and 32% on days 1, 8 and 15 of continuous treatment 
with a once-daily dose of 110 
𝑚𝑔
𝑚2
 RA, respectively. It is important to note that the maximum 
reduction happens at the sTM peak time after oral administration of RA.  
Our results indicated that the reduced levels of RA on days 8 and 15 of continuous 
treatment with a single daily dose of 110 
𝑚𝑔
𝑚2
 RA could decrease thrombin peak levels and 
ETP significantly. However, the way this progressive reduction affects the efficacy of RA 
in treating cancer depends on cancer type, stage and the patient’s health conditions. In 
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general, drug dose and route of administration are determined in such a way that the plasma 
concentration of drug lies within the therapeutic window of the drug. Any significant 
reduction in plasma concentration of RA over the course of treatment can potentially 
decrease the efficacy of RA in treatment of cancer in at least some patients. Figure 10 
indicates that the peak plasma concentration of RA decreases by almost 60% within two 
weeks of RA treatment, while our results show that the peak thrombin level is reduced up 
to 44% and 32% on days 8 and 15 of treatment, respectively. The obtained values for percent 
decrease in peak thrombin level on days 8 and 15 of RA therapy are comparable with a 41% 
decrease in peak thrombin level on day 1 of treatment. Our results raise the hypothesis that 
RA therapy has more consistent, corrective effects on clotting abnormalities than on cancer. 
Further studies on different patients with different cancer types and stages are needed to 
reveal how the observed reductions in plasma levels of RA over the course of RA therapy 
affect the efficacy of RA in treatment of cancers versus hemostatic abnormalities.  
 
3.3.4.3. Effects of physiological levels of RA on thrombin generation 
We used our RA model to obtain the elevated levels of cellular TM and sTM, when the 
cells were treated with a physiological concentration of RA, RAplasma = 5 nM [46]. 
Treating the combination of the gene expression model and the sTM model with 5 nM of 
RA resulted in a 9% increase in the mean cellular TM level and subsequently the mean 
plasma level of sTM. We then investigated the effects of physiological concentrations of 
RA on the thrombin generation profile (Fig. 15). The absence of vitamin A in the diet 
increased the peak level of thrombin up to 10%, while this increase was up to 11% for the 
ETP.  
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Figure 15. Impacts of physiological levels of RA on thrombin generation profile. The blue line 
indicates thrombin generation profile for the control condition with physiological level of RA. The 
red line shows the mean thrombin generation profile when there is no RA in the plasma. The 
shaded red region indicates the 99% confidence interval of the mean result. 
 
 
 
3.4. Discussion 
Clinical observations have shown that RA has therapeutic effects on blood coagulation 
disorders such as DIC and thrombosis in cancer patients. Previous studies have mainly 
looked at RA as a treatment for cancer. Corrective effects of RA on coagulation disorders, 
which is a positive side effect of RA therapy, have rarely been studied. Elucidating the 
mechanism of action of RA in the treatment of coagulation disorders is important, since this 
can help to understand why some patients respond to the drug better than others. This is 
also useful in developing new drugs with better therapeutic effects. Down regulation of TF 
and CP on cancer cells and monocytes, upregulation of u-PA, PAI-1 and PAI-2 in cancer 
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cells, and upregulation of TM and t-PA in endothelial cells have been introduced as the 
possible mechanisms for RA to ameliorate blood coagulation disorders. In this study, we 
investigated how RA therapy regulates TM expression and how this variation affects the 
thrombin generation profile. We developed a gene expression model for the RA-induced 
upregulation of TM. Coupling the gene expression model with a two-compartment 
pharmacokinetic model of RA, we simulated the time-dependent variations of TM and TMR 
concentrations after taking different oral doses of RA. Our results indicate that the TM 
concentration increases almost twofold after taking a 110 
𝑚𝑔
𝑚2
  oral dose of RA. Since most 
of the patients who are under RA treatment take RA on a daily basis, TM expression on the 
endothelial cell surface changes over time. Our results indicate that RA treatment increases 
the mean value of TM concentration, while the nature of this regulation is oscillatory. To 
examine the effects of the upregulated TM on the blood coagulation system, we used a 
mathematical model for the human coagulation cascade [39]. Our simulations show that 
taking a 45 
𝑚𝑔
𝑚2
 or 110 
𝑚𝑔
𝑚2
  oral dose of RA reduces ETP by 45% and 49%, respectively. 
Furthermore, our results are useful in predicting the times when a patient is at a higher risk 
of clot formation. Almost fourteen hours after drug ingestion, the TM concentration begins 
to decrease, and reaches its minimum level almost before taking the next dose of the drug. 
However, the minimum level of TM during the RA treatment period is higher than the 
normal level of TM when there is no RA treatment. We also investigated the effects of 
progressive reductions in the plasma concentration of RA over a course of continuous 
treatment on thrombin generation. Our results indicated that the progressive reductions in 
plasma concentration of RA over the course of RA therapy with daily oral dosing (110 
𝑚𝑔
𝑚2
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), which has been observed in some cancer patients, do not affect the corrective effects of 
RA therapy on thrombin generation significantly. These results prompt the hypothesis that 
coagulation abnormalities may become resistance later than cancer to RA. The validity of 
this hypothesis depends on various patient- and cancer-specific factors such as the RA route 
of administration, the adequate plasma concentration of RA for cancer treatment, the 
acceptable range of reduction in plasma RA over the course of RA therapy, and the 
allowable range of toxicity. Thus, the validity of this hypothesis should be tested for 
different groups of patients with various cancer types, stages and health conditions such as 
liver and kidney health, independently. Taken together, our simulations indicate that 
oscillatory expression of TM over the course of RA therapy can play a critical role in the 
regulation of thrombin production. This finding may explain why RA therapy improves 
DIC and thrombosis in some cancer patients better than in others. Our simulation results 
suggest that one possible reason might be the impairment of PC pathway because of cancer, 
cancer treatment, etc. It is important to note that the current study cannot compare the 
significance of TM with other potentially important proteins such as t-PA, u-PA, PAI-1, 
PAI-2, TF and CP, in RA-induced improvement of clotting disorders in cancer patients. 
Further experimental and numerical studies are needed to investigate the contributions of 
the above pathways to RA therapy of DIC in cancer.  This study can be considered as a 
starting point for research studies exploring the possible effects of oscillatory protein 
expression after drug administration, on the blood coagulation cascade.  
There are some limitations to this study. First, we simulated the thrombin generation 
process using the physiological levels of all blood factors except TF and TM. This is 
because some cancer patients have coagulation factor levels within the normal ranges [65, 
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66]. However, this is not true for all cancer patients. Plasma concentrations of coagulation 
factors in cancer patients depend on several factors such as type and stage of the cancer, 
and type of the antitumor therapy. Thus, the quantitative aspect of our results on corrective 
effects of RA therapy on thrombin generation, cannot be applied to all patients with 
different disease conditions. Second, we did not consider the effects of RA treatment on the 
cancer cells’ ability to produce inflammatory cytokines. Previous in vitro studies have 
indicated that RA treatment increased the production of some inflammatory cytokines such 
as IL-1β by cancer cells [67, 68]. In theory, induction of cytokine release can favor the 
prothrombotic potential of the endothelium by upregulating TF and downregulating TM 
expression [69, 70]. However, we believe that the elevated levels of plasma cytokines after 
treatment with the specified doses of RA in this study should not influence the TF and TM 
expression significantly [67, 69, 71]. Third, the model we used for simulating thrombin 
generation was developed based on in vitro assays. Even though all coagulation factor 
concentrations were physiological concentrations, the model cannot capture some essential 
features of the coagulation in vivo, such as the cellular involvement and the effects of flow. 
In fact, our model cannot describe exactly how RA therapy improves clotting disorders in 
vivo. Instead, our simulation results indicate that the oscillatory variation in TM expression 
over the course of RA therapy significantly influenced in vitro thrombin generation. In vivo 
studies are needed to confirm the key role of TM in RA treatment of coagulopathy. Fourth, 
in constructing the sTM release model, for simplicity we assumed that the cellular TM is 
degraded by a first-order reaction. The kinetic order of the reaction depends upon the types 
and concentrations of degradation enzymes and the severity of cell injury. However, little 
is known about the types and concentrations of the enzymes which are primarily responsible 
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for producing sTM from cellular TM. Furthermore, the severity of cell injury depends on 
the type and stage of the cancer. Thus, the model presented in this section cannot describe 
TM cleavage for all cancer patients with different conditions. The model can be improved 
once more information about the degradation pathway is available. We have also assumed 
that the amount of cellular TM is not significantly reduced due to release of the TM into the 
plasma. This is because the number of sTM molecules in plasma is much smaller than the 
number of TM molecules on the endothelium under physiological conditions. Next, we 
assumed that the unbound fraction of RA in plasma was constant over the course of RA 
treatment. However, the unbound fraction of RA depends on different variables, such as the 
serum albumin concentration in plasma, the total concentration of RA in plasma, and the 
levels of other drugs in blood. Cancer patients usually take different medications at the same 
time. Furthermore, the serum albumin level can be affected by cancer and cancer treatment. 
Thus, the exact quantitative effects of RA therapy on TM expression can vary from patient 
to patient.  
3.5. Conclusions 
All-trans retinoic acid (RA) has been widely used to treat various types of cancer. RA 
treatment also improves coagulation abnormalities in cancer patients. However, it is not 
clear how RA therapy ameliorates coagulation disorders. In this study, for the first time, we 
developed a mechanistic model to investigate the role of thrombomodulin (TM) in RA 
therapy of cancer-induced coagulation disorders. Our results indicate that RA-induced TM 
upregulation reduces thrombin generation significantly. Daily administration of the drug 
results in oscillatory expression of TM on endothelial cells. We also demonstrate that within 
two weeks of continuous RA treatment, TM expression patterns remain almost unchanged, 
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while some cancers become resistant to RA therapy. This result raises the hypothesis that 
RA therapy has longer lasting corrective effects on coagulation disorders than on cancer. 
Clinical studies and in vivo experiments are required to test the validity of this hypothesis. 
Overall, our findings indicate the key role of TM in RA treatment of blood coagulation 
abnormalities in cancer patients. These results are in line with recent clinical observations 
regarding the therapeutic effects of recombinant human thrombomodulin, an anticoagulant 
drug with the same external structure of TM, in the treatment of DIC [72-76]. 
Moving forward, we plan to couple this model with other mechanistic models that 
simulate the effects of RA therapy on the expression levels of TF, CP, PAI-1, PAI-2, t-PA 
and u-PA, and compare the significance of different pathways in RA therapy of clotting 
disorders in cancer patients. Such models should be able to simulate how the RA treatment 
downregulates the expression of TF and CP and upregulates the synthesis of PAI-1, PAI-2, 
t-PA and u-PA in various cell types such as endothelial cells, monocytes, and tumor cells. 
Mechanistic modeling of these pathways requires concurrent experimental studies to 
explore the relevant biological pathways. 
3.6. Supplementary information 
3.6.1. All-trans retinoic acid pathway 
RA is highly bound to albumin in plasma [45] and in the cell culture medium [40]. Free 
RA molecules start to passively diffuse across the cellular membrane once the cultured cells 
are treated by RA. Passive diffusion continues to occur until the concentration of free RA 
on both sides of the cellular membrane are equal. Equilibrium is achieved relatively quickly 
due to the high permeability coefficient of RA across the endothelial cell membrane [77] 
and high surface area per volume of endothelial cells. After diffusing across the membrane, 
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RA molecules bind to different receptors (Fig. S1). Some of the RA binding receptors can 
initiate the transcription of target genes after binding to RA. When the transcription factors 
bind to RA molecules, they become activated and trigger the transcription of the TM gene 
by binding to DNA at a retinoic acid response element (RARE) located in enhancer regions 
of the gene [78, 79].    
 
Figure S1. Simplified schematic of the RA signaling pathway. RA is mainly bound to albumin 
outside of the cells. RA molecules (red circles) can diffuse across the cellular membrane and bind 
to different receptors (REC1, REC2, REC3, etc). Some of the RA binding receptors (REC1, in this 
cartoon diagram) can initiate the transcription of the TM gene after binding to RA molecules.    
 
The binding of RA to a single site on a RA binding receptor (REC) is expressed by 
RA + REC
𝑘d1
⇔ RA: REC , 
where 𝑘d1 is the equilibrium dissociation constant, 
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𝑘d1 =
[RA][REC]
[RA: REC]
 ,                                                                                                                         (S1) 
and [] indicates molar concentration. Thus, [RA], [REC] and [RA: REC] represent molar 
concentrations of free RA, free RA binding receptor and bound receptor (RA: REC), 
respectively. Assuming that RA is either free in the cell or bound to the RA binding 
receptors (REC), Eq. S1 can be written as 
𝑘d1 =
[RA]([RECt] − [RA: REC])
[RA: REC]
 ,                                                                                          (S2) 
where [RECt] stands for molar concentration of all RA binding receptors, 
[RECt] = [REC1] + [REC2] + ⋯                                                                                              (S3) 
Solving Eq. S2 for the bound fraction of RA binding receptors yields  
 
[RA: REC]
[RECt]
=
[RA]
[RA] + 𝑘d1
 .                                                                                                          (S4) 
 
The concentration of the specific transcription factor (REC1) which can activate the 
transcription of the TM gene is a portion of the total concentration of RA binding receptors 
(RECt). Assuming that RA has the same affinity to bind to different RA binding receptors, 
the ratio of the activated transcription factor concentration ([RA: REC1]) to the total 
transcription factor concentration ([REC1t])  is the same as the ratio of the activated RA 
receptors concentration ([RA: REC]) to the total RA receptors concentration ([RECt]), thus 
[RA: REC]
[RECt]
=
[RA: REC1]
[REC1t]
 .                                                                                                           (S5) 
The assumption that RA binds to various types of RA binding receptors with the same 
affinity is reasonable, since the majority of RA binding receptors found in endothelial cells 
are from the nuclear hormone receptor family. The retinoic acid receptors 
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(RARα, RARβ, RARγ) and retinoid X receptors (RXRα, RXRβ, RXRγ) are the main members 
of the nuclear hormone receptor family.  
The transcription rate of the TM gene depends on the promoter occupancy. The binding 
of an activated transcription factor to a promoter can be described by 
RA: REC1 + Promoter
𝑘d2
⇔ RA: REC1: Promoter , 
where 𝑘d2 is the equilibrium dissociation constant of the transcription factor binding to the 
promoter. The fraction of time that any given promoter spends in the transcription factor-
bound state is given by [80-82] 
Fraction of binding time =
[RA: REC1]
[RA: REC1] + 𝑘d2
 .                                                                   (S6) 
The rate of the gene transcription is proportional to the fraction of the binding time, 
𝐼
𝐼max
=
[RA: REC1]
[RA: REC1] + 𝑘d2
 ,                                                                                                          (S7) 
where 𝐼max is the maximum transcription rate by a specific transcription factor (REC1).  
The transcription rate (𝐼) can be obtained as a function of RA, REC1t, and  𝐼max by 
combining Eqs. S4, S5 and S7, 
𝐼 = 𝐼max
[RA][REC1t]
[RA][REC1t] + 𝑘d2([RA] + 𝑘d1)
 .                                                                            (S8) 
It is important to note that we assumed the association/dissociation event between RA 
and REC, and the binding/unbinding of RA: REC1 to promoter are in equilibrium. This is 
because these reactions occur on much faster time scales than gene transcription [51, 83, 
84]. Furthermore, DNA-transcription factor reactions are much faster than protein-ligand 
reactions [84, 85]. 
3.6.2. Estimation of gene expression model parameters 
3.6.2.1. Parameter estimation algorithm  
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The gene expression model had four species, i.e. TMR, TM, RA and REC1t, and seven 
parameters, namely 𝐼0, 𝑘trans, 𝐼max, 𝑘dp, 𝑘dm, 𝑘d1 and 𝑘d2. The model parameters and 
species were defined in Table 1. The values of 𝑘dp, 𝑘dm, 𝑘d1 and 𝑘d2 were taken from the 
literature (Table 1), while the values of the remaining parameters, and the initial 
concentrations of the model species, i.e. 𝐼𝐶TM, 𝐼𝐶TMR and [REC1t] were unknown. 𝑘trans 
and basal transcription rate (𝐼0) were the only parameters that depended on the other 
parameters. Assuming that the TM and TMR concentrations were in steady state before RA 
treatment (t=0), we calculated 𝑘trans  and 𝐼0 by  
𝑘trans =
𝑘dp𝐼𝐶TM
ICTMR
,                                                                                                                         (S9) 
    𝐼0 = 𝑘dm𝐼𝐶TMR .                                                                                                                                       (S10)    
                                                                                                
Overall, the gene expression model had three independent unknown parameters namely, 
𝐼max, 𝐼𝐶TMR, [REC1t], and two dependent parameters, namely 𝑘trans and 𝐼0. We instituted 
some bounds for all model unknown parameters (Table 1). The bounds for 𝐼𝐶TM were due 
to the experimental errors (Fig. 2), while the other unknown parameters had physiological 
bounds. The gene expression model unknown parameters were estimated by minimizing 
the squared difference between simulation results and the experimental data following a 
parameter estimation algorithm. The parameter estimation process was designed in such a 
way that the simulation results for the TMR concentration at different time points, i.e. 0, 3, 
6, 12, 24 h, when RA =10 µM and the simulation results for TM concentration at different 
RA concentrations, i.e. 0.1, 1, 10 µM, when t= 24 h fit the experimental data shown in Fig 
2. The objective function was defined by 
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𝐸 =∑(Mi
s − [TMR]i
s)2 +
5
i=1
∑(1− [TM]j
s)2
3
j=1
.                                                                                                   (S11) 
The first term in the objective function quantified the difference between the scaled 
experimental TMR concentration (Mi
s) and scaled numerical results for TMR level ([TMR]i
s)  
at time point i. Time points i=1, 2, 3, 4 and 5 stand for t=0, 3, 6, 12 and 24, respectively, 
while the superscript s shows that the values are scaled. Scaled experimental TMR 
concentration and scaled numerical TMR levels were given by 
Mi
s =
Mi −M1
M5 −M1
                                                                                                                                                          (S12) 
[TMR]i
s =
[TMR]i − [TMR]1
[TMR]5 − [TMR]1
                                                                                                                                 (S13) 
where the indices i=1 and 5 correspond to t=0 and 24 h, respectively. The values of Mi were 
shown in Fig. 2b, while [TMR] was the output of gene expression model. It is important to 
note that the experimental results presented in Fig. 2b were normalized by TMR 
concentration before RA treatment. However, under the new scaling (Eq. S12), the lowest 
TMR concentration in the data set was 0, while the largest TMR concentration was 1 (0 ≤ 
Mi
s ≤ 1). 
The second term in Eq. S11 represented the sum of squared differences between the 
scaled numerical results and the experimental observations for TM concentration at t= 24h 
for different RA concentrations, i.e. 0.1 µM, 1µM and 10 µM. Different values of index j 
in Eq. S11 represent different RA concentrations; j=1, 2 and 3 represent RA=0.1, 1 and 10 
µM, respectively. The scaled numerical TM level ([TM]j
s) was defined as the TM 
concentration from the model divided by experimental observation  
[TM]j
s =
[TM]j
t=24
Nj
t=24                                                                                                                                                      (S14) 
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where [TM] and N denote simulation results and experimental data for TM concentration, 
respectively. Subscript j denotes RA concentration, while superscript (t=24) indicates that 
the values are for 24 hours after RA treatment. The ranges of variation of Ni were shown in 
Fig. 2a, while [TM] was the output of gene expression model. 
The parameter estimation process was initiated by determining TM initial concentration 
(𝐼𝐶TM) at various concentrations of RA. The experimental measurements for the TM 
concentration contained error bars (Fig. 2a). However, we needed to have constant values 
for the TM concentration at the different concentrations of RA. Thus, we randomly selected 
values for the TM concentration at the various concentrations of RA following a normal 
distribution. The bars in Fig. 2a denote the mean values of the TM level at various 
concentrations of RA, while the standard deviation is half the length of the total error bar.  
Using Particle swarm optimization (PSO), a population-based stochastic optimization 
technique, we estimated the independent unknown parameters, i.e. 𝐼max, 𝐼𝐶TMR and [REC1t] 
in a way such that the simulation results for TMR and TM levels fit the experimental data 
for various concentrations of RA (Fig. 3). After estimating the unknown parameters, we 
calculated the dependent parameters, i.e. translation rate constant and basal transcription 
rate via Eq. 4 and Eq. 5, respectively. If the calculated values were within the physiological 
ranges shown in Table 1, the obtained set of the parameters was accepted. Otherwise, we 
took a step back and chose a new set of values for the TM concentration at the various 
concentrations of RA, and the same procedure for fitting the parameters was repeated. 
Figure S2 outlines the implemented procedure for model parameter estimation. 
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Figure S2. Flow chart of the parameter estimation algorithm.  
It is important to note that our problem does not have a unique solution, since the 
experimental data used for fitting the model parameters is subject to error (Fig. 2a). The 
estimated values for the unknown parameters depend on the randomly selected values for 
the TM concentration at RA=10 μM, RA= 1 μM, and RA=0.1 μM.  Thus, we repeated the 
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parameter estimation algorithm 150 times independently and obtained several sets of valid 
solutions.  
The obtained values for 𝐼𝐶TMR, 𝐼𝑚𝑎𝑥 and [REC1t] were within the ranges shown in Fig. 
S3. The y-axis range in Fig. S3 shows the physiological range for each parameter.   
 
Figure S3. Ranges of the obtained values for the TM transcription rate, the TMR initial 
concentration, and the total concentration of the transcription factor that activates TM gene. These 
results were based on 150 valid solutions. 
 
The mean estimated value for total transcription factor concentration were 7 × 10−8M 
(Fig. S3), which is comparable with the reported value of 5 × 10−8M for RAR concentration 
in promyelocytic leukemia cells [86]. The obtained values for dependent unknown 
parameters, i.e. 𝑘trans and 𝐼0 were within the ranges shown in Fig. S4. The y-axis range in 
Fig. S4 shows the physiological range for each parameter.   
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Figure S4. Ranges of the obtained values for the translation rate constant and the basal 
transcription rate. 
 
3.6.2.2. Particle swarm optimization  
The particle swarm optimization (PSO) method has been shown to be efficient in 
estimating ODE model parameters [53, 87, 88]. PSO involves a swarm of particles, where 
each particle represents a point in a D-dimensional space, where D is the number of 
parameters to be estimated. PSO finds the global optimum of the objective function by 
iteratively changing the positions of the particles. In PSO, the position of each particle in 
the parameter space is changed based on the experience, or knowledge, of the particle and 
its neighbors. Suppose that particles are randomly distributed in the parameter space at t=0, 
and the position of the ith particle in a D dimensional parameter space can be described by 
the vector 
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 𝒙i = [𝑥i1, 𝑥i2, … , 𝑥iD].                                                                                                        (S15) 
PSO calculates the objective function value (aka fitness value) for each particle and 
iteratively updates the position of each particle by 
𝒙i(𝑡 + 1) = 𝒙i(𝑡) + 𝒗i(𝑡 + 1)                                                                                                (S16) 
where 𝑡 and 𝑡 + 1 are two consecutive iterations of the algorithm, and 𝒗i indicates the vector 
of velocity components of the ith particle in the D-dimensional parameter space. The 
velocity of the ith particle is defined by 
𝒗i(𝑡 + 1) = 𝒗i(𝑡) + θ1(pi − 𝒙i(𝑡))R1 + θ2(g − 𝒙i(𝑡))R2,                                             (S17) 
where  pi and g denote the local best solution found by the ith particle and the best solution 
found over the entire population of the particles. θ1 and θ2, which are cognitive and social 
coefficients, respectively, modulate the magnitude of the steps taken by the particle. In this 
study, we used (θ1, θ2)=(0.05564, 0.02886), [53].  R1 and R2 are random vectors generated 
from a uniform distribution in [0,1]. The first term in Eq. S17 is called the inertia component 
and prevents the particle from significantly changing direction, while the second term in 
Eq. S17 is called the cognitive component, which indicates that the particles prefer to return 
to their own previously found best positions. The third term in Eq. S17 is named the social 
component, which accounts for the tendency of the particles to move towards the position 
of the particle which has the lowest objective function value. After updating the particle 
positions at each time step, PSO calculates the objective function value for all particles. 
PSO then updates the personal best position for each particle and the global best position 
over the whole population of the particles. This iterative optimization continues until a 
stopping criterion is met. The global best particle is represented as the best solution at the 
end of optimization process. Figure S5 shows the flow diagram of the PSO. In this study, 
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the population size (number of particles) was 1000, while the number of generations (Gen) 
was 100. 
 
Figure S5. Flow chart of the particle swarm optimization algorithm.  
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3.6.3. Population pharmacokinetic modelling of RA 
We constructed a two-compartment pharmacokinetic model (Fig. 6) in MATLAB 
SimBiology and fit the model parameters, i.e. 𝑘a, 𝑘d , 𝑘cp, 𝑘pc, 𝑉c and 𝑉p to the data shown 
in Fig. 5. 𝑘cp and 𝑘pc were the distribution rate constant from the central compartment to 
the peripheral compartment, and the distribution rate constant from the peripheral 
compartment to the central compartment, respectively. 𝑘cp and 𝑘pc were defined by  
𝑘cp =
𝑄cp
𝑉c
                                                                                                                                      (S18) 
𝑘pc =
𝑄cp
𝑉p
,                                                                                                                                     (S19) 
where 𝑄cp is the intercompartmental clearance [89]. We used a MATLAB function called 
nlmefista, which is designed to find the maximum likelihood estimates of the parameters 
by fitting a nonlinear mixed-effects regression model. Nonlinear mixed-effects regression 
models have been widely used for the analysis of pharmacokinetic data, as they can consider 
inter-subject variability in parameters by incorporating random effects into the model [90]. 
The estimated values for  𝑘a, 𝑘d , 𝑄cp, 𝑉c and 𝑉p were 0.62 1/h, 0.56 1/h, 0.011 L/h , 81.92 
L and 3.01 L, respectively. The simulation results corresponding to these estimated values 
were shown by solid lines in Fig. 5. We used other fitting methods in MATLAB SimBiology 
such as fminsearch and lsqcurvefit which are used to fit a model to data using a derivative 
free method [91] and a nonlinear least-square curve fitting technique [92]. The curves fit by 
different methods looked very similar. The estimated values for 𝑘a, 𝑘d  and 𝑉c by different 
methods were very close, while the estimated values for 𝑄cp and 𝑉p depended strongly on 
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the fitting method. Thus, 𝑄cp and 𝑉p were not identifiable considering the size of the data 
set. Additional data points were needed to obtain more accurate estimates for the parameter. 
However, the main goal of this study was not estimating the pharmacokinetic parameters 
following oral administration of RA. We aimed to investigate the effects of RA therapy on 
thrombin generation by coupling four different models, i.e. the pharmacokinetic model, the 
gene expression model, the sTM release model and the ODE model of the coagulation 
cascade. Since the curves fit to the pharmacokinetic data through different methods were 
almost the same, we used the output of the pharmacokinetic model, i.e. fitted curves, as 
input in the gene expression model to investigate the variations of TM and TMR following 
RA therapy. Pharmacokinetic parameters of RA following oral dosing can be better 
estimated using the presented model in this paper once there is more clinical data available.    
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Chapter 4 
Regulation of CSF and brain tissue sodium levels by the blood-CSF and blood-
brain barriers during migraine 
 
4.1.  Introduction 
Migraine is ranked among the top five causes of disability in the world [1]. Although 
the exact underlying causes of migraine are not known, common triggers of migraine 
include dehydration, stress, sleep disorders, hunger, etc. Understanding the 
pathophysiology of migraine is challenging because migraine triggering is different for 
everyone. Many of the triggers of migraine change the sodium balance in the brain. Animal 
and human studies [2-5] have revealed that migraine sufferers have higher levels of 
cerebrospinal fluid (CSF) and brain interstitial fluid (ISF) sodium than control groups, while 
there is no significant difference between blood concentration of sodium in migraineurs and 
healthy controls.  Studies have indicated that elevated levels of ISF sodium increase 
neuronal excitability [6, 7], which subsequently results in migraine  Brain sodium levels 
ultimately derive from peripheral circulation. Sodium is exchanged between the blood and 
brain across two major blood-brain interfaces, namely the blood-brain barrier (BBB) and 
the blood-CSF barrier (BCSFB). The BBB is formed by specialized endothelial cells lining 
the cerebral microvasculature and controls sodium exchange between the ISF and blood, 
while the BCSFB is formed by choroid plexus epithelial cells and regulates sodium 
transport between ventricular CSF and blood. Transfer of sodium across the BBB and the 
BCSFB predominantly take places via active, hence transcellular mechanisms. However, 
sodium may be able to cross the BCSFB and the BBB via a paracellular route through tight 
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junctions between epithelial cells at the BCSFB and between endothelial cells at the BBB 
[8].  
It is believed that the BCSFB and BBB are highly responsible for maintaining ion 
homeostasis in the brain. Thus, a disturbance in sodium transport mechanisms at the BCSFB 
and/or BBB can alter CSF and brain tissue sodium concentrations. However, the relative 
contributions of the two interfaces in the regulation of brain sodium homeostasis have yet 
to be determined. In this work, we use mechanistic modeling to study the significance of 
the BCSFB and BBB in controlling brain tissue and CSF sodium levels. We develop a 
mathematical model consisting of four compartments: the ventricular system, subarachnoid 
space, brain tissue and blood. Net movement of sodium across the BCSFB and BBB through 
different active and passive transport mechanisms is modeled by influx and efflux 
permeability coefficients of the interfaces to sodium. Influx permeability coefficients of the 
BCSFB and BBB to sodium refer to sodium movement from blood to CSF and brain tissue, 
respectively, whereas efflux permeability coefficients of the BCSFB and BBB to sodium 
represent sodium movement from CSF and brain tissue to blood, respectively. We study the 
dynamics of sodium distribution in the brain following a perturbation in the influx and 
efflux permeabilities of the BCSFB and BBB to sodium. We then perform a global 
sensitivity analysis (GSA) to assess the significance of the BCSFB and BBB in controlling 
sodium concentrations in the brain tissue, ventricular CSF and subarachnoid CSF. Our 
results reveal that the influx permeability coefficient of the BCSFB to sodium is the most 
sensitive model parameter in controlling ventricular CSF sodium concentration. Depending 
on the time elapsed from perturbations of the permeability coefficients, brain tissue and 
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subarachnoid space CSF sodium levels can be significantly controlled by the BCSFB and/or 
BBB. 
The computational model presented in this study can not only shed light on the dynamics 
of sodium exchange between CSF, brain tissue and blood, but can also provide insight for 
future experimental studies. In addition, this work can potentially offer a new strategy to 
normalize the elevated levels of brain sodium in migraine sufferers and potentially treat 
migraines. 
 
4.2.  Methods 
4.2.1.  Model Development 
We modeled a rat’s brain by three concentric spheres representing the ventricular 
system, brain tissue and subarachnoid space (Fig. 1). Brain tissue was modeled as a single 
compartment. We assumed that blood vessels are distributed randomly, following a uniform 
distribution, throughout the brain tissue.  
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(a) (b) 
 
 
Figure 1. Schematic of the model. (a) A 3D model of a rat’s brain. (b) A 2D view of the cross 
section of the 3D model. The inner circle, shown in blue, represents the ventricular system, while 
the outer ring, shown in blue, is subarachnoid space. The white region between two dashed circles 
is brain tissue. Blood vessels, shown in red filled circles, are distributed uniformly in the brain 
tissue. The green circular border which separates blood from the brain tissue is the BBB. The 
BCSFB which is depicted by a yellow ellipsoid separates blood from the ventricular CSF. 
Numbers in the figure specify the types and locations of sodium transport: 1. capillary-brain 
transport across the BBB; 2. exchange between CSF and ISF; 3. blood-CSF exchange across the 
BCSFB; 4. diffusive transport in the radial direction in the brain tissue; 5. transport by the CSF 
flow from the ventricular system to the subarachnoid space; 6 transport by the CSF flow from the 
subarachnoid space to the blood. Arrows 5 and 6 indicate CSF flow direction from the ventricular 
system to the subarachnoid space, and from the subarachnoid space to the blood. Although CSF 
flow has been modeled (Eqs 1-2), the model does not include actual channels for transferring CSF 
flow between the ventricular system, subarachnoid space and blood. It should be noted that the 
size and number of the graphic symbols of blood vessels, as well as the size of the graphic symbol 
of choroid plexus (a.k.a BCSFB) do not represent their realistic values given in Table 1. 
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The inner sphere, which represents the ventricular system, includes the BCSFB. CSF is 
secreted by the BCSFB cells, a.k.a the choroid plexus epithelial cells, flows into the 
ventricular system, and then passes through small openings (foramina) into the 
subarachnoid space where it is absorbed through blood vessels into the bloodstream. It has 
also been suggested that a part of subarachnoid CSF moves into the brain along paravascular 
routes surrounding cerebral arteries, where it mixes with brain ISF and leaves the brain 
along veins [9, 10]. In the current model, we have ignored CSF flow from subarachnoid 
space to brain ISF (See Section 4 for further discussion of this subject). Thus, we have 
assumed that the CSF secretion rate is equal to the CSF absorption rate from the 
subarachnoid space to the blood. We have also assumed that sodium can be easily 
exchanged between the brain tissue and the CSF at the interface of brain tissue and the 
ventricular system, and at the contact surface of the subarachnoid space and brain tissue 
(dashed circles in Fig. 1b). This is due to the negligible permeability of the contact surfaces. 
This transport can be considered as a diffusive transport with a very large diffusion 
coefficient, and is different from the convective CSF flow from the subarachnoid space to 
the ISF, which has been ignored in this work. Sodium is also exchanged between blood and 
brain tissue across the BBB, and can also diffuse in the brain tissue down its concentration 
gradient.  
4.2.2. Formulation of the model 
Ventricular and subarachnoid CSF sodium concentrations were modeled by ordinary 
differential equations (ODEs) represented by Eqs. 1-2, while the variation of sodium level 
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across brain tissue was modeled by a partial differential equation (PDE), represented by Eq. 
3.   
𝜕𝐶𝑣(𝑡)
𝜕𝑡
=
𝑃𝐵𝐶𝑆𝐹𝐵𝐴𝐵𝐶𝑆𝐹𝐵
𝑉𝑣
𝐶𝑏𝑙𝑜𝑜𝑑 −
𝑃𝐵𝐶𝑆𝐹𝐵
′ 𝐴𝐵𝐶𝑆𝐹𝐵
𝑉𝑣
𝐶𝑣 +
𝑃𝑣𝑏𝐴𝑣𝜆
𝑉𝑣
(
𝐶𝑏𝑟(𝑡, 𝑟𝑖)
𝑓𝑑
− 𝐶𝑣) −
𝑄𝑐𝑠𝑓
𝑉𝑣
𝐶𝑣       (1) 
𝜕𝐶𝑠(𝑡)
𝜕𝑡
=
𝑃𝑠𝑏𝐴𝑠𝜆
𝑉𝑠
(
𝐶𝑏𝑟(𝑡, 𝑟𝑜)
𝑓𝑑
− 𝐶𝑠) +
𝑄𝑐𝑠𝑓
𝑉𝑠
𝐶𝑣 −
𝑄𝑐𝑠𝑓
𝑉𝑠
𝐶𝑠                                                                     (2) 
𝜕𝐶𝑏𝑟(𝑡, 𝑟)
𝜕𝑡
= 𝑃𝐵𝐵𝐵𝐴𝐵𝐵𝐵𝐶𝑏𝑙𝑜𝑜𝑑 −
𝑃𝐵𝐵𝐵
′ 𝐴𝐵𝐵𝐵
𝑓𝑑
𝐶𝑏𝑟 +
𝜆
𝜌𝑓𝑑𝑟2
𝜕
𝜕𝑟
(𝐷𝑟2
𝜕𝐶𝑏𝑟
𝜕𝑡
),               𝑟𝑖 < 𝑟 < 𝑟𝑜  (3) 
 
where 𝐶𝑣, 𝐶𝑠, 𝐶𝑏𝑙𝑜𝑜𝑑, 𝐶𝑏𝑟 and 𝑡 represent ventricular CSF sodium concentration, 
subarachnoid CSF sodium concentration, blood sodium concentration, sodium level in brain 
tissue and time, respectively. 𝐶𝑣, 𝐶𝑠  and 𝐶𝑏𝑙𝑜𝑜𝑑 are expressed in mole ml
−1, while 𝐶𝑏𝑟 is 
defined as moles of sodium per gram of brain (mole g−1). 𝐶𝑏𝑟 includes sodium content in 
brain ISF and in brain cells. The ISF sodium concentration (mole ml−1) was estimated from 
the brain tissue sodium level (mole g−1) by [11] 
𝐶𝐼𝑆𝐹(𝑡, 𝑟) =
𝐶𝑏𝑟(𝑡, 𝑟)
𝑓𝑑
                                                                                                                      (4) 
where 𝐶𝐼𝑆𝐹 and 𝑓𝑑  are the ISF sodium concentration and sodium distribution factor, 
respectively. The model’s parameters are defined in Table 1.  
Table 1. Physiological values of the model’s parameters for an adult rat 
Parameters Description Value Reference 
𝑃𝐵𝐶𝑆𝐹𝐵 
BCSFB influx permeability 
coefficient to sodium (from blood 
to CSF) 
3.8 × 10−5  (cm s−1) [11] 
𝐴𝐵𝐶𝑆𝐹𝐵 Surface area of BCSFB 1 (cm
2) [11] 
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𝑃𝐵𝐶𝑆𝐹𝐵
′  
BCSFB efflux permeability 
coefficient to sodium (from CSF 
to blood) 
6.9 × 10−7  (cm s−1) Calculated 
𝑉𝑠 Subarachnoid space volume 0.2 (cm
3) [11, 12] 
𝑉𝑣 Ventricular system volume 0.1 (cm
3) [11, 12] 
𝑉𝑏 Brain tissue volume 1.1 (cm
3) [13] 
𝑃𝐵𝐵𝐵 
BBB influx permeability 
coefficient to sodium (from blood 
to brain tissue) 
1.4 × 10−7  (cm s−1) [11] 
𝐴𝐵𝐵𝐵 Surface area of the BBB 140 (cm
2 g−1) [11] 
𝑃𝐵𝐵𝐵
′  
BBB efflux permeability 
coefficient to sodium (from brain 
tissue to blood) 
1.35 × 10−7 cm s−1 Calculated 
𝑓𝑑 Sodium distribution factor 0.34  (cm
3 g−1) [11] 
𝐷 
Diffusion coefficient of 
sodium in the brain ISF 
1.15 × 10−5 
(cm2 s−1) 
[14] 
𝑄𝑐𝑠𝑓 CSF flow rate 
3.6 × 10−5 
(cm3 s−1) 
[11] 
𝑃𝑣𝑏 
Permeability coefficient of the 
contact surface of brain tissue and 
ventricular system to sodium 
106  (cm s−1) 
A large 
value was used 
𝑃𝑠𝑏 
Permeability coefficient of the 
contact surface of brain tissue and 
subarachnoid space to sodium 
106  (cm s−1) 
A large 
value was used 
𝜆 ISF/brain volume fraction 0.2 (dimensionless) [11, 15] 
𝜌 Rat brain density 1 (g cm−3) [11] 
 
The parameters 𝑟𝑖 and 𝑟𝑜, which specify the boundaries of brain tissue in Eq. 3 and 
Figure 1b, were obtained via the relationships 
𝑉𝑣 =
4
3
𝜋𝑟𝑖
3                                                                                                                                        (5) 
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and 
𝑉𝑣 + 𝑉𝑏 =
4
3
𝜋𝑟𝑜
3,                                                                                                                             (6) 
where 𝑉𝑣 and 𝑉𝑏 represent the ventricular system volume and brain tissue volume, 
respectively. 𝑟𝑖 is the radius of the inner sphere representing the ventricular system, while 
𝑟𝑜 is the radius of the middle sphere that represents the outer boundary of the brain tissue 
(Fig 1b). The terms on the left-hand side of Eqs. 1 and 2 represent the rate of change of 
sodium concentration (mole ml−1) in the ventricular and subarachnoid CSF, respectively, 
while the term on the left-hand side of Eq. 3 represents the rate of change of sodium level 
(mole g−1) in the brain tissue. The four terms on the right-hand side of Eq. 1 represent 
sodium transport from the blood to the ventricular CSF, sodium movement from the 
ventricular CSF to the blood, exchange of sodium between the ventricular CSF and the brain 
tissue, and sodium loss from the ventricular system due to bulk flow of CSF from the 
ventricular system to the subarachnoid space, from left to right, respectively. The three 
terms on the right-hand side of Eq. 2 denote exchange of sodium between the subarachnoid 
CSF and the brain tissue, sodium input to the subarachnoid CSF due to the bulk flow of 
CSF, and sodium loss from the subarachnoid space due to CSF absorption into the blood, 
from left to right, respectively. The three terms on the right-hand side of Eq. 3 represent 
sodium transport from the blood to the brain tissue, sodium movement from the brain tissue 
to the blood, and diffusive transport of sodium across the brain tissue, from left to right, 
respectively.            
The initial conditions for the ODEs (Eqs. 1-2) are given by [16, 17] 
𝐶𝑣 = 𝐶𝑠 = 145 mM.                                                                                                                       (7) 
We have also assumed that 𝐶𝑏𝑙𝑜𝑜𝑑 is 140 mM at steady state [16]. 
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Rates of exchange of sodium at the boundaries of Eq. 3 are defined by  
 
𝑄𝑣 = 𝑃𝑣𝑏𝐴𝑣𝜆 (𝐶𝑣 −
𝐶𝑏𝑟(𝑡, 𝑟)
𝑓𝑑
)                                        𝑟 = 𝑟𝑖                                                  (8) 
𝑄𝑠 = 𝑃𝑠𝑏𝐴𝑠𝜆 (𝐶𝑠 −
𝐶𝑏𝑟(𝑡, 𝑟)
𝑓𝑑
) .                                       𝑟 = 𝑟𝑜                                                 (9) 
We used large values for 𝑃𝑠𝑏 and 𝑃𝑣𝑏  due to high permeability of the contact surfaces 
to sodium. Thus, the ISF sodium concentration is approximately in equilibrium with 
ventricular and subarachnoid sodium concentrations at the interface of brain tissue and CSF. 
It is important to note that passive transport of sodium across the boundaries of brain tissue 
and CSF is regulated by the concentration gradient between the CSF and brain ISF (Eqs. 7-
8). Brain ISF sodium concentration is estimated from brain tissue sodium level by Eq. 4. 𝐴𝑣 
and 𝐴𝑠 in Eqs. 8 and 9 represent the contact surface area of the brain tissue and the 
ventricular system, and the contact surface area of the brain tissue and the subarachnoid 
space, respectively. The contact surfaces were modeled as concentric spheres with the 
radiuses of 𝑟𝑖 and 𝑟𝑜 (Fig. 1). 𝐴𝑣 and 𝐴𝑠 were obtained by 
𝐴𝑣 = 4𝜋𝑟𝑖
2                                                                                                                                      (10) 
and 
𝐴𝑠 = 4𝜋𝑟𝑜
2                                                                                                                                     (11) 
where 𝑟𝑖 and 𝑟𝑜 were calculated from Eqs. 5 and 6 using the physiological values of 𝑉𝑣 and 
𝑉𝑏 (Table 1). In this model, 𝐴𝑣 and 𝐴𝑠 were obtained to be 1 and 5.5 cm
2, respectively, 
consistent with experimental estimates of the contact surfaces areas [18, 19].   
𝑃𝐵𝐶𝑆𝐹𝐵
′  and 𝑃𝐵𝐵𝐵
′  were calculated assuming that the CSF sodium level is in equilibrium 
with the brain tissue sodium concentration at t=0 (steady state): 
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 𝐶𝑏𝑟(𝑡, 𝑟) = 𝐶𝑣 × 𝑓𝑑 = 𝐶𝑠 × 𝑓𝑑 .                                                 for          𝑟𝑖 ≤ 𝑟 ≤ 𝑟𝑜      (12) 
This assumption implies that there is no sodium exchange between the CSF and the 
brain tissue at the two contact surfaces of brain tissue and CSF at t=0 [20, 21]. The obtained 
values for 𝑃𝐵𝐶𝑆𝐹𝐵
′  and 𝑃𝐵𝐵𝐵
′  were 6.9 × 10−7  cm s−1  and 1.35 × 10−7 cm s−1, respectively. In 
order to assess the validity of the obtained value for 𝑃𝐵𝐵𝐵
′ , we calculated the rate constant 
for total sodium efflux from the brain tissue to the blood, defined by 
𝑃𝐵𝐵𝐵
′ 𝐴𝐵𝐵𝐵
𝑓𝑑
 [22]. The 
average value of 
𝑃𝐵𝐵𝐵
′ 𝐴𝐵𝐵𝐵
𝑓𝑑
 was 5.5 × 10−5  s−1 in this work, which is consistent with the value 
of 1 × 10−4  s−1 reported by Cserr et al [22]. 
In Section 3, we perform a local sensitivity analysis to investigate how perturbations in 
𝑃𝐵𝐶𝑆𝐹𝐵, 𝑃𝐵𝐵𝐵, 𝑃𝐵𝐶𝑆𝐹𝐵
′  or 𝑃𝐵𝐵𝐵
′  affect brain and CSF sodium concentrations. We also perform 
a global sensitivity analysis (GSA) to further analyze the significance of variations in the 
permeability coefficients in controlling the levels of sodium in the CSF and brain tissue. To 
solve the system of differential equations described by Eqs 1-3, we discretize Eq. 3 with 
respect to the variable 𝑟 using the central difference approximation, and we approximate 
the time derivatives via backward differences. The main advantage of this fully implicit 
scheme, a.k.a. backward time central space, is that it is unconditionally stable.    
4.2.3. Global sensitivity analysis  
Global sensitivity analysis (GSA) is a numerical method designed to analyze the impacts 
of uncertain parameters on a model’s output. Compared to local sensitivity analysis, which 
assesses the changes of model response by making small perturbations to each parameter 
while keeping the remaining parameters unchanged, GSA analyzes the variations in the 
model output when all model parameters can vary simultaneously over specified ranges. In 
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other words, GSA investigates how the uncertainty of the model’s output is apportioned to 
variations in multiple model inputs. This feature makes GSA useful for understanding the 
contributions of uncertain model parameters to the variations of the model output. In this 
work, we use GSA to compare the importance of 𝑃𝐵𝐶𝑆𝐹𝐵, 𝑃𝐵𝐵𝐵, 𝑃𝐵𝐶𝑆𝐹𝐵
′  and 𝑃𝐵𝐵𝐵
′   in 
controlling brain tissue and CSF sodium concentrations, while taking into account the inter-
subject variability in all of the model’s parameters. We use a MATLAB toolbox for GSA, 
called SAFE [23]. We perform Sobol’s sensitivity analysis, which quantitively ranks the 
relative importance of the parameters by decomposing the model’s output variance into the 
contributions associated with each model’s input. Sobol’s method, which has been widely 
applied to complex systems biology and pharmacology models [24-32], calculates the first-
order and total-effect sensitivity indices for each model parameter. The first-order indices 
(𝑆𝑖) measure the individual contributions of each input to the variance of the model output, 
while the total-effect indices (𝑆𝑇𝑖) represent the total contribution of the input, including its 
first-order effect and all higher-order interactions. The total-effect sensitivity indices can be 
used to identify unimportant model parameters. Non-influential parameters can be fixed at 
any value within their range of variability without significantly affecting the model 
response. In Sobol’s sensitivity analysis technique, the model parameters that have total-
effect sensitivity indices below 0.01 are often considered non-influential [33, 34] (see 
Supplementary Information in Section 4.6 for further details).   
4.3. Results 
It is believed that brain sodium homeostasis is highly regulated by the BCSFB and the 
BBB. Elevated levels of sodium in the CSF and brain tissue of migraine sufferers can be 
due to variations in the influx and/or efflux permeability coefficients of the BCSFB and/or 
  
 
130 
the BBB to sodium. Heuristically, one may expect that the elevated CSF sodium 
concentration is due to increased transport of sodium from blood into CSF and/or decreased 
uptake of sodium from CSF into blood. Figure 2 shows the variations in brain tissue, 
ventricular and subarachnoid CSF sodium concentrations within 2 hours after either a 20% 
increase in the influx permeability coefficient of the BCSFB to sodium (𝑃𝐵𝐶𝑆𝐹𝐵), or a 20% 
decrease in the efflux permeability coefficient of the BCSFB to sodium (𝑃𝐵𝐶𝑆𝐹𝐵
′ ). 
 
  
(a) (b) 
  
(c) (d) 
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(e) (f) 
 
Figure 2. Variations of (a) 𝐶𝑣 after increasing 𝑃𝐵𝐶𝑆𝐹𝐵 by 20%, (b) 𝐶𝑠 after increasing 𝑃𝐵𝐶𝑆𝐹𝐵 
by 20%, (c) 𝐶𝑏𝑟 after increasing 𝑃𝐵𝐶𝑆𝐹𝐵 by 20%, (d) 𝐶𝑣 after decreasing 𝑃𝐵𝐶𝑆𝐹𝐵
′  by 20%, (e) 𝐶𝑠 
after decreasing 𝑃𝐵𝐶𝑆𝐹𝐵
′  by 20% (f) 𝐶𝑏𝑟 after decreasing  𝑃𝐵𝐶𝑆𝐹𝐵
′  by 20%. 
 
Ventricular CSF sodium concentration increases after a 20% rise in 𝑃𝐵𝐶𝑆𝐹𝐵 or a 20% 
decrease in 𝑃𝐵𝐶𝑆𝐹𝐵
′  (Figs. 2a and 2d). We assumed that sodium exchange between blood 
and CSF does not change blood concentration of sodium significantly, due to the large 
volume of blood compared to CSF. Thus, 𝐶𝑏𝑙𝑜𝑜𝑑 remains unchanged after changing the 
influx or efflux permeability coefficients of BCSFB to sodium. Figures 2c and 2f show that 
the elevated levels of sodium in the ventricular CSF lead to diffusion of sodium from CSF 
to brain tissue and distribution of sodium into the brain tissue over time [11, 35]. Sodium 
moves by bulk flow of CSF from the ventricular system to the subarachnoid space, where 
it can be exchanged between CSF and brain tissue. Subarachnoid CSF sodium concentration 
increases after increasing 𝑃𝐵𝐶𝑆𝐹𝐵 or decreasing 𝑃𝐵𝐶𝑆𝐹𝐵
′  by 20% (Figs. 2b and 2e). Our results 
indicate that ventricular CSF and subarachnoid CSF sodium concentration values at any 
given time point are more sensitive to variations of 𝑃𝐵𝐶𝑆𝐹𝐵 than of 𝑃𝐵𝐶𝑆𝐹𝐵
′ .. Similarly, brain 
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tissue sodium concentration values at any given time point and spatial location are more 
sensitive to changes of 𝑃𝑐𝑝 than of 𝑃𝑐𝑝
′ . These behaviors  can be explained by the observation 
that steady state loss of ventricular CSF sodium is largely due to bulk flow of CSF from the 
ventricular system into the subarachnoid space rather than to sodium uptake by blood across 
the BCSFB (Eq. 1 and physiological data in Table 1). However, the only source for sodium 
in the ventricular system is the choroid plexus epithelial cells, a.k.a BCSFB cells, at steady 
state. Thus, a 20% decrease in 𝑃𝐵𝐶𝑆𝐹𝐵
′  has a less significant impact than a 20% increase in 
𝑃𝐵𝐶𝑆𝐹𝐵 on CSF sodium content. It should be noted that we assume that there is no sodium 
exchange between the ventricular CSF and brain tissue at steady state (t=0).  
Similarly, one may expect that the elevated brain tissue sodium levels during migraine 
are due to increased sodium transport from blood to brain tissue and/or reduced sodium 
uptake from brain tissue into blood. Figure 3 depicts the changes in ventricular CSF, 
subarachnoid CSF and brain tissue sodium levels within 2 hours of either increasing the 
influx permeability coefficient of the BBB to sodium (𝑃𝐵𝐵𝐵) by 20%, or decreasing the 
efflux permeability coefficient of the BBB to sodium (𝑃𝐵𝐵𝐵
′ ) by 20%. 
  
(a) (b) 
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(c) (d) 
  
(e) (f) 
Figure 3. Variations of (a) 𝐶𝑣 after increasing 𝑃𝐵𝐵𝐵 by 20%, (b) 𝐶𝑠 after increasing 𝑃𝐵𝐵𝐵 by 20%, 
(c) 𝐶𝑏𝑟 after increasing 𝑃𝐵𝐵𝐵 by 20%, (d) 𝐶𝑣 after decreasing 𝑃𝐵𝐵𝐵
′  by 20%, (e) 𝐶𝑠 after decreasing 
𝑃𝐵𝐵𝐵
′  by 20% (f) 𝐶𝑏𝑟 after decreasing 𝑃𝐵𝐵𝐵
′  by 20% 
 
A 20% increase in 𝑃𝐵𝐵𝐵 or a 20% decrease in 𝑃𝐵𝐵𝐵
′  results in an accumulation of sodium 
in the brain tissue (Figs. 3c and 3f). The elevated levels of sodium in the brain tissue increase 
sodium transport from brain tissue to the ventricular system and subarachnoid space (Figs. 
3a, 3b, 3d and 3e). Our results indicate that brain tissue, ventricular CSF and subarachnoid 
CSF sodium levels are almost equally sensitive to variations in 𝑃𝐵𝐵𝐵 and 𝑃𝐵𝐵𝐵
′ .  
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Figure 4 shows the sodium flux between the brain tissue and CSF at the interface of 
brain tissue and the ventricular system, and at the contact surface of brain tissue and the 
subarachnoid space, after perturbation of 𝑃𝐵𝐶𝑆𝐹𝐵, 𝑃𝐵𝐵𝐵, 𝑃𝐵𝐶𝑆𝐹𝐵
′  or 𝑃𝐵𝐵𝐵
′   by 20%. Our results 
indicate that sodium flux from the ventricular system to the brain tissue is larger than 
sodium flux from the subarachnoid space to the brain tissue.  
  
(a) (b) 
  
(c) (d) 
Figure 4. Comparison of sodium flux at the interface of the brain tissue and the ventricular system 
with sodium flux at the interface of the brain tissue and the subarachnoid space after (a) increasing 
𝑃𝐵𝐶𝑆𝐹𝐵, (b) decreasing 𝑃𝐵𝐶𝑆𝐹𝐵
′ , (c) increasing 𝑃𝐵𝐵𝐵 (d) decreasing 𝑃𝐵𝐵𝐵
′  by 20%. The positive sign 
of the flux indicates that sodium is diffusing from the CSF to the brain tissue, while the negative 
sign indicates that sodium is diffusing from the brain tissue to the CSF. 
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Figure 2 and Figure 3 compare the variations in 𝐶𝑣, 𝐶𝑠,  and 𝐶𝑏𝑟 when a single parameter 
(i.e. 𝑃𝐵𝐶𝑆𝐹𝐵, 𝑃𝐵𝐵𝐵, 𝑃𝐵𝐶𝑆𝐹𝐵
′  or 𝑃𝐵𝐵𝐵
′ ) is perturbed and the rest of the parameters remain 
unchanged. However, in the case of migraines, all influx and efflux permeability 
coefficients can potentially vary. Additionally, Table 1 shows the average values of the 
physiological model’s parameters. These values can change across a population of rats of 
the same type. Thus, we used GSA [23] to consider the effects of variations in all model 
parameters. In this regard, we assumed that physiological concentration of sodium in CSF 
and blood can vary within 5% of the in vitro values (i.e. 𝐶𝑣 = 𝐶𝑠 = 145 mM, 𝐶𝑏𝑙𝑜𝑜𝑑 =
140 mM), while the remaining independent model parameters (𝑃𝐵𝐶𝑆𝐹𝐵, 𝐴𝐵𝐶𝑆𝐹𝐵, 𝑉𝑠, 𝑉𝑣, 𝑉𝑏, 
𝑃𝐵𝐵𝐵, 𝐴𝐵𝐵𝐵, 𝑓𝑑, 𝐷, 𝑄𝑐𝑠𝑓, 𝜆, 𝜌) can vary within 25% of the in vitro values (Table 1). This is 
due to considering the impacts of intrinsic variations between a population of rats of the 
same type, and the effects of measurement errors in the estimations of physiological model 
parameters on our simulations. Following a uniform distribution, we sampled 105 sets of 
parameters within their ranges of variability. We then calculated the dependent parameters, 
i.e. 𝑃𝐵𝐶𝑆𝐹𝐵
′  and 𝑃𝐵𝐵𝐵
′  for each set of parameters, assuming that the model is at steady state 
at t=0. Each of these 105 sets of parameters characterizes one healthy rat with different 
physiological parameters. We then assumed that 𝑃𝐵𝐶𝑆𝐹𝐵, 𝑃𝐵𝐵𝐵 , 𝑃𝐵𝐶𝑆𝐹𝐵
′ , and 𝑃𝐵𝐵𝐵
′  can 
undergo pathophysiological changes within 50% of their control values due to migraine 
triggers. We performed a GSA to investigate the significance of pathophysiological 
variations of 𝑃𝐵𝐶𝑆𝐹𝐵, 𝑃𝐵𝐵𝐵 , 𝑃𝐵𝐶𝑆𝐹𝐵
′ , and 𝑃𝐵𝐵𝐵
′  in influencing ventricular sodium 
concentration during episodic migraines. The model output was defined as the percent 
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change of total ventricular sodium concentration within 2 hours after perturbations of 
physiological 𝑃𝐵𝐶𝑆𝐹𝐵, 𝑃𝐵𝐵𝐵, 𝑃𝐵𝐶𝑆𝐹𝐵
′ , and 𝑃𝐵𝐵𝐵
′ : 
Model Output= 
(
∫ 𝐶𝑣 𝑑𝑡
𝑡𝑚𝑎𝑥
0
𝑡𝑚𝑎𝑥
) − 𝐶𝑣(𝑡=0)
𝐶𝑣(𝑡=0)
 . 
Our results indicate that pathophysiological variation of 𝑃𝐵𝐶𝑆𝐹𝐵 is much more important 
than that of 𝑃𝐵𝐵𝐵 , 𝑃𝐵𝐶𝑆𝐹𝐵
′ , and 𝑃𝐵𝐵𝐵
′  in influencing ventricular CSF sodium concentration 
(Fig. 5). It is important to note that each permeability coefficient is defined at two states: 
physiological and pathophysiological. A given permeability coefficient (e.g. 𝑃𝐵𝐶𝑆𝐹𝐵) in the 
physiological and pathophysiological state is shown by 𝑃𝐵𝐶𝑆𝐹𝐵( 𝑝ℎ𝑦𝑠𝑖𝑜𝑙𝑜𝑔𝑖𝑐𝑎𝑙) and 
𝑃𝐵𝐶𝑆𝐹𝐵( 𝑝𝑎𝑡ℎ𝑜𝑝ℎ𝑦𝑠𝑖𝑜𝑙𝑜𝑔𝑖𝑐𝑎𝑙), respectively. Variations in 
𝑃𝐵𝐶𝑆𝐹𝐵(𝑝ℎ𝑦𝑠𝑖𝑜𝑙𝑜𝑔𝑖𝑐𝑎𝑙 ) account for intrinsic variations between a population of rats of the 
same type and/or measurement errors in the estimations of the permeability coefficients. 
However, migraine triggers can cause a disturbance in sodium transport mechanisms at the 
BCSFB and/or BBB [36, 37]. This implies that migraine triggers can change physiological 
permeability coefficients. 𝑃𝐵𝐶𝑆𝐹𝐵(𝑝𝑎𝑡ℎ𝑜𝑝ℎ𝑦𝑠𝑖𝑜𝑙𝑜𝑔𝑖𝑐𝑎𝑙) represents the extent of variations 
in 𝑃𝐵𝐶𝑆𝐹𝐵(𝑝ℎ𝑦𝑠𝑖𝑜𝑙𝑜𝑔𝑖𝑐𝑎𝑙) due to migraine triggers. For a given rat with a given 
𝑃𝐵𝐶𝑆𝐹𝐵(𝑝ℎ𝑦𝑠𝑖𝑜𝑙𝑜𝑔𝑖𝑐𝑎𝑙), different migraine triggers can change 𝑃𝐵𝐶𝑆𝐹𝐵(𝑝ℎ𝑦𝑠𝑖𝑜𝑙𝑜𝑔𝑖𝑐𝑎𝑙) 
differently; these changes are represented by 𝑃𝐵𝐶𝑆𝐹𝐵(𝑝𝑎𝑡ℎ𝑜𝑝ℎ𝑦𝑠𝑖𝑜𝑙𝑜𝑔𝑖𝑐𝑎𝑙). Our results 
indicate that variations of 𝑃𝐵𝐶𝑆𝐹𝐵(𝑝ℎ𝑦𝑠𝑖𝑜𝑙𝑜𝑔𝑖𝑐𝑎𝑙) and 𝑃𝐵𝐵𝐵(𝑝ℎ𝑦𝑠𝑖𝑜𝑙𝑜𝑔𝑖𝑐𝑎𝑙) are much less 
important than those of 𝑃𝐵𝐶𝑆𝐹𝐵(𝑝𝑎𝑡ℎ𝑜𝑝ℎ𝑦𝑠𝑖𝑜𝑙𝑜𝑔𝑖𝑐𝑎𝑙) and 𝑃𝐵𝐵𝐵(𝑝𝑎𝑡ℎ𝑜𝑝ℎ𝑦𝑠𝑖𝑜𝑙𝑜𝑔𝑖𝑐𝑎𝑙) in 
influencing the percent change of total ventricular sodium concentration during migraines. 
This is mainly because the model output was defined as the percent change of total 
ventricular CSF sodium concentration between the pathophysiological and physiological 
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states. These results suggest that the ventricular CSF sodium concentration is more sensitive 
to an alteration in homeostasis of the transporters which mediate sodium influx into CSF 
across the BCSFB than to a variation in homeostasis of the transporters which regulate 
sodium uptake from the CSF across the BCSFB. In addition, these results indicate that the 
BBB plays a much less important role than the BCSFB in regulation of the ventricular CSF 
sodium concentration. It is important to note that total-effect sensitivity indices, which 
account for total contribution of the inputs to variations in the model response, should be 
used to compare the significance of the model inputs in controlling the model output. 𝑃𝐵𝐶𝑆𝐹𝐵 
has a larger 𝑆𝑇𝑖 than 𝑃𝐵𝐵𝐵, 𝑃𝐵𝐶𝑆𝐹𝐵
′ , and 𝑃𝐵𝐵𝐵
′ , which indicates that 𝑃𝐵𝐶𝑆𝐹𝐵 is a more 
influential parameter in the model. 
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Figure 5. Sensitivity ranking of the model parameters. The model output was set to the time 
integral of 𝐶𝑣 within 2 hours after perturbation of the model’s parameters. The blue bars represent 
first-order sensitivity indices, while the green bars show the total-effect sensitivity indices. The 
error bars, shown in red, indicate the bootstrap confidence intervals (95% confidence intervals) of 
the mean values. 
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Total-effect sensitivity indices of some of the parameters are smaller than 0.01 (Fig. 5). 
This means that the variations of these parameters do not influence the variance of the model 
output significantly; thus these parameters can be fixed at arbitrary values within their 
ranges [33, 34]. Figure 6 demonstrates the rank order of the model parameters when the 
model output was defined as the percent change of total subarachnoid sodium concentration 
within 2 hours after perturbations of physiological  𝑃𝐵𝐶𝑆𝐹𝐵, 𝑃𝐵𝐵𝐵, 𝑃𝐵𝐶𝑆𝐹𝐵
′ , and 𝑃𝐵𝐵𝐵
′  due to 
migraine triggers: 
Model Output= 
(
∫ 𝐶𝑠 𝑑𝑡
𝑡𝑚𝑎𝑥
0
𝑡𝑚𝑎𝑥
) − 𝐶𝑠(𝑡=0)
𝐶𝑠(𝑡=0)
. 
Our results indicate that subarachnoid CSF sodium concentration is highly sensitive to 
pathophysiological changes in 𝑃𝐵𝐶𝑆𝐹𝐵, 𝑃𝐵𝐵𝐵 and 𝑃𝐵𝐵𝐵
′  (Fig.6). The fact that 
pathophysiological variations of 𝑃𝐵𝐵𝐵 and 𝑃𝐵𝐵𝐵
′  are more important in influencing 
subarachnoid sodium concentration than ventricular sodium concentration (Figs. 5-6) is 
because variations in 𝑃𝐵𝐵𝐵 and 𝑃𝐵𝐵𝐵
′  not only can affect sodium exchange at the contact 
surface of subarachnoid CSF and brain tissue, but also can influence sodium exchange 
between the ventricular system and brain tissue, thus affecting the amount of sodium 
entering the subarachnoid space from the ventricular system.  
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Figure 6. Relative significance of the model parameters in controlling subarachnoid CSF 
sodium concentration (𝐶𝑠) within 2 hours of the perturbation onset (𝑡𝑚𝑎𝑥 = 2 h). The blue bars 
represent first-order sensitivity indices, while the green bars show the total-effect sensitivity 
indices. The error bars, shown in red, indicate the bootstrap confidence intervals (95% confidence 
intervals) of the mean values. 
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We also performed a GSA to identify the influential parameters when the model output 
was the percent change in total level of brain sodium after 2 hours of perturbations of the 
physiological 𝑃𝐵𝐶𝑆𝐹𝐵, 𝑃𝐵𝐵𝐵, 𝑃𝐵𝐶𝑆𝐹𝐵
′ , and 𝑃𝐵𝐵𝐵
′  due to migraine triggers: 
Model Output= 
(∫ 𝐶𝑏𝑟 4𝜋𝑟
2𝑑𝑟
𝑟𝑜
𝑟𝑖
)−𝐶𝑏𝑟(𝑡=0)×(𝑡𝑜𝑡𝑎𝑙 𝑣𝑜𝑙𝑢𝑚𝑒 𝑜𝑓 𝑏𝑟𝑎𝑖𝑛 𝑡𝑖𝑠𝑠𝑢𝑒 )
𝐶𝑏𝑟(𝑡=0)×(𝑡𝑜𝑡𝑎𝑙 𝑣𝑜𝑙𝑢𝑚𝑒 𝑜𝑓 𝑏𝑟𝑎𝑖𝑛 𝑡𝑖𝑠𝑠𝑢𝑒 )
,                   t= 2 hr. 
Our results demonstrate that brain tissue sodium level is highly sensitive to 
pathophysiological variations in 𝑃𝐵𝐶𝑆𝐹𝐵, 𝑃𝐵𝐵𝐵, 𝑃𝐵𝐵𝐵
′  and 𝑃𝐵𝐶𝑆𝐹𝐵
′  in order of decreasing 
sensitivity (Fig. 7). This result implies that sodium exchange between CSF and brain tissue 
at the contact surface of the ventricular system and brain tissue, as well as at the contact 
surface of the subarachnoid space and brain tissue can significantly influence brain sodium 
levels during migraine.  
  
 
142 
 
Figure 7. Relative importance of the model parameters in controlling brain tissue sodium 
levels within 2 hours of the perturbation onset (𝑡𝑚𝑎𝑥 = 2 h). The blue bars represent first-order 
sensitivity indices, while the green bars show the total-effect sensitivity indices. The error bars, 
shown in red, indicate the bootstrap confidence intervals (95% confidence intervals) of the mean 
values. 
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The above results were obtained after perturbing 𝑃𝐵𝐶𝑆𝐹𝐵, 𝑃𝐵𝐵𝐵, 𝑃𝐵𝐶𝑆𝐹𝐵
′ , and 𝑃𝐵𝐵𝐵
′  at t=0 
and keeping them unchanged during the experiment time, i.e. t= 2 h. In order to investigate 
the impact of total experiment time on our results, we repeated our numerical experiments 
using different total experiment times including t= 1min, t= 5 min, t= 10 min, t= 30 min,  t= 
1 h and t=3 h. Our results show that brain tissue, ventricular CSF and subarachnoid CSF 
sodium levels are mainly sensitive to pathophysiological variations in 𝑃𝐵𝐶𝑆𝐹𝐵, 𝑃𝐵𝐵𝐵, 𝑃𝐵𝐵𝐵
′  
and 𝑃𝐵𝐶𝑆𝐹𝐵
′  (See Supplementary Information in Section 4.6: Figures S1-S18). The 
significance of pathophysiological changes of 𝑃𝐵𝐶𝑆𝐹𝐵, 𝑃𝐵𝐵𝐵, 𝑃𝐵𝐵𝐵
′  and 𝑃𝐵𝐶𝑆𝐹𝐵
′   in 
influencing the ventricular CSF, subarachnoid CSF and brain tissue sodium levels at 
different total experiment times is shown in Table 2.   
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Table 2. Total-effect sensitivity indices of the permeability coefficients at different total 
experiment times  
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Our results demonstrate that the ventricular CSF sodium concentration is highly 
sensitive to pathophysiological variations in 𝑃𝐵𝐶𝑆𝐹𝐵 , independent of experiment duration 
time. However, brain tissue and subarachnoid CSF sodium levels are more sensitive to 
pathophysiological variations of 𝑃𝐵𝐵𝐵 and 𝑃𝐵𝐵𝐵
′  than pathophysiological variations  of 
𝑃𝐵𝐶𝑆𝐹𝐵 at short total experiment times (such as 1, 5, 10  and 30 minutes). Pathophysiological 
variations of 𝑃𝐵𝐶𝑆𝐹𝐵 become more important than variations of 𝑃𝐵𝐵𝐵 and 𝑃𝐵𝐵𝐵
′  in controlling 
brain tissue and subarachnoid CSF sodium concentrations at longer experiment times (such 
as 1,  2 and 3 hours). This implies that the BCSFB becomes more important in controlling 
brain tissue sodium homeostasis as time passes. This change in the significance of BCSFB 
and BBB in the regulation of brain tissue and subarachnoid CSF sodium levels over time is 
mainly due to the model structure, physiological model parameters and the model output 
expression. For instance, increasing brain tissue volume by two-fold (which is not realistic) 
makes the BBB permeability coefficients (𝑃𝐵𝐵𝐵 and 𝑃𝐵𝐵𝐵
′ ) the most sensitive parameters in 
controlling brain tissue and subarachnoid CSF sodium levels, independent of the duration 
of the experiment (data not shown). This trend is due also in part to the fact that the 
ventricular CSF, whose sodium content is largely regulated by the BCSFB, would have 
enough time to influence sodium levels of its downstream compartments, including the 
brain tissue and the subarachnoid space.    
To investigate the dynamics of sodium exchange between the CSF and brain tissue at 
the interface of brain tissue and the ventricular system, and at the contact surface of brain 
tissue and subarachnoid space during an episode of migraine, we randomly sampled 105 sets 
of parameters, following a uniform distribution over a 18-dimensional parameter space and 
compared the average absolute sodium flux (𝑞𝑣) between brain tissue and ventricular CSF, 
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with the average absolute sodium flux (𝑞𝑠) between the brain tissue and subarachnoid CSF. 
The average absolute fluxes 𝑞𝑣 and 𝑞𝑠 are defined by  
𝑞𝑣 =
∫ |𝑃𝑣𝑏𝜆(𝐶𝑣 −
𝐶𝑏𝑟(𝑡, 𝑟𝑖)
𝑉𝑏𝑟
)| 𝑑𝑡
𝑡𝑚𝑎𝑥
0
𝑡𝑚𝑎𝑥
                                                                                     (13) 
𝑞𝑠 =
∫ |𝑃𝑠𝑏𝜆(𝐶𝑠 −
𝐶𝑏𝑟(𝑡, 𝑟𝑜)
𝑉𝑏𝑟
)| 𝑑𝑡 
𝑡𝑚𝑎𝑥
0
𝑡𝑚𝑎𝑥
   ,                                                                                 (14) 
where 𝑡𝑚𝑎𝑥 = 2 h. Figure 8 shows the ratio of 𝑞𝑣 to 𝑞𝑠 for the 10
5 randomly sampled 
parameters. Our results indicate that the ratio of 𝑞𝑣 to 𝑞𝑠 is greater than 1 for the majority 
of the samples, which indicates that the absolute sodium flux at the interface of the 
ventricular system and the brain tissue is greater than the absolute sodium flux at the contact 
surface of the subarachnoid space and the brain tissue. Similar results were obtained for 
other total experiment times including 𝑡𝑚𝑎𝑥 = 10 min, 30 min, 1 h  (data not shown). 
 
Figure 8. The ratio of absolute sodium flux at the interface of the ventricular system and the 
brain tissue (𝑞𝑣) to absolute sodium flux at the interface of the subarachnoid space and the brain 
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tissue (𝑞𝑠). 10
5 points were sampled randomly following a uniform distribution to generate this 
Figure. 
 
 
4.4. Discussion 
Previous studies [2-5] have indicated that migraine sufferers have higher levels of CSF 
and brain tissue sodium than the control group. However, blood levels of sodium remain 
unchanged during migraine [2]. Under the hypothesis that these elevated sodium levels are 
due to variations in the influx and/or efflux permeability of the BCSFB and/or the BBB to 
sodium, we investigated the significance of variations in the influx and efflux permeabilities 
of the BCSFB and the BBB to sodium in influencing CSF and brain tissue sodium levels. 
In this regard, first we developed a computational model for sodium exchange between 
different brain compartments, i.e. blood, brain tissue, ventricular and subarachnoid CSF. 
The model presented in this paper is similar in some respects to that of Smith and Rapoport 
[11]. However, there are two major differences between our model and theirs. First, our 
model includes the ventricular system and subarachnoid space as separate compartments. 
Thus, our model can distinguish between the ventricular and subarachnoid CSF, as well as 
provide insight into the dynamics of sodium exchange between the CSF and brain tissue at 
the interface of brain tissue and the ventricular system, and at the contact surface of brain 
tissue and the subarachnoid space. Second, we have proposed a more realistic model of 
brain tissue compared to previous studies [11, 38, 39]. Unlike previous studies that modeled 
brain tissue as a rectangular sheet bathed on two opposite sides by CSF, we modeled brain 
tissue as the area between two concentric spheres. Concentric spheres are more similar to 
the real shape of a rat brain, which resembles an ellipsoid. As a result, the contact surface 
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area of the brain tissue and the subarachnoid space is larger than that of the brain tissue and 
the ventricular system in our model. Thus, sodium exchange between the CSF and brain 
tissue at the two contact surfaces, as well as sodium diffusion in the brain tissue have been 
modeled more accurately in this work than in previous studies.  
We performed a global sensitivity analysis to compare the significance of the BCSFB 
and the BBB in controlling CSF and brain sodium levels. Our results indicate that 
pathophysiological variations of the BCSFB influx permeability coefficient to sodium 
(𝑃𝐵𝐶𝑆𝐹𝐵) are more important than variations of the BCSFB efflux permeability coefficient 
(𝑃𝐵𝐶𝑆𝐹𝐵
′ ), the BBB influx permeability coefficient (𝑃𝐵𝐵𝐵) and the BBB efflux permeability 
coefficient (𝑃𝐵𝐵𝐵
′ ) to sodium in controlling ventricular CSF sodium concentrations. Brain 
tissue and subarachnoid CSF sodium levels are more sensitive to pathophysiological 
variations of 𝑃𝐵𝐵𝐵 and 𝑃𝐵𝐵𝐵
′  than to variations of 𝑃𝐵𝐶𝑆𝐹𝐵 when total experiment time is 1, 
5, 10  and 30 minutes, while 𝑃𝐵𝐶𝑆𝐹𝐵 becomes more important that 𝑃𝐵𝐵𝐵 and 𝑃𝐵𝐵𝐵
′  in 
influencing brain tissue and subarachnoid CSF sodium levels when total experiment time is 
1,  2 and 3 h. Overall, our results show that 𝑃𝐵𝐶𝑆𝐹𝐵 plays an important role in the regulation 
of brain sodium homeostasis. 𝑃𝐵𝐶𝑆𝐹𝐵 represents the net movement of sodium from blood to 
CSF, which is regulated by a variety of BCSFB sodium transporters such as Na+, K+-
ATPase [40-43], ENaC [40, 44] and NKCC1 [45]. Thus, variations in 𝑃𝐵𝐶𝑆𝐹𝐵 can be 
attributed to hyperactivity and/or hypoactivity of one or more of these sodium transporters. 
Our theoretical mechanism implies that the disturbed sodium homeostasis in the brain 
during a migraine is most likely due to overactivity of Na+, K+-ATPases at the BCSFB and 
the BBB [36]. Na+, K+-ATPase is a highly-conserved membrane protein which is expressed 
in all cells. One Na+, K+-ATPase mediates active transport of three sodium ions out of the 
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cell for every two potassium ions entering the cell against the concentration gradients. We 
believe that disturbed homeostasis of Na+, K+-ATPase plays a key role in the 
pathophysiology of migraine [37], as  many regulators of Na+, K+-ATPase such as estrogen, 
adrenaline, insulin [46, 47], dopamine [48, 49], glutamate [50], etc are involved in the 
pathophysiology of migraine (See [36] for a comprehensive review). Furthermore, there are 
several lines of evidence supporting that CSF secretion as well as sodium transport from 
the BCSFB cells, a.k.a choroid plexus epithelial cells, to CSF is mostly mediated by Na+, 
K+-ATPases, which are expressed on the CSF-facing (apical) membrane of the BCSFB cells 
[42, 51, 52]. It has been shown that intracerebroventricular infusion of ouabain, an Na+, K+-
ATPase inhibitor, at 10 µg/day decreases CSF sodium concentration by almost 8 mM in 
Wister rats on a high-salt diet [41]. Ouabain can also reduce sodium transport from blood 
to CSF by 34% and 60% in frogs and rabbits, respectively [42, 43]. Thus, not only can the 
altered homeostasis of BCSFB Na+, K+-ATPases be a potential cause of the elevated CSF 
sodium concentration in a migraine, but also BCSFB Na+, K+-ATPase could be a candidate 
drug target to correct the elevated levels of sodium in CSF of migraine sufferers, potentially 
treating migraine. This hypothesis needs to be tested experimentally for different migraine 
triggers. ENaC is another sodium transporter which can play a key role in the regulation of 
CSF sodium levels. ENaC mediates passive sodium transport along a concentration gradient 
across the BCSFB. In Wister rats, ENaC is expressed at both membranes of BCSFB cells 
with a higher density at the CSF-facing (apical) membrane compared to the blood-facing 
(basolateral) membrane [53, 54]. This suggests that ENaC may play a major role in sodium 
uptake from CSF into BCSFB cells [55]. It should be noted that sodium movement through 
ENaC is likely to be unidirectional; thus, variations in the activity levels of ENaC at the 
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apical membrane of BCSFB cells can potentially change 𝑃𝐵𝐶𝑆𝐹𝐵
′ , while variations in ENaC 
activity levels at the basolateral membrane of BCSFB cells can possibly change 𝑃𝐵𝐶𝑆𝐹𝐵. It 
is not known how the expression levels of ENaC on the different membranes of BCSFB 
cells are affected by migraine triggers. The other main BCSFB sodium transporter is 
NKCC1, which can regulate CSF production [56] and sodium movement from blood to CSF 
[45]. Overall, sodium transport from blood to CSF across the BCSFB is regulated by a 
variety of transporters, channels and proteins, whose interactions with each other are not 
well understood. Further experimental studies are needed to elucidate the potential effects 
of various migraine triggers on the activity and expression levels of BCSFB Na+, K+-
ATPase, ENaC and NKCC1.  
Our results suggest that the BBB can play a more important role than the BCSFB in the 
regulation of brain tissue and subarachnoid CSF sodium concentrations within 30 minutes 
of pathophysiological perturbations of 𝑃𝐵𝐶𝑆𝐹𝐵, 𝑃𝐵𝐵𝐵, 𝑃𝐵𝐵𝐵
′  and 𝑃𝐵𝐶𝑆𝐹𝐵
′ . 𝑃𝐵𝐵𝐵 and 𝑃𝐵𝐵𝐵
′  were 
used in the current model to simulate the net movement of sodium from blood to brain 
tissue, and from brain tissue to blood, respectively. Variations in  𝑃𝐵𝐵𝐵 and 𝑃𝐵𝐵𝐵
′  can be 
attributed to altered homeostasis of the transporters, which mediate sodium movement 
across the BBB. The principal routes for sodium entry across the luminal membrane of the 
BBB endothelial cells are likely to be NKCC1 [57, 58] and NHE1,2 [59], while sodium is 
mainly pumped out of the BBB endothelial cells into brain ISF by Na+, K+-ATPase [8, 60, 
61]. It has been suggested that sodium transport from the brain ISF into the BBB endothelial 
cells is mainly mediated by sodium-linked transporters of organic solutes, including those 
for amino acids [8]. NHE 1,2 can also potentially contribute to sodium entry across the ISF-
facing (abluminal) membrane of endothelial cells. However, the impacts of migraine 
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triggers on the activity and expression levels of these sodium transporters are yet to be 
understood. Our results suggest that alterations of BBB sodium transporters homeostasis 
have more significant effects than variations of BCSFB sodium transporters homeostasis on 
brain tissue sodium levels within 30 minutes of the perturbation onset. It should be noted 
that our results were obtained using GSA, which gives us some insight into the importance 
of influx and efflux permeability of the BCSFB and the BBB to sodium in controlling CSF 
and brain tissue sodium by covering the entire parameter space, where all model parameters 
can vary within the specified ranges. Thus, in a rat model, the intrinsic variations between 
a population of rats of the same type were considered in this work.  
This study has some limitations. First, for simplicity, we modeled the rat brain with 
three spheres. However, the real geometry of a rat brain is more complicated. A more 
realistic model of the brain and ventricles can provide a better understanding of the 
phenomenon under study. Second, we modeled the CSF with two well-mixed 
compartments, i.e. the ventricular system and the subarachnoid space. However, CSF flows 
through the lateral ventricles, the third ventricle, the cerebral aqueduct, the fourth ventricle, 
the cisterns and the subarachnoid space. Sodium concentration can vary slightly to 
significantly from one ventricle to another one and to the subarachnoid space. Thus, the 
current model can be improved to include all of the ventricles and subarachnoid space as 
separate compartments. CSF flow can be modeled using various numerical methods [62-
65]. However, further information regarding the dynamics of sodium transport between 
different ventricles and adjacent brain tissues is needed.  Furthermore, we assumed that 
there is no rate-limiting diffusion between the CSF and brain tissue at the two contact 
surfaces of the CSF and brain tissue. This results in instantaneous equilibrium between CSF 
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sodium concentration and brain ISF sodium concentration at the contact surface of brain 
tissue and CSF [11]. This assumption may not be true for some ependymal regions such as 
those in the third ventricle as it has been shown that benzamil, an ENaC blocker can prevent 
sodium movement from the third ventricle CSF into brain tissue across the ependyma [55]. 
Third, for simplicity we assumed that the value of the sodium distribution factor (𝑓𝑑) 
remains constant after perturbations of the BCSFB and the BBB permeability coefficients 
to sodium. Thus, we estimated the ISF sodium concentration by 
𝐶𝑏𝑟
𝑓𝑑
 (Eq. 4). This assumption 
implies that the ratio of extracellular sodium concentration to intracellular sodium 
concentration remains unchanged at any time after perturbations of the permeability 
coefficients. In other words, sodium is always distributed between the ISF and the brain 
cells in the ratio of their physiological sodium contents. Previous studies made a somewhat 
similar assumption to estimate the ISF sodium concentration from brain tissue sodium 
levels, using the cerebral distribution volume of sodium [11]. The physiological value of 𝑓𝑑 
was found to be 0.34 ml/g using the average physiological ISF sodium concentration of 145 
mM [16] and the average brain tissue sodium concentration of 50 mM (=50 × 10−6 mol/g) 
[66]. The obtained value of 0.34 ml/g for 𝑓𝑑 in this work is the same as the value of the 
cerebral distribution volume of sodium [11]. The dynamics of sodium exchange between 
the brain cells and the ISF can be better understood by adding the brain cells as a new 
compartment to the current model. Our model can be expanded to include brain cells once 
more information becomes available regarding the permeability coefficients of different 
types of brain cell to sodium. One approach to modeling of dynamic sodium exchange 
between the brain cells and the ISF is to use neuron models which are based on Hodgkin-
Huxley type dynamics and extended to include time-dependent intracellular and 
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extracellular sodium concentration [67-69]. These dynamic models include differential 
equations for concentration of sodium, potassium and chloride. However, coupling these 
models with the current model may require modeling of further mechanisms that regulate 
potassium and chloride in the CSF and ISF. Fourth, we perturbed  𝑃𝐵𝐶𝑆𝐹𝐵, 𝑃𝐵𝐵𝐵, 𝑃𝐵𝐶𝑆𝐹𝐵
′ , 
and 𝑃𝐵𝐵𝐵
′  at t=0 and kept them unchanged during the experiment time. However, in reality 
the BCSFB and the BBB permeability coefficients likely change over time. Thus, the model 
presented in this study can be used to study the contribution of the BCSFB and the BBB to 
variations in the brain tissue and CSF sodium concentrations once there is more information 
about time-dependent variations of the BBB and BCSFB permeabilities to sodium during 
an episode of migraine with a particular trigger. Fifth, we assumed that diffusion is the 
major mechanism of sodium movement in the brain tissue. Although there are several lines 
of evidence supporting the existence of a convective transport mechanism called the 
glymphatic system in the brain [9, 10], several aspects of glymphatic circulation, including 
whether interstitial transport is propagated by convective flow or diffusion [70, 71], the 
identity of the ISF bulk flow driving forces [72, 73], and the role of astrocyte water 
permeability/aquaporin4 [71] are still controversial. Furthermore, it is not well understood 
how the proposed transport mechanisms are affected during migraine and how these 
mechanisms interact with the BBB to regulate ionic homeostasis in the brain. In this work, 
we ignored sodium transport between the CSF and brain ISF via convection, as it has been 
shown that diffusion (without convection) in the brain tissue is enough to account for many 
experimental transport studies in the brain parenchyma [71]. Intuitively, we think that 
adding the convective CSF transport from the subarachnoid space to the brain ISF, based 
on the proposed glymphatic circulation, will increase the effects of subarachnoid CSF (in 
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general CSF) on the brain tissue sodium levels, as the convective transport mechanism 
allows more sodium to be transported in a shorter amount of time compared to diffusive 
transport. Thus, the BCSFB would become more important in controlling brain tissue 
sodium levels. However, the exact extent of the contribution of the glymphatic system to 
the regulation of brain sodium homeostasis depends on not only the dynamical properties 
of the glymphatic system such as the rate of glymphatic flow, the glymphatic efflux 
pathways and the ISF bulk flow driving force, but also the dynamic interactions between 
the glymphatic flow, the BBB and brain diffusive transport mechanisms. The current model 
can be expanded to include the convective CSF flow from the subarachnoid space to brain 
ISF once more information regarding the contribution of the glymphatic flow to the 
regulation of brain sodium homeostasis becomes available. Finally, we ignored water fluxes 
between the model compartments. Thus, the volumes of the model compartments remain 
unchanged during the experiment time. This is because variations of the permeability 
coefficients within the specified ranges in this study result in gradual changes in the brain 
ISF sodium concentration, which suggests that the ISF osmolality changes gradually. The 
gradual variations in the ISF osmolality give the brain cells enough time to adjust to the 
changes in the extracellular space; so that they can minimize the variations in their volume 
through regulating the influx and efflux of osmotically active solutes between the 
intracellular and extracellular fluids. Previous in vitro studies showed that the cultured 
cerebellar neurons and C6 rat glioma cells can exhibit isovolumetric regulation when the 
extracellular osmolality changes at a rate less than or equal to 1.8 and 3 mOsmol/kg/min, 
respectively [74, 75]. The maximum possible rate of change of ISF sodium concentration 
in this work is 1.5 mM/min, equivalent to 1.5 mOsmol/kg/min.  Thus, we believe that the 
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brain cells, which make up 80% of total volume of the brain can significantly maintain their 
volume under the assumptions/conditions in our numerical simulation. This argument is in 
agreement with another experimental observation which suggests that a 50% decrease in 
the activity levels of Na+, K+-ATPase on the brain microvessels does not change total water 
content in the brain significantly [76]. Assuming that the brain tissue volume remains almost 
unchanged in this work, one can conclude that the CSF volume remains almost constant, 
due to the rigid confines of the skull. We have also assumed that the CSF secretion rate 
remains unchanged after pathophysiological variations of the influx and/or efflux 
permeability coefficients of the BCSFB to sodium. Although it has been suggested that 
there is a positive correlation between the CSF secretion and sodium transport rates across 
the BCSFB [8], it is not known how and to what extent water movement is linked to sodium 
transport in the BCSFB during migraine. Migraine is accompanied with a complex chain of 
biochemical changes in the CSF and brain which may contribute, together with sodium, to 
regulation of water movement across the BCSFB. For instance, it has been shown that CSF 
(and plasma) content of organic osmolytes such as taurine and glutamate, which can 
significantly regulate brain cell volume homeostasis [77, 78], changes during migraine [79-
82]. However, it is yet to be determined how the variations in organic osmolyte levels can 
influence the osmotically driven water transport across the BCSFB. Thus, future 
experimental studies are needed to explore whether/how/to what extent the water movement 
rate depends on the sodium transport rate during migraine. The results presented in this 
work may vary depending on how the CSF flow rate changes during migraine. The current 
model can be extended to include dynamic water movement across the BCSFB once further 
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information regarding the extent to which water movement is linked to sodium transport 
during migraine becomes available, 
The fact that the CSF and brain tissue sodium levels are higher in migraine and in an 
analogue of migraine in a rat model than the control groups [2, 3] has relevance to the pain 
of migraine, since increasing extracellular sodium concentration immediately increases the 
firing rate of primary cultures of neurons [7]. We propose that the increasing sodium 
concentration mainly arises from the BCSFB in the cerebral ventricles due to overactivity 
of Na+, K+-ATPases. When the higher CSF sodium concentration emerges from the fourth 
ventricle via the foramina of Luschka and Magendie, it meets the unmyelinated trigeminal 
nerves and the trigeminal ganglions. Unlike the cranial nerves such as the facial nerve that 
are protected by their myelin, we predict that firing of the trigeminal nerve would increase 
in the presence of the elevated sodium concentration, with trigeminal pain as a consequence. 
Moreover, we also predict that this CSF efflux from the fourth ventricle may well be 
lateralized through one of the small foramina of Luschka, and hence would give rise to 
unilateral trigeminal stimulation. An alternative interpretation to the primary effect of CSF 
sodium in the initiation of migraine is that the sodium is a consequence of migraine. We 
consider this to be less likely, since we have recently demonstrated that specific inhibition 
of the BCSFB Na+, K+-ATPase protected the animal migraine model from nitroglycerin-
triggered sensitization [37].   
It is important to note that the altered Na+, K+-ATPase activity simultaneously shifts 
sodium and potassium. However, we have not modeled potassium since we originally found 
that sodium concentration changed in CSF, while potassium concentration did not change 
during migraines [2]. Furthermore, the potassium concentration in the ISF and CSF is 
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maintained lower than in the remainder of the body by active astrocyte reuptake and, if 
potassium is not kept down, neurons will undergo apoptosis [83]. The mechanisms that 
regulate extracellular potassium concentration are substantially independent from Na+, K+-
ATPase-driven changes in sodium. The current model can be improved to include more 
mechanisms once more experimental data for multiple ion and water fluxes and their 
regulation in conjunction with sodium becomes available.  
4.5. Conclusions 
Our proposed mechanism for migraine suggests that a disturbance in brain sodium 
homeostasis causes migraine [36]. This sodium dysregulation is most likely due to 
variations in the influx and/or efflux permeability of the BCSFB and/or the BBB to sodium. 
The influx and efflux permeability of the BCSFB and the BBB to sodium represent the net 
effect of all transporters, channels and enzymes which contribute to movement of sodium 
across the interfaces. Thus, variations of the permeability coefficients can be caused by 
altered homeostasis of one or some of the sodium transport mechanisms at the interfaces. 
Unfortunately, understanding migraine pathophysiology is difficult, not only because the 
effects of various triggers on permeability of the BCSFB and the BBB to sodium are not 
known, but also because migraines have different triggers in different people. To approach 
this problem, we used mechanistic modeling together with global sensitivity analysis (GSA) 
to assess the relative importance of the BCSFB and the BBB in controlling CSF and brain 
tissue sodium levels. GSA provides insight into the significance of the BCSFB and the BBB 
in the regulation of brain sodium concentration when the exact extents of variations in the 
influx and efflux permeability coefficients of the BCSFB and the BBB to sodium are 
unknown. Our results show that the ventricular CSF sodium concentration is highly 
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influenced by pathophysiological variations in the influx permeability coefficient of the 
BCSFB to sodium. Brain tissue and subarachnoid CSF sodium levels are more sensitive to 
pathophysiological variations in the BBB permeability coefficients than the BCSFB 
permeability coefficients to sodium at shorter total experiment times (such as 1,5, 10 and 
30 minutes), while the BCSFB becomes more important that the BBB in influencing total 
brain tissue and subarachnoid CSF sodium levels at longer experiment times (such as 1, 2 
and 3 h). These results suggest that the efficacy of different migraine treatment strategies 
may depend on the time elapsed from migraine onset. This prediction needs to be tested 
experimentally for different models of migraines. This study prompts the hypothesis that 
increased influx permeability of the BCSFB to sodium caused by altered homeostasis of the 
enzymes which transport sodium from blood to CSF is the potential cause of elevated brain 
sodium levels in migraines. This hypothesis needs to be tested experimentally. The current 
model can be used to simulate sodium transport across the BBB, the BCSFB and the 
ependymal surfaces for a particular migraine trigger, given that the effects of the migraine 
trigger on the BBB and the BCSFB permeabilities are known. Further studies on the activity 
levels of different BCSFB and BBB sodium transporters during migraine episodes with 
different triggers can help better understand migraine pathophysiology. 
4.6. Supplementary Information  
4.6.1. Global Sensitivity Analysis 
In this work, we used a MATLAB toolbox called SAFE [23] to perform a global 
sensitivity analysis (GSA). SAFE implements several GSA methods such as the Elementary 
Effects Test, Regional Sensitivity Analysis, and Sobol's technique. Sobol’s method is a 
variance-based global sensitivity analysis technique which evaluates the sensitivity of the 
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solutions with respect to the model parameters as well as the interactions between different 
parameters. Using the principles of variance decomposition, Sobol’s method ranks the 
parameters in terms of their importance. Given an integrable function 𝑓 over a p-
dimensional parameter space Ω𝑝, 
𝑦 = 𝑓(𝑥1, 𝑥2, … , 𝑥𝑝)                                                                                                                      (S1)  
Each parameter can vary within a finite range. Sobol’s method considers expansion of the 
response into a set of functions of increasing dimensionality, 
𝑓(𝑥) = 𝑓0 +∑𝑓𝑖
𝑝
𝑖=1
+∑∑𝑓𝑖𝑗
𝑝
𝑗>𝑖
𝑝
𝑖=1
+⋯+ 𝑓123…𝑝 ,                                                                     (S2) 
where each individual term is a function of the parameters in its index. The total variance 
of the function output is defined by 
𝐷(𝑦) = ∫ 𝑓2(𝑥) 𝑑𝑥 − ( ∫ 𝑓(𝑥) 𝑑𝑥
Ω𝑝
)
2
Ω𝑝
.                                                                               (S3) 
Sobol’s technique is based on decomposition of the total variance 𝐷 into partial variances 
indicating the contributions from effects of individual parameters and combined effects of 
pairs of parameters. This decomposition is accomplished using the expansion of 𝑓 into 
terms of increasing dimensions (Eq. S2), 
𝐷(𝑦) =∑𝐷𝑖(𝑦)
𝑝
𝑖=1
+∑∑𝐷𝑖𝑗(𝑦)
𝑝
𝑗>𝑖
𝑝
𝑖=1
+⋯+ 𝐷123…𝑝(𝑦) .                                                        (S4) 
According to Sobol’s method, the first-order sensitivity index for each parameter is given 
by 
𝑆𝑖 =
𝐷𝑖(𝑦)
𝐷(𝑦)
 ,                                                                                                                                     (S5) 
The first-order sensitivity index accounts for the main individual contribution of each model 
parameter to the variance of the model output. The Sobol’s total-effect index, on the other 
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hand, represents total contribution of the input to the response variation. The total-effect 
index for parameter 𝑥𝑖  is calculated by the sum of all sensitivity indices which have 𝑖 in 
their index 
𝑆𝑇𝑖 = 𝑆𝑖 +∑𝑆𝑖𝑗
𝑖≠𝑗
+ ∑ 𝑆𝑖𝑗𝑙
𝑖≠𝑗,𝑖≠𝑙,𝑗<𝑙
+⋯                                                                                    (S6) 
Based on Sobol’s approach, the necessary and sufficient condition for parameter 𝑥𝑖 to be a 
noninfluential factor is 𝑆𝑇𝑖 = 0. However, previous studies have indicated that a parameter 
can be considered noninfluential if its total-effect sensitivity index is smaller than 0.01, and 
significantly smaller than total-effect sensitivity indices of the rest of the parameters [33, 
34, 84-85].  
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Figure S1. Relative significance of the model parameters in controlling ventricular CSF sodium 
concentration (𝐶𝑣) within 3 hours of the perturbation onset (𝑡𝑚𝑎𝑥 = 3 h). The blue bars represent 
first-order sensitivity indices, while the green bars show the total-effect sensitivity indices. The 
error bars, shown in red, indicate the bootstrap confidence intervals (95% confidence intervals) of 
the mean values. 
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Figure S2. Relative significance of the model parameters in controlling ventricular CSF sodium 
concentration (𝐶𝑣) within 1 hour of the perturbation onset (𝑡𝑚𝑎𝑥 = 1 h). The blue bars represent 
first-order sensitivity indices, while the green bars show the total-effect sensitivity indices. The 
error bars, shown in red, indicate the bootstrap confidence intervals (95% confidence intervals) of 
the mean values. 
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Figure S3. Relative significance of the model parameters in controlling ventricular CSF sodium 
concentration (𝐶𝑣) within 30 minutes of the perturbation onset (𝑡𝑚𝑎𝑥 = 30 m). The blue bars 
represent first-order sensitivity indices, while the green bars show the total-effect sensitivity 
indices. The error bars, shown in red, indicate the bootstrap confidence intervals (95% confidence 
intervals) of the mean values. 
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Figure S4. Relative significance of the model parameters in controlling ventricular CSF sodium 
concentration (𝐶𝑣) within 10 minutes of the perturbation onset (𝑡𝑚𝑎𝑥 = 10 min). The blue bars 
represent first-order sensitivity indices, while the green bars show the total-effect sensitivity 
indices. The error bars, shown in red, indicate the bootstrap confidence intervals (95% confidence 
intervals) of the mean values. 
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Figure S5. Relative significance of the model parameters in controlling ventricular CSF sodium 
concentration (𝐶𝑣) within 5 minutes of the perturbation onset (𝑡𝑚𝑎𝑥 = 5 min). The blue bars 
represent first-order sensitivity indices, while the green bars show the total-effect sensitivity 
indices. The error bars, shown in red, indicate the bootstrap confidence intervals (95% confidence 
intervals) of the mean values. 
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Figure S6. Relative significance of the model parameters in controlling ventricular CSF sodium 
concentration (𝐶𝑣) within 1 minute of the perturbation onset (𝑡𝑚𝑎𝑥 = 1 min). The blue bars 
represent first-order sensitivity indices, while the green bars show the total-effect sensitivity 
indices. The error bars, shown in red, indicate the bootstrap confidence intervals (95% confidence 
intervals) of the mean values. 
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Figure S7. Relative significance of the model parameters in controlling subarachnoid CSF sodium 
concentration (𝐶𝑠) within 3 hours of the perturbation onset (𝑡𝑚𝑎𝑥 = 3 h). The blue bars represent 
first-order sensitivity indices, while the green bars show the total-effect sensitivity indices. The 
error bars, shown in red, indicate the bootstrap confidence intervals (95% confidence intervals) of 
the mean values. 
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Figure S8. Relative significance of the model parameters in controlling subarachnoid CSF sodium 
concentration (𝐶𝑠) within 1 hour of the perturbation onset (𝑡𝑚𝑎𝑥 = 1 h). The blue bars represent 
first-order sensitivity indices, while the green bars show the total-effect sensitivity indices. The 
error bars, shown in red, indicate the bootstrap confidence intervals (95% confidence intervals) of 
the mean values. 
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Figure S9. Relative significance of the model parameters in controlling subarachnoid CSF sodium 
concentration (𝐶𝑠) within 30 minutes of the perturbation onset (𝑡𝑚𝑎𝑥 =  30 min). The blue bars 
represent first-order sensitivity indices, while the green bars show the total-effect sensitivity 
indices. The error bars, shown in red, indicate the bootstrap confidence intervals (95% confidence 
intervals) of the mean values. 
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Figure S10. Relative significance of the model parameters in controlling subarachnoid CSF 
sodium concentration (𝐶𝑠) within 10 minutes of the perturbation onset (𝑡𝑚𝑎𝑥 = 10 min). The blue 
bars represent first-order sensitivity indices, while the green bars show the total-effect sensitivity 
indices. The error bars, shown in red, indicate the bootstrap confidence intervals (95% confidence 
intervals) of the mean values. 
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Figure S11. Relative significance of the model parameters in controlling subarachnoid CSF 
sodium concentration (𝐶𝑠) within 5 minutes of the perturbation onset (𝑡𝑚𝑎𝑥 = 5 min). The blue 
bars represent first-order sensitivity indices, while the green bars show the total-effect sensitivity 
indices. The error bars, shown in red, indicate the bootstrap confidence intervals (95% confidence 
intervals) of the mean values. 
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Figure S12. Relative significance of the model parameters in controlling subarachnoid CSF 
sodium concentration (𝐶𝑠) within 1 minute of the perturbation onset (𝑡𝑚𝑎𝑥 = 1 min). The blue 
bars represent first-order sensitivity indices, while the green bars show the total-effect sensitivity 
indices. The error bars, shown in red, indicate the bootstrap confidence intervals (95% confidence 
intervals) of the mean values. 
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Figure S13. Relative importance of the model parameters in controlling brain tissue sodium levels 
within 3 hours of the perturbation onset (𝑡𝑚𝑎𝑥 = 3 h). The blue bars represent first-order 
sensitivity indices, while the green bars show the total-effect sensitivity indices. The error bars, 
  
 
174 
shown in red, indicate the bootstrap confidence intervals (95% confidence intervals) of the mean 
values. 
 
 
 
Figure S14. Relative importance of the model parameters in controlling brain tissue sodium levels 
within 1 hour of the perturbation onset (𝑡𝑚𝑎𝑥 = 1 h). The blue bars represent first-order sensitivity 
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indices, while the green bars show the total-effect sensitivity indices. The error bars, shown in red, 
indicate the bootstrap confidence intervals (95% confidence intervals) of the mean values. 
 
Figure S15. Relative importance of the model parameters in controlling brain tissue sodium levels 
within 30 minutes of the perturbation onset (𝑡𝑚𝑎𝑥 = 30 min). The blue bars represent first-order 
sensitivity indices, while the green bars show the total-effect sensitivity indices. The error bars, 
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shown in red, indicate the bootstrap confidence intervals (95% confidence intervals) of the mean 
values. 
 
Figure S16. Relative importance of the model parameters in controlling brain tissue sodium levels 
within 10 minutes of the perturbation onset (𝑡𝑚𝑎𝑥 = 10 min). The blue bars represent first-order 
sensitivity indices, while the green bars show the total-effect sensitivity indices. The error bars, 
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shown in red, indicate the bootstrap confidence intervals (95% confidence intervals) of the mean 
values. 
 
Figure S17. Relative importance of the model parameters in controlling brain tissue sodium levels 
within 5 minutes of the perturbation onset (𝑡𝑚𝑎𝑥 = 5 min). The blue bars represent first-order 
sensitivity indices, while the green bars show the total-effect sensitivity indices. The error bars, 
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shown in red, indicate the bootstrap confidence intervals (95% confidence intervals) of the mean 
values. 
 
 
Figure S18. Relative importance of the model parameters in controlling brain tissue sodium levels 
within 1 minute of the perturbation onset (𝑡𝑚𝑎𝑥 = 1 min). The blue bars represent first-order 
sensitivity indices, while the green bars show the total-effect sensitivity indices. The error bars, 
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shown in red, indicate the bootstrap confidence intervals (95% confidence intervals) of the mean 
values. 
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